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Scientific abstract
Type 2 Diabetes affects over 415 million people worldwide. The condition is associated with
an increased risk of blindness, kidney failure, heart attacks and premature death. Improved
glucose control is shown to substantially reduce these risks. However, most guildelines for Type
2 Diabetes management are reactive and can be seen to be more of a trial and error system until
a potential cure is found. There are major uncertainties regarding the likely effectiveness of
different treatments at an individual level. Personalised Medicine aims to look at the individual
instead of the whole population to estimate how they will respond on each treatment to de-
termine the most effective therapy for them personally. This thesis develops different models for
starting drugs for individuals with newly diagnosed Type 2 Diabetes. Using data from the UK
Prospective Diabetes Study (UKPDS) two models were created. The first uses a Bayesian mix-
ture regression model to predict glycated haemoglobin (HbA1c), an overall measure of glycaemic
exposure, after the first year of therapy. Then increments of HbA1c were modelled via a Wiener
process with baseline covariate effects and an individual fraility parameter. This second model
predicts the next HbA1c level as well as an estimate for how long an individual can stay on a
particular therapy before they reach a critical HbA1c boundary. These two models could assist
diabetes management by indicating a patients most effect therapy for them, as well as estimating
the likely time before an additional or replacement therapy would be required.
Keywords and AMS Classification Codes:
Bayesian, Statistics, Diabetes, Personalised Medicine, Regression, Mixture Model, Degradation,
Brownian Motion.
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1
Introduction
Type 2 Diabetes Mellitus (T2DM) is a condition of relative insulin deficiency. Insufficient insulin
is produced by the pancreas and in addition, the cells become resistant to insulin. Insulin is a
hormone which is used within the body to control glucose, or sugar, levels in the blood. Type 2
diabetes is progressive in nature and this can be managed with diet and exercise for some time
but will eventually required some medication. The longer one has diabetes the less responsive
beta-cells become and so over time the beta-cells in the pancreas are are no longer able to
produce enough insulin.
The main symptoms of T2DM are excess thirst, frequent urination and constant hunger.
Type 2 Diabetes makes up around 90% of all diabetes cases, with the other 10% being either
Type 1 - where there is an absolute lack of insulin due to a loss of beta cells in the pancreas and
monogenic forms of diabetes. The main risk factors for T2DM as listed on the Diabetes UK
website [1] are
• Being overweight or having a high BMI.
• Having a large waist (≥ 80 c.m in women and ≥ 94 c.m in men).
• Those of Afro-Caribbean, Black African, Chinese or South Asian descent and being over
the age of 25.
• Those of any other ethnicity and over the age of 40.
• Previous history of high blood pressure, a heart attack or stroke.
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• Having a parent or sibling who has Diabetes.
• A history of polycystic ovaries, gestational diabetes or a baby born weighing over 10 pounds
/ 4.5kg.
• Those who suffer from schizophrenia, bipolar, depression or take anti-psychotic medication.
Uncontrolled diabetes is associated with a three fold risk of cardiovascular disease [2], a
reduction in life expectancy [3] and is also a major cause of blindness, renal failure and ampu-
tation. The prevalence of diabetes is rising rapidly throughout the world [4], in 2010 there were
an estimated 285 million people diagnosed worldwide compared to 10 million in 1985, with an
estimation that the lifetime risk for Americans born in 2000 or later will be one in three [5].
The cost burden to the NHS in relation to care, monitoring, drug prescribing and controlling
the adverse effects of diabetes is increasing yearly. The cost of treating diabetes complications
such as kidney failure, stroke, blindness and amputations is expected to almost double from
£7.7 billion yearly to £13.5 billion by 2035 [6].
1.1. Diagnosis of Diabetes
The World Health Organisation (WHO) created guidelines for diagnosing diabetes, impaired
glucose tolerance (IGT) and impaired fasting glucose (IFG) [7]. Impaired glucose tolerance (IGT)
is when the glucose levels are above the normal range but not so high that they are diagnosed
with diabetes. It is associated with a risk of later developing diabetes and cardiovascular disease
and is also a risk factor for mortality. Impaired fasting glucose (IFG) is when the fasting plasma
blood glucose (FPG) levels are consistently elevated above the normal levels. This also has an
increased risk of cardiovascular pathology, although this risk is less then for IGT. Having IFG
means there is a 50% risk over 10 years of progressing to diabetes, with the average time for
progression from IFG to diabetes being less than 3 years [8]. Diabetes tests have traditionally
been carried out using blood glucose tests after fasting for 12 hours to get FPG and then 2 hours
after a meal for the 2h plasma glucose levels.
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An overview of the WHO diagnosis guidelines are presented in Table 1.1.
Diagnosis Criteria
Fasting Plasma Glucose ≥ 7.0mmol/l
Diabetes OR
2h Plasma Glucose ≥ 11.1mmol/l
Fasting Plasma Glucose < 7.0mmol/l
IGT AND
2h Plasma Glucose ≥ 7.8mmol/l and < 11.1mmol/l
Fasting Plasma Glucose ≥ 6.1mmol/l and ≤ 6.9mmol/l
IFG AND
2h Plasma glucose < 7.8mmol/l
Table 1.1: Diagnosis of Diabetes from WHO Guidelines.
In 2009 the World Health Organization released a document stating that Haemoglobin A1C
(HbA1c) can also be used for the diagnoses of diabetes. Haemoglobin is found in the red blood
cells which carry oxygen throughout the body. When blood sugar is high, the sugar builds
up in the blood and combines with the haemoglobin making it ‘glycated’. This HbA1c can be
measured to identify the average plasma glucose concentrations over the last 2 to 3 months,
making it less susceptible to the large fluctuations which can be seen in the plasma glucose. The
diagnosis guidelines for diabetes with HbA1c levels are presented in Table 1.2.
Diagnosis Criteria
Diabetes HbA1c ≥ 6.5%
Normal HbA1c < 5.7%
Pre-diabetes HbA1c between 5.7 and 6.4%
Table 1.2: Diagnosis of Diabetes using HbA1c.
1.1.1. Treatment of Diabetes
Early diagnosis of T2DM is vital to improve the outcome of health for a person with diabetes
and pharmacological treatment should always be complemented with lifestyle changes such as
dieting, weight loss and exercise. The American Diabetes Association (ADA) released a position
statement stating the importance of medical nutrition therapy in preventing, managing and
preventing complications for diabetes [9].
To reduce the development of microvascular complications, treatment for diabetes should
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make the management of hyperglycaemia (high blood glucose) a top priority [10]. Improved
glucose control has been shown to delay the development and progression of retinopathy, neph-
ropathy and neuropathy in patients with T2DM [11] [12]. Earlier studies assessing haemoglobin
A1c (HbA1c) have shown that levels above the normal range were associated with an increased
risk of cardiovascular disease [13].
The American Diabetes Association (ADA) and the European Association for the Study of
Diabetes (EASD) created a joint position statement to recommend therapy and this focused
on a target of lowering HbA1c to < 7%, or as close to the non-diabetic range as possible and
maintaining near normoglycaemia [14]. However, it has been shown that only slightly more
than half of patients with diabetes achieve this target, which leaves them exposed to prolonged
periods of damaging hyperglycaemia [15].
More recently the ADA and EASD have released an updated document highlighting a patient
centered approach to treatment [16]. This is defined as an approach to “providing care that is
respectful of and responsive to individual patient preferences, needs and values and ensuring
that patient values guide all clinical decision” [17].
First line treatment for diabetes usually begins with lifestyle changes and metformin mono-
therapy as this is the only oral hypoglycaemic drug with proven efficacy, safety, and cost effect-
iveness and is recommended by international guidelines for the first line treatment of T2DM [16].
Metformin is usually well tolerated with the main side effects being gastrointestinal and include
an increase in frequency of bowel movements, diarrhoea, nausea and abdominal pain. The main
non glycaemic effect is weight stability or modest weight loss and with lifestyle changes this
will typically lower HbA1c by approximately 1.5 percentage points. Extra treatments are added
with the goal of lowering glucose, when target glycemic goals are not achieved or substained. An
example of an algorithm for glucose-lowering in people with Type 2 diabetes from the National
Institute for Health Care Excellence (NICE) is given is Figure 1.1 [18].
Figure 1.1 shows the progressive nature of diabetes in that over time more or different
therapies will be required for individuals. In reality, one would want to wish to prescribe
individuals to the most suitable drug for them as early as possible in treatment.
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NICE clinical guideline 66 – type 2 diabetes 42 Figure 1.1: NICE Guideline Algorithm of Treatment for diabetes
1.2. Personalised Medicine
The current practice for treating type 2 diabetes and many other diseases are guideline based
and can be seen as a trial and error system, until the most suitable treatment is found for
an individual. Many clinicians use a one size fits all approach, starting with standard doses,
observing responses to this treatment and changing when necessary. However, with the limita-
tions to a “one size fits all” approach becoming more evident [19] there is now a push to move
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towards the concept of personalised medicine. The idea of personalising medicine is not strictly
a new idea. A clinician’s decision has always been made based on the available knowledge and
probability that a treatment will benefit each patient. Traditional theories of medication from
Hippocrates, Garrod, Osler and others focus on ‘treating the patient, not the disease’. However,
recent advances in technologies, genetics and knowledge of disease have meant there has been a
greater push to personalise therapies for individuals. Since phenotypic factors are different for
everyone, the nature of the disease, onset, course and response to drugs and other interventions
differ from person to person [20].
For many diseases there is a lack of effective or curing therapies for the population as a
whole and even with well established therapies there are patients who will not always respond,
or they can lead to unwanted or adverse side effects. This evidently means that there is not
one cure for all and with less and less drugs passing the Food and Drug Administration (FDA)
approval process [21] there is a need to better utilize the existing drugs, by prescribing each
individual with the medication most likely to work for them. Margaret Hamburg defines the
idea of personalising therapies as the process of “Optimizing prescribing by steering the patients
to the right drug at the right dose at the right time” [22].
There are many advantages to personalised medicine over the more generic guideline based
approach, which is based on all the evidence for a particular question, instead of sub groups [23].
Firstly, by being able to optimize existing drugs to specific sub-populations, it is estimated
to potentially save millions of US dollars every year [24]. As well as saving money, the concept
of personalising therapies will be efficacious to the individual. By patients being allocated to
the best treatment for them individually early on, it will give them a reduced chance of long
term complications as well as reducing the risk of adverse side effects. This means there will
be a capability to make more informed medical decisions with a higher likelihood of desired
outcomes.
The use of personalised medicine is also thought to be beneficial in drug development, by
designing trials that will identify which patients will benefit most from a drug. If trials can
target and recruit the patients most likely to respond to a particular treatment, it can lead to
better safety within the trial, smaller and faster trials and thus, in turn, a lower cost. This also
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means that any treatments which are found not to be efficacious for the overall population by
the Food and Drug Association (FDA) could instead become licensed for a smaller set of the
population and be more beneficial for them. The FDA have made a start to integrate this idea
of personalised medicine into their regulatory policies. In October 2013, they released a report
titled “Paving the way for personalised medicine: FDAs role in the era of medical product
development”. This document outlined steps which can be used for genetic and biomarker
information for both clinical use and for drug development.
1.3. Personalised Medicine in Diabetes
Although T2DM has long since been recognised as a heterogeneous disorder, patients are gen-
erally treated similarly regardless of different clinical factors which may affect their response
to treatment. The clinical course following the diagnosis of diabetes for an individual is highly
variable. It is seen that some patients have fast deterioration in glycaemic control, while others
can maintain a healthier level for many years. Recognising factors which are associated with
this would help aid the management of patients with type 2 diabetes.
Although there was some early stratification into types 1 and 2 within diabetes, progression
of subsquent T2DM sub groups has since been slow. Therefore, the idea of finding sub groups
for which patients react similarly to each other, yet different to other sub groups, is still a very
important goal. Risk factors for diabetes have been studied and summarised by Noble [25].
These include clinical factors such as age, sex, ethnicity, family history and obesity, as well as
glucose and biochemical factors such as HDL cholesterol. However, the interaction between these
and other risk factors with each other is a more complex process, varying across populations.
It is known that early detection of diabetes, which can be assessed from the stated risk factors,
improve the glycaemic control, however, the evidence for screening for these factors across a
population is weak [26]. Thus meaning, that although one may be able to predict the risk
of diabetes, this may not always predict a subjects course over time once diabetes has been
diagnosed.
At a 2011 Medical Research Council (MRC) Obesity, Diabetes and related Metabolic dis-
orders workshop, which aimed to develop strategies and plans for the next 5 years, the main
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focus was on ‘stratification of disease’ and ‘identification of patients who will respond positively
to new treatments.’ The workshop suggested using existing datasets to identify sub groups of
patients who respond to specific treatments, which can then be used in the future to stratify
patients for future trials and may result in new opportunities for research. This workshop high-
lighted the want and need for personalising therapies within diabetes and this is therefore an
area of research of importance over the next 5 years.
During April 16-17 2009, a 29 member international working group with expertise in dia-
betes, participated in a conference to discuss individualising therapies for T2DM and their
recommendations were summarised by a writing group led by Smith [27]. Smith and colleagues
highlight that diabetes is a heterogeneous disease and that this begins at the pre diabetes stage.
However, they state that although this heterogeneity is known and has been for some time, there
is still a uniform approach when it comes to treatment of T2DM, but that this is unsurprising
given that clinical trials are rarely designed or analysed to determine the effectiveness of the
treatment for specific sub groups and instead focus on the entire diabetes population.
Due to this heterogeneity within Type 2 Diabetes, Smith et al state that more targeted stud-
ies are needed to recognise these subtypes which may effect an individual’s response to treatment
and that this is an area which remains largely unexplored. This is due to the design of clinical
trials which are powered for main effects and not sub group analysis, due to manufacturers not
being motivated by personalised medicines and individualising treatments which may limit the
market for their product.
Despite there being rapid progress in drug development, Jia Weiping notes that it is still
challenging to achieve good glycaemic control [28]. By not taking into account individual char-
acteristics which may affect their drug response, it may lead to poor responses and thus is
another reason towards a push for personalised medicine. Therefore, a method of being able to
assess which is the most suitable treatment for an individual would be helpful for this concept
of personalised medicine. By being able to predict the outcome after initial therapy and over
the progressive nature of the disease, one could provide individuals with the most suitable drug
for them personally at an earlier stage of treatment.
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1.3.1. Treatment Response
A literature review was performed by Cantrell et al using PubMed/MEDLINE, Cochrane Library
and EMBASE, to find relevant papers which measured pharmacological treatment response
in terms of HbA1c, fasting plasma glucose (FPG) or other outcome measures such as insulin
response, therapy adherence or cardiovascular outcomes [29]. After performing the literature
review online, Cantrell et al extracted key data elements and individually evaluated each paper
to determine the level of evidence using NICE criteria [30]. A total of 43 articles were found
and these mainly measured HbA1c or FPG during follow up and identified numerous clinical
characteristics which were shown in some way to have an effect on treatment response.
The only clinical factor Cantrell et al determined to be of strong evidence for treatment
response was baseline glycaemic control - HbA1c or FPG. A study has shown that lower baseline
HbA1c or FPG was associated with lower glycaemia after initial treatment [31]. It was also
shown that higher baseline HbA1c was associated with a greater absolute reduction in glycaemia
after treatment and a recent study looking at response predictors of Exenatide backed up this
idea [32]. Although these studies seem promising with regards to treatment responses they have
some limitations. For example in the study by Anderson et al [32] they define a responder as
one who has a decrease in HbA1c of greater than 0.5% between baseline and 12 to 30 weeks post
Exenatide initiation. However, in the non-responder group almost half of the patients had a
baseline HbA1c level at goal or below < 7.0% and thus are less likely to decrease by more than
0.5% to be defined as a responder. The study is also small in size and there is little follow up to
see what occurs over a longer time period. This trend between baseline HbA1c and treatment
response has also been seen in other agents in earlier studies [33]. This shows that it appears
to be the elevated baseline HbA1c and not the presence of any particular treatment which is
driving the treatment benefit. Also as the study has the same factor as an outcome variable
it seems to follow on naturally that a level at baseline will be a strong predictor post baseline.
Therefore, it seems reasonable to look at other variables and factors also in future work.
The Cantrell literature review also highlighted studies which were deemed to be of moderate
evidence for a response predictor, for characteristics which are different to the outcome measure.
Lower baseline insulin sensitivity appears to have a relationship with a greater reduction in
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glycaemia after treatment [34] and lower total cholesterol is also associated with lower glycamia
as well as less likelihood of switching to insulin therapy after initial treatment [35].
The Cantrell review provides a good tool to see which characteristics may have an affect on
treatment response. However, these studies only look at one single response variable at a time,
rather than a comparative study of numerous characteristics. The studies looked at here are
also often small with a short period of follow up time and so do not give enough of an insight
into management of an individuals’ treatment response over time.
1.3.2. Treatment Progression
To provide the best management of diabetes the aim should be to delay diabetes progression
and thus any need for different or additional therapies. Finding characteristics of those who
progress rapidly or slowly will be a big aim for personalised medicine and treatment itself. Then
by being able to predict a subjects course of the disease over time could help provide tools for
personalised medicine.
There have been some studies assessing the association between factors and the rate of
diabetes progression. A study looking at progression from oral sulphonylureas to insulin therapy
found that in 6 years 44% of patients required some sort of additional therapy [36]. Of these it
showed that Fasting plasma glucose (FPG) at baseline was strongly associated with progression.
Splitting the population into 3 groups based on baseline FPG - ≥ 10.0mmol/l, between 7.8
and 10 mmol/l and < 7.8mmol/l the numbers requiring additional therapy were 61%, 39%
and 23% respectively. The study also showed a link between beta-cell function and progression
with lower beta-cell function having a higher probability of progression to additional therapies.
Splitting into 3 groups again of < 27.1%, 27.1−55.1% and ≥ 55.1% the probabilities were 61.6%,
40.9% and 27.9% respectively. A follow up study of the 10 year Belfast Diet study also found a
relationship between beta-cell function and progression [37].
Similar studies have also shown an association between time to insulin treatment and age
(HR=1.24, CI: 1.03 to 1.50 for those under the age of 65), those who initiated oral treatment
with more then 1 agent compared to 1 agent(HR=2.71, CI: 2.15 to 3.43) and HbA1c at start
of oral treatment (HR=1.20, CI: 1.146 to 1.25) [38]. A significant trend between decreasing
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adherence and the number of co-medications was also shown [39].
A recent study by Zhou et al looked at the risk of progression from diagnosis to requirement
of insulin treatment [40]. This study concluded that the risk of progression was associated
with both high and low BMI, such that the risk formed an almost U shape over the range of
BMI. Zhou et al stratified their analysis by BMI and HbA1c at diagnosis and found that faster
progression was associated independently with younger age at diagnosis, higher triclyglyceride
concentrations (HR= 1.28, CI: 1.15 to 1.42) and lower HDL concentrations (HR=0.70, CI: 0.55
to 0.87). The study also looked at genetic factors but no association was found from these.
Within these and other studies a number of factors are associated univariately with progres-
sion of diabetes, but they often do not look comparatively over a number of covariates. They
find independent associations and not set sub groups which possibly could be found. None of
these also look comparatively over different treatments to look at how patients with the same
characteristics react to different therapies to predict which would be most efficacious for them
individually.
Although these studies give either probabilities or hazard ratios for risk of complications,
there is still no real idea as to how long an individual will stay on a specific treatment for. Some
sort of prediction of the length of time someone can maintain good glycaemic control whilst on
a particular drug would also be interesting to see and perhaps of more clinical relevance.
1.3.3. Genetics in Personalised Medicine
Recently there has also been some research into the use of genetics within personalised medicine
for diabetes. The before mentioned paper by Smith et al [27] focused mainly on genetic sub
groups. Previous studies have identified over 65 genetic diabetes risk variants [41], however,
these show little predictive promise over more traditional and readily available clinical charac-
teristics [42]. Our knowledge of genetic variants that increase diabetes risk is improving and it
was recently identified that diabetes is one of the few areas where this known genetic etiology
leads to improvement in treatment response. However, the most powerful demonstration of
genetic subtypes which affect treatment response are from identification of monogenic forms of
diabetes, which have provided evidence for personalised medicine.
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Although some small associations have been found within genetics, the cost of screening for
these genetics and the small amount of subjects who have them, means that finding these out for
the individual may not in fact be cost effective. For this reason, for the time being, personalised
medicine needs to also stem beyond the realm of genetics and look for more readily available
patient characteristics and those which span a larger proportion of the population of those with
diabetes. Due to this and the smaller amount of available data, this thesis will focus on readily
available characteristics for an individual.
This literature review of personalised medicine in diabetes shows that there have been studies
to look at risk factors, however, we are still not close to actually being able to fully perform
personalised medicine. A more comparative look across numerous factors and treatments is
where this thesis will begin to try and predict how long an individual can stay on a specific
treatment before their HbA1c deteriorates and a different or additional therapy will be required.
1.4. Synopsis of Thesis
The main aim of this thesis is to create prediction models to use as tools for personalised
medicine. These models could then be used for clinical purposes when treating diabetes to help
decide which treatment an individual should be on. All models in the thesis are Bayesian and
parameters are estimated via Gibbs Sampling A.2.1..
Chapter 2 gives an overview of the UK Prospective Diabetes Study (UKPDS), which was
a randomised intervention trial designed to determine whether improved glucose control would
prevent complications of diabetes and reduce the associated mortality and morbidity. The data
from this study was used throughout the rest of the thesis for the creation of the prediction
models. The chapter outlines the study and the main findings from this as well as presenting
the baseline characteristics of the data used.
Chapter 3 and 4 then focus on creating a model for predicting HbA1c response after the first
year of monotherapy treatment. To begin, chapter 3 outlines the method and results for Bayesian
variable selection to determine which covariates to use within the models for each treatment.
After this the idea of invertibility is focused on to see whether any transformations for the
variables are required. It then moves on to creating a linear regression model for predicting
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the response to first year of treatment and analyses the results from the model. From here
it is shown that there are some issues with the fit and that one singular model may not be
appropriate for the data. Therefore, in chapter 4 a mixture model is put forward and outlined.
For this the data is split into separate groups or components, for which a different model is
fitted to each of the groups. The model is estimated and results are given for the predictions.
Then a comparison of the the groups found and their corresponding models are looked at to see
how baseline characteristics effect the models. Finally, a Naive Bayes classifier is summarised
as a method of deciding which group or batch an individual belongs to, to know which model
they should use.
After looking at an initial response after the first year of treatment, chapter 5 then extends
this to look at modeling the degradation of an individuals HbA1c over time. This model can
then be used for predicting the next time point as well as an estimate of how long a patient can
remain under a critical boundary level of HbA1c. To do this a Wiener process model is described
and outlined to find a positive drift for an individuals degradation. This model is run and the
results are used to predict both next marker values as well as a prediction of a first passage
time (FPT) or time until a boundary has been reached. This is then extended to look firstly
at purely baseline data with no time information about an individual known and then how to
update the model with more knowledge. This can then be used as a tool for predicting future
markers from baseline and is thus easier for predictions of newly diagnosed individuals.
The final chapter discusses the conclusions of the thesis and future work which will continue
from the results, such as an app for prediction using the formulae found.
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2
UK Prospective Diabetes Study
For all the analysis within this thesis, the UK Prospective Diabetes Study (UKPDS) data was
used and this chapter will outline the study, its objectives, results and give baseline characterist-
ics. It will also introduce HOMA modeling to include variables which monitor beta-cell function
and insulin sensitivity for the analysis.
The UK Prospective Diabetes Study (UKPDS) began in 1977 and was a landmark multi-
centre, prospective, randomised intervention trial, designed to determine whether improved
blood glucose control could prevent complications of diabetes, reduce the associated mortality
and morbidity and to compare the effectiveness of all available therapies at the time [43]. The
study recruited 5102 patients with newly-diagnosed type 2 diabetes, between the ages of 25 to
65 with a median age of 53, median BMI of 28 and a median fasting plasma glucose (FPG) of
11.3 mmol/l. The inclusion criteria for the study was to have newly-diagnosed diabetes defined
by having a FPG level of > 6mmol/l on two mornings 1 to 3 weeks apart. UKPDS ran for
20 years between 1977 and 1997 in 23 UK clinical sites. It showed conclusively that improving
blood glucose could improve the risk complications from having diabetes which were previously
thought of as inevitable. After the main intervention study ended in 1997, all surviving UKPDS
patients were entered into a 10 year post-trial monitoring programme to look at the follow up
and this was completed in December 2007.
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2.0.1. UKPDS Study design
Once subjects were initiated into the UKPDS study they had an initial 3 or 4 months on diet
alone and then were randomised to a treatment according to their FPG and weight. The initial
diet was a “prudent” one with 50% carbohydrate, low saturated fat and moderate high fibre,
with a reduced energy content for obese patients, with a goal to attain ideal body weight.
Overweight patients were classified as those with a weight of ≥ 120% of their ideal body weight
according to gender and height [44]. Subjects were randomised to either diet on its own, or an
active policy whilst still receiving dietary advice.
The active treatments were an oral sulphonylurea of either chlorpropamide, glibenclamide
(or glipizide in later years), insulin therapy, or metformin but only for overweight participants.
Insulin therapy gives patients exogenous insulin and for the study patients started on ultralenta.
The initial dose was calculated using the subjects baseline FPG as (FPG− 2)× 3 units per day
(IU). For overweight patients the dose was increased to be IU × (2.5× actual body weigh/ideal
weight −1.5). Sulphonylureas are a type of drug which increase the insulin release from the beta-
cells in the pancreas and patients were randomly allocated to either chlorpropamide (maximum
500mg daily) or glibenclamide (maximum 10mg twice daily). In the years following 1987, pa-
tients were randomised to glipizide (max 20mg twice daily) instead of glibenclamide. Metformin
on the other hand works by suppressing glucose production in the liver. Patients on metformin
were given a maximum dose of 1700mg at breakfast and 850 mg in the evening. For all therapies,
the dose for each patient was individually increased at approximately 2 week intervals until the
goal of FPG being reduced to < 6mmol/l was achieved, or the maximum dose was reached.
Patients remained on monotherapy until either their FPG rose to > 15mmol/l or until
hyperglycaemic symptoms developed. They were then transferred either to a different treatment
or additional therapies were added depending on their current treatments.
The aims of the main study are listed below:
1. To determine whether treatment aiming for near-normal plasma glucose levels of< 6mmol/l,
reduces morbidity and improves life expectancy.
2. To determine whether diet alone, sulphonylurea, insulin or metformin therapy has a par-
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ticular advantage in terms of improving prognosis.
The main end points for the study were major clinical events which would affect the life and
well being of a patient. These were classified to be events such as heart attacks, angina, strokes,
amputation, blindness and renal failure.
After the 3 months of initially diet alone, patients were categorised as follows:
1. Main Randomisation - 68%. Patients with an FPG between 6 and 15 mmol/l. In
non-overweight patients the randomisation proportions were 30% to diet, 30% to insulin
and 40% to the two sulphonylureas. In overweight patients the randomisation proportions
were altered to 24% to diet, 24% to insulin, 32% to sulphonylurea and 20% to metformin.
2. Primary Diet Failure - 14%. Patients with an FPG of > 15 mmol/l. In non-obese
patients the randomisation proportions were 44% to insulin and 56% to sulphonylurea. In
obese patients the randomisation proportions were 32% to insulin, 42% to sulphonylurea
and 26% to metformin.
3. Diet Satisfactory - 18%. Patients with an FPG of < 6 mmol/l. These patients stayed
on diet alone, until FPG rose to above 6 mmol/l at which point they were entered into
the main randomisation. This occured for 69% of diet satisfactory patients.
Patients were recruited to the study after a referral through a local General Practitioner
and were usually seen within a few weeks of referral. Their FPG was then measured in the
morning after an overnight fast and diabetes was confirmed if they had two readings of greater
than 6mmol/l. The WHO criteria for diagnosis of diabetes using FPG is 7.0mmol/l and 85%
of recruited patients satisfied the WHO criteria [7] see Table 1.1. As can be seen in Table
1.1 the WHO diagnosis using 2h- glucose is ≥ 11.1mmol/l. Using a regression model with
y = 0.50x + 1.54 this relates to a FPG of 7.1mmol/l of which 92% of recruited patients would
then have fullfilled the WHO criteria.
There were a number of exclusion criteria such a myocardial infarction in the previous year
and previous retinopathy requiring laser treatment. The clinical end points for the UKPDS
study included fatal end points, non fatal end points, major morbidity and clinical end points
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not included in the stopping criteria. This study went on for many years, stopping recruitment
in 1991, with a long follow up. This means there is data over a long period of time for many
patients, and across a wide range of treatments, which are changed and/or added as necessary
for the patient.
As well as the glucose study, the patients could be randomly allocated into the smaller
Hypertension in Diabetes Study (HDS) which was a factorial design to assess whether improved
blood pressure control would be advantageous which recruited 1060 patients. Patients with
a high blood pressure (≥ 160/90mmHg) were randomly allocated to either tight control with
either an angiotensis-converting enzyme inhibitor or a beta-blocker aiming for < 150/85mm/Hg
or to a less stringent control aiming for < 200/105mm/Hg.
2.1. UKPDS Results
2.1.1. Main Interaction UKPDS Study Results
Of the 5102 patients recruited into UKPDS, 4209 entered the main or primary diet failure
randomisation. The study was split into two main sections with the first looking at the effect
of intensive metformin treatment in overweight patients and the second comparing intensive
treatment with insulin and sulphonylureas with conventional therapy of diet.
The main outcomes for the studies were categorised into 3 composite end points.
• Diabetes-related end point - sudden death, death from hyperglycaemia or hypoglycaemia,
fatal or non-fatal myocardial infarction (MI), angina, heart failure, stroke, renal failure,
amputation, vitreous haemorrhage, retinopathy requiring photocoagulation, blindness in
one eye or cataract extraction.
• Diabetes-related death - Death from myocardial infarction (MI), stroke, peripheral
vascular disease, renal disease, hyperglycaemia, hypoglycaemia and sudden death.
• All cause mortality.
The first study looked at the effect of intensive blood-glucose control with metformin in
overweight patients with type 2 diabetes [45]. 1704 overweight patients (> 120% ideal body
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weight) were recruited in 15 centres around the UK with a raised FPG between 6.1 and 15.0
mmol/l without hyperglycaemia symptoms. 753 of these were then included in the randomised
controlled trial with a median duration of 10.7 years comparing conventional policy primarily
with diet alone (n = 411) with intensive blood-glucose control with metformin (n = 342) aiming
for an FPG < 6.0mmol/l. For the metformin intensive-control group a lower median glycated
haemoglobin (HbA1c) was achieved during the follow up of 7.4% compared to 8.0% median in
the conventional therapy group. Significant reductions in risk were also seen for the metformin
patients compared to the conventional therapy patients with risk reductions of 32% (95% CI:
13 to 47, p=0.002) for any diabetes-related end point, 42% (95% CI: 9 to 63, p=0.017) for
diabetes-related death and 36% (95% CI: 9 to 55,p=0.011) for all cause mortality.
The same paper [45] also involved a secondary analysis which compared the patients on
metformin (n = 342) versus the 951 other overweight patients allocated to a different intensive
glucose control of either chlorpropamide (n = 265), glibenclamide (n = 277) or insulin (n = 409).
Metformin showed a significantly greater effect in risk reduction compared to the other intensive
treatments for any diabetes related end point (p=0.0034), all cause mortality (p=0.021) and
stroke (p=0.032).
Another point of note was that when comparing the early addition of metformin in Sulphonylurea-
treated patients compared to continued Sulphonylurea alone, there was an increased risk of
diabetes-related death (96% increased risk (95% CI: 2 to 275,p=0.039). However this analysis
contained very small numbers of only 26 versus 14 and so this result could likely be down to
chance.
Metformin was also shown to incur no significant weight gain for the overweight subjects and
had significantly less hypoglycaemia episodes than the other intensive treatments. These results
favour metformin therapy and backs up that many patients first line treatment, especially for
overweight patients, is metformin.
The second main study looked at intensive blood-glucose control with Sulphonylureas and
insulin compared with conventional treatment and the risks of complications in patients with
type 2 diabetes [12]. Within this study 3867 patients were randomly allocated to either intensive
blood-glucose control with a sulphonylurea or insulin, or to conventional therapy. In the intensive
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group the goal was to achieve an FPG of < 6.0 mmol/l and the goal in the conventional therapy
group was to maintain FPG with diet alone and additional therapies were added when FPG
reached 15.0 mmol/l. Over 10 years of follow up the intensive group achieved a lower median
HbA1c of 7.0% (6.2−8.2) compared with conventional therapy 7.9% (6.9−8.8), an 11% reduction.
No significant difference was seen between the intensive group treatments for HbA1c.
The intensive groups saw some numerical risk reductions compared to the conventional group,
however, only the any diabetes-related end point was significant with a 12% risk reduction (95%
CI: 1 to 21, p=0.029). For any diabetes-related death there was an insignificant risk reduction
of 10% (95% CI: −11 to 27,p=0.34) and for all cause mortality a risk reduction of 6% (95% CI:
−10 to 20, p=0.44). Most of the reduction seen in the any diabetes related end point was due
to a 25% risk reduction (95% CI: 7 to 40, p=0.0099) in microvascular endpoints including the
need for retinal photocuagulation. There was no difference in any of the end points between the
intensive treatment groups.
A significant increase in the number of hypoglycaemia episodes was seen in the intensive
treatment compared with conventional therapy (p=0.0001) with 0.7% on conventional therapies,
1% on chlorpropamide, 1.4% on glibenclamide and 1.8% on insulin. Weight gain was also
significantly higher for the intensive treatment groups (p< 0.0001).
2.1.2. The Hypertension in Diabetes Study Results
The Hypertension in Diabetes Study (HDS) included 1148 hypertensive subjects from the main
UKPDS patients who had a blood pressure greater than 160/90 mmHg [46] at entry. Of these
758 were allocated to tight control of blood pressure and 390 allocated to less stringent control.
There was a median follow up of 8.4 years.
During the follow up period the tight control group were seen to have a significantly lower
blood pressure (mean - 144/82 mmHg) compared with the less tight control group (154/87
mmHg), p< 0.0001.
The tight control group also saw many significant risk reductions in end points compared
with the less tight control group with a 24% risk reduction (95% CI: 8 to 38, p=0.0046) for
any diabetes related end point, a 32% reduction (95% CI: 6 to 51, p=0.00921) for any diabetes
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related death, a 44% reduction (95% CI: 11-65, p=0.013) for stroke and a 37% reduction (95%
CI: 11-56, p=0.0092) for microvascular end points. No significant difference was seen between
the two groups for all cause mortality. One thing of note however, was that after 9 years of
follow up 29% of the patients in the tight control group required 3 or more therapies to control
their blood pressure and achieve the set targets.
This study thus showed that tight blood pressure control in patients with hypertension and
type 2 diabetes achieves clinically important and significant reductions in the risk of death and
other diabetes related complications compared to less stringent control.
2.1.3. Baseline Characteristics
For the analysis it was decided that only easily attainable variables would be included so that
in future predictions for individuals can be obtained. This included 18 different variables and
these are summarised at baseline for each treatment and for the overall population in Table
2.1. This table also gives a p-value for the difference between the means of the groups. These
were calculated by Chi-squared tests for categorical varaibles, anova for continuous means and
Kruskal-Wallis for medians.
2.1.4. HOMA Values
Insulin resistance (IR) is a condition in which the cells fail to respond to insulin, so that they
become resistant to insulin and are unable to use it effectively. Insulin resistance subsequently
leads to beta cells (β-cells) increasing insulin production. The β cell is a cell in the pancreas
whose primary function is to store and release insulin. In general type 2 diabetes develops when
the β cells fail to secrete sufficient insulin to meet the demands. Pancreatic beta cell dysfunction
is a core disorder in the etiology of type 2 diabetes [47]. Insulin resistance and progressive
pancreatic beta-cell dysfunction have been identified as the two fundamental features in the
pathogensis of type 2 diabetes, hence why they are considered here.
To assess the levels of insulin resistance and β-cell activity in the blood the Homeostatic
model assessment (HOMA) model was created, which estimates β-cell function and insulin
resistance from fasting glucose and insulin levels. The model was first described in 1985 by
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Variable Overall Insulin Metformin Chlorpropamide Glibenclamide P-Value
n 3265 1105 463 833 864
Age 52.23 (8.9) 52.2 (9.0) 51.6 (8.7) 52.3 (9.1) 52.5 (9.0) 0.453
Male (%) 1837 (56.3%) 649 (58.7%) 208 (44.9%) 464 (55.7%) 516 (59.7%) < 0.0001
Race - 2656 (81.3%) 897 (81.2%) 385 (83.2%) 667 (80.1%) 707 (81.8%) 0.5639
Caucasian (%)
Smoker - 1188 (37.4%) 386 (34.9%) 200 (43.2%) 307 (36.9%) 295 (34.1%) 0.0066
Never (%)
BMI 27.6 (5.5) 26.9 (5.4) 31.1 (5.4) 27.1 (5.2) 27.1 (5.1) < 0.0001
Height (cm) 167.0 (9.6) 167.3 (9.4) 165.5 (10.0) 166.8 (9.6) 167.5 (9.7) 0.0017
Waist (cm) 94.7 (13.4) 93.3 (13.2) 101.0 (13.8) 93.8 (12.9) 93.9 (12.8) < 0.0001
Systolic BP 135.4 (21.4) 135.1 (21.5) 127.8 (20.1) 134.9 (22.1) 135.1 (21.3) .0892
(mm Hg)
Diastolic BP 82.75 (11.8) 82.3 (12.0) 84.5 (11.3) 92.6 (12.2) 82.6 (11.3) 0.0119
(mm Hg)
HbA1c † 7.5 (6.5-0.3) 7.5 (6.5-9.4) 7.5 (6.5-9.2) 7.5 (6.4-9.4) 7.5 (6.4-9.2) 0.916
FPG (mmol/L)† 9.1 (7.5-12.6) 9.2 (7.6-12.6) 8.9 (7.5-12.2) 9.1 (7.5-12.7) 9.1 (7.5-12.7) 0.4783
Triglyceride † 1.5 (1.1-2.2 1.5 (1.1-2.1) 1.7 (1.3-2.5) 1.5 (1.1-2.2) 1.5 (1.1-2.2) 0.0005
mmol/L
Fasting Insulin † 13.0 (8.8-18.7) 13.0 (8.8-18.7) 15.8 (11.0-22.1) 12.5(8.6-18.3) 12.8 (8.7-17.5) < 0.0001)
(µ lU/mL)
Cholesterol 5.46 (1.1) 5.45 (1.1) 5.56 (1.3) 5.45 (1.2) 5.44 (1.1) 0.374
mmol/L
LDL Cholesterol 3.56 (1.0) 3.58 (1.0) 3.67 (1.1) 3.52 (1.0) 3.52 (1.0) 0.0944
mmol/L
HDL Cholesterol 1.07 (0.2) 1.07 (0.2) 1.06 (0.2) 1.06 (0.3) 1.07 (0.3) 0.779
mmol/L
HOMA-%B † 42.4 (23.7-65-3) 41.6 (21.8-65.4) 50.5 (30.5-73.9) 41.0 (23.4-62.8) 41.9 (23.7-64.9) < 0.0001
HOMA-%S † 49.6 (43.2-74.5) 51.9 (35.6-75.2) 50.5 (30.5-73.9) 40.9 (23.4-62.8) 41.9 (23.7-64.9) < 0.0001
†Median and i.q range, n is number of subjects belonging to each group.
Table 2.1: Baseline Variable Table
Matthews et al [48] and is a mathematical assessment of the interaction between β-cell function
and insulin sensitivity in an idealised model, through non-linear equations. HOMA is based on
physiological studies to develop mathematical equations describing glucose control as a feedback
loop. This model is calibrated to give normal beta-cell function of 100% and a normal insulin
resistance (IR) of 1. This is a computer model which is free to download and use. Insulin
sensitivity is the inverse of insulin resistance and thus also calibrated to give a normal insulin
sensitivity of 100%.
This chapter has outlined the UKPDS study, its aims and results found for the data which
will be used in the rest of the thesis. The varaibles defined in Table 2.1 were used for variable
selection for each treatment in chapter 3 and then subsequent model creations. Prediction of
HbA1c after the first year of treatment using linear regression models are done in chapter 3 and
then chapter 4 extends this to create a mixture model by splitting the data into components
of batches and then separate models are fited to the different groups. After this in chapter 5 a
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Wiener process degradation model is fit to the data to estimate future values of HbA1c as well
as to predict how long a patient can remain below a critical boundary.
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3
Model Selection and Bayesian Regression for Predicting HbA1c
Response to First Treatment.
This chapter will focus on creating a linear regression model for the prediction of HbA1c for an
individual after their first year of treatment. Firstly, to do this, variable selection is required
to determine which baseline variables to include in the model for each of the treatments. A
robust prior is introduced as a way to give results for variable selection with a stochastic search
algorithm to iterate through prospective models. After this the results from the robust prior
are given and then these variables are used to create a linear regression model for prediction of
HbA1c after 1 year of treatment. The model is then analysed through Bayesian P values and
rank histograms to highlight some of the issues when creating a single regression model.
Once treatment for diabetes has begun, an individual will usually see a sharp decrease in
their HbA1c levels. After this a subjects levels will slowly increase with some fluctuations over
time. Once HbA1c levels gets too high again then treatment will be added or changed according
to the NICE guidelines - see Figure 1.1. An example of a patients HbA1c over time after diagnosis
can be seen in Figure 3.1.
Figure 3.1 shows a typical response after treatment with a large initial drop, followed by
increasing non-monotonic levels. This means that an individuals response to a certain treatment
can be split into two different parts. First the initial drop in levels of HbA1c and then the
degradation over time. To begin with chapters 3 and 4 focus on this first initial fall in HbA1c.
In terms of personalising medicine it would be beneficial to be able to predict how an individual
would respond in the first year on a certain treatment, to then be able to prescribe them to the
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CHAPTER 3. MODEL SELECTION AND BAYESIAN REGRESSION FOR PREDICTING
HBA1C RESPONSE TO FIRST TREATMENT.
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Figure 3.1: Example Patients HbA1c over time.
best medicine. Also from here, sub groups of the population who respond best to certain drugs
may also be able to be found, which can then help to further personalised medicine as well as
drug development.
Therefore, the first thing of interest is to create a model with which one can predict an
individuals drop in HbA1c for each of the different treatments focused on in this thesis - insulin,
chlorpropamide, glibenclamide and metformin, using their baseline covariates which can be
measured at diagnosis. The natural first step here would then be to create a regression model.
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3.1. Bayesian Variable Selection
The first thing when creating models for regression, is to decide which variables to include within
the model. Consider a full linear regression model
yi = α+ x1iβ1 + · · ·+ xPiβP + i, (3.1)
i ∼ N(0, σ2).
Let X be the N×P design matrix for all subjects i = 1, . . . , N , α be the intercept coefficient
and βp, p = 1, . . . , P be the unknown regression coefficients for each of the P variables and define
the vector β = (β1, . . . , βP ).Y = (y1, y2, . . . , yN ) is N × 1 vector of outcomes. As having too
many variables in a regression model can overfit the data and hence give poor results on any
external data, variable selection must first be done to see which variables to include in the final
model.
For each possible model one can define a corresponding γj = (γj1, . . . , γjP ), a P dimensional
binary vector with γjp = 1 if βp 6= 0 for model j and hence is included in the model and 0
otherwise, j = 1, . . . , 2P . This then generates a corresponding Xj , a design matrix which
includes only covariates with γjp = 1 and a vector of regression coefficients βj including only
the non-zero γj variables. Then each γj has a corresponding model Mj with Pγj variables.
By setting M0 to be the null model where γ0 = (0, . . . , 0), the full set of models are
M0 : f0(Y |α, σ) = N(Y |Iα, σ2I), (3.2)
Mj : fj(Y |α,βj , σ) = NPγk (Y |Iα+Xjβj , σ2I),
j = 1, . . . , 2P .
In this design the only variable common to all models is α the intercept. For all the common
variables it would be standard to define X0 to be the N × l0 design matric corresponding to the
l0 variables common to all models and in this case l0 = 1 - the intercept α. This then means
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that X0 is equivalent to the identity matrix I. Xj is the N × lj design matrix including lj of
the P possible explanatory variables, those which are included in model Mj .
3.1.1. The Principle of Parsimony
A critical issue when making inferences is “what is the best model to use”. A true model as
such cannot be explicitly found and so model selection is more about the art of approximation.
It is known that a poor model will in turn generate poor inferences. For regression models,
an estimate of any unknown parameters θ, given the data and a defined model can be found.
However, it still does not answer the question of the best model for formulating inferences. Thus,
in this case variable selection to create the best model is essential. This ‘best’ model needs to
be objective and repeatable, and based on the principle of parsimony highlighted by Box and
Jenkins [49]. The principle essentially addresses the question that if fit is consistently improved
by a model with more parameters then when should we stop? Box and Jenkins stated that this
should be the “smallest possible number of parameters for adequate representation of the data”.
To achieve this a bias versus variance trade off is required. As the number of parameters
increases, the bias decreases but the variance increases, so the ideal number should create a
balance of the two. This was illustrated by Burnham and Anderson [50] and is shown in Figure
3.2.
All model selection problems are based to some extent on this principle which is crucial to
avoid both overfitting and underfitting of a model. Underfitting of a model may miss important
treatment effects, which would lead to poor inferences. On the other hand overfitting a model
may then be free of bias in the estimates, but the estimates and actual sampling variance will be
needlessly large. An overfitted model would be seen to be unstable and tailored too much the
data which the model is trained on, which is then likely to vary considerably if other sampled
data were to become available. This subsequently leads to predictions well below what would
be expected, on any external data.
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Figure 3.2: The Principle of Parsimony
3.1.2. Bayes Factor
To calculate the so-called “best model”, a standard way of doing this within Bayesian inference is
to calculate the Bayes Factor [51], which is a standard way of comparing two competing models.
The probability of a model given the data can be calculated by
Pr(Mj |Y ) = Bj0
1 + (
∑2P−1
h=1 Bh0P0)
, (3.3)
where
Bj0 =
mj(Y )
m0(Y )
, (3.4)
mj(Y ) =
∫
fj(Y |α,βj , σ)pij(α,βj , σ)dαdβjdσ, (3.5)
P0 =
1
2P
. (3.6)
Bj0 is defined to be the Bayes Factor between model j - Mj and the null model - M0, with
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a higher value equating to “better” model. pij(α,βj , σ) is the prior probability of the unknown
parameters and P0 is the prior probability of the model which here is assumed to be equal for
all models.
Although calculating the Bayes Factor and finding the optimal model seems easy, when
there is a large number of variables, the number of models increases greatly. For example, with
P = 40, the number of possible models is equal to 240 ≈ 1012 different models. Just storing the
binary vectors for each model would take around 5 terabytes of memory. Therefore, calculating
the Bayes Factor and comparing them for each possible model would be unfeasible. Also (3.5)
is a high-dimensional integral which can be difficult to compute, meaning that a closed form
Bayes Factor would be beneficial when estimating the “best model” for prediction.
3.2. The Robust Prior
To decide which variables are to be included within the model the robust prior is introduced as
a way of determining which model gives the highest corresponding Bayes Factor. This section
will outline the criteria behind the creation of this prior and outline how this can be run to give
an estimate for the “best model”.
For each model j, j = 1, . . . , 2P there are the regression coefficients βj , the intercept α and
the standard deviation σ, which are unknown quantites and thus need estimating.
There are many arguments concerning the choice of priors for variable and model selection
mainly since these can be seen to be highly sensitive and cannot be improper, which was first
highlighted by Jeffreys [52] and the arguments surrounding the choice are often called Jeffreys
desiderata [53].
It is known that when models have differing dimensions and non-common parameters, results
are typically highly sensitive to the choice of priors for the non-common parameters. Unlike in
estimation, this does not vanish as the sample size grows and as such the choice of prior is critical,
see Kass and Raftery [51]. This means that criteria for creating the model are essential and the
method used for choosing these priors was outlined by Bayarri et al [54] and will be explored in
the next section. This method was chosen over other similar priors, due to its derivation, which
was all pursuaded by criteria to make the model selection process as robust as possible.
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3.2.1. Criteria for the Robust Method of Variable Selection
The robust method builds on ideas from others to try and take into account all the criteria for
model selection and to begin the main criteria for this model are outlined.
Criterion 3.1. Basic Criterion - Each conditional prior pij(βj |α, σ) must be proper and not
vague.
From (3.5) it is seen that when calculating the posteriors for the model, priors for α and βj
are needed and are of the form
pij(α, σ,βj) = pij(α, σ)pij(βj |α, σ). (3.7)
Hence, it can be seen that the prior for the βj cannot be improper or vague (large variance) as
this would violate the ‘basic criterion’ and would make a Bayes Factor (3.4) essentially arbitary.
Criterion 3.2. Group Invariance Criterion - If all models are invariant under a group of
transformations G0, then the conditional distribution pij(βj |α, σ) should be chosen so that
fj(Y |α, σ) =
∫
fj(Y |α, σ,βj)pij(βj |α, σ)dβj , (3.8)
are also invariant under the group of transformations G0.
It is useful to note that all models in (3.5) are invariant under the group of transformations
G0 = {g = (c, b) ∈ (0,∞) : g(Y )→ cY +X0b}, (3.9)
and as such Criterion 3.2 holds.
Since all models are invariant (3.9) and from the group invariance criterion then the func-
tional predictive distribution must be also.
Result 3.3. The conditional marginals in (3.8) are invariant under G0 if and only if pij(βj |α, σ)
is of form
pij(βj |α, σ) = σ−ljhj
(
βj
σ
)
. (3.10)
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For the proof see Bayarri et al [54].
So βj must be scaled by σ, centered at 0 and not depend on the intercept α.
Criterion 3.4. Predictive Matching Critera - All priors should be appropriately “matched”
across models of different dimensions.
It is therefore proposed to use pij(α, σ) = σ
−1, the right-Haar density as proposed by Berger,
Pericchi and Varshavsky [55].
pij(α, σ) = σ
−1. (3.11)
This then leads the model prior to be of the form
pij(βj , α, σ) = σ
−1−ljhj
(
βj
σ
)
. (3.12)
Result 3.5. For a given model Mj, let the prior be of the form (3.12), where hj is symmetric
about zero. Then all the model prior pairs {Mj , pij} are exact predictive matching for n∗ = l0 +1.
For the proof see Berger, Pericchi and Varshavsky [55].
Therefore, if hj is then chosen to be such that is symmetric around 0, then the model and
prior pairs {Mj , pij} are exact predictive matching for n∗ = l0 + 1. Thus showing that for
appropriate hj , the predictive matching and group invariance criteria hold. The robust prior is
a particular form of hj in (3.12) with
hRj (u) =
∫
Nlj
(
u|0, g(V Tj Vj)−1
)
pRj (g)dg (3.13)
,
where
Vj =
(
In −X0(XT0 )−1XT0
)
Xj . (3.14)
Since this hRj has a scale matrix proportional to (V
T
j Vj)
−1 and it can be shown that no
conditional scale matrix other than this leads to full predictive matching for sample size of l0+lj ,
the proof of this can be found in the paper by Bayarri et al [54]. This seems to then strongly
support the robust prior which will be shortly outlined in full. Another advantage of having the
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conditional scale matrix of (V Tj Vj)
−1 is that the Bayes Factor will be unaffected by changes in
the units of measurements for either the outcome variable Y or the model parameters. Thus
any scaling which will be required will not affect the outcome of the model selection parameters.
The full form of the robust prior using the above mentioned criterion is proposed to be
pij(α,βj , σ)
R = σ−1 ×
∞∫
0
Nj(βj |0, gΣj)ρRi (g)dg, (3.15)
where
Σj = Cov(βˆj) = σ
2(V Tj Vj)
−1, (3.16)
which is the covariance of the maximum likelihood estimator of βj and
Vj = (In −X0(XT0 )−1XT0 )Xj , (3.17)
with X0 the initial model matrix and Xj the current model matrix. Finally set
ρRi (g) = a[%i(b+N)]
a(g + b)−(a−1)1g≥%i(b+N)−b, (3.18)
for
a > 0, b > 0, %i ≥ b
b+ n
The full conditional of the βi induced by (3.15) generalises the robust prior considering the
sampling distribution of the maximum likelihood estimator, namely
βˆj ∼ Nlj(βj , σ2(V Tj Vj)−1). (3.19)
Many priors have previously been considered for the values of a, b and %, namely Liang
et al [56] who proposed the hyper-g prior with a = 1/2, b = 1, % = 1/(1 + N) and Cui and
George [57] with a = 1, b = 1 and % = 1/(1 +N).
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However, these choices of the hyperparameters can be seen to violate some criteria for model
selection outlined by Bayarri [54] which are based on Jeffreys desiderata [52]. For example, the
consistency criteria which is split into 3 seperate parts.
Criterion 3.6. Consistency Criteria -
• Model Selection Consistency - If Y has been generated by a model Mj, then the
posterior probability of Mj should converge to 1 as N tends to ∞.
• Information Consistency - Consider a sequence of data vectors for which the corres-
ponding F (or t) values tend to ∞, then the corresponding Bayes Factor should do so
also.
• Additional Consistency - The prior for the models specific parameters of a model Mj
- pij(βj |α, σ, n), should converge to a proper prior pij(βj |α, σ) as N tends to ∞.
These consistency criteria can provide guidance to a suitable choice to a, b and %.
Result 3.7. The consistency criteria are satisfied by the robust prior (3.15) if a and % do not
depend on N , limN→∞ bN = c ≥ 0, limN→∞%j(b+N) =∞ and n ≥ l0 + lj + 2a.
For the full proof see the full proposed method by Bayarri et al [54] and the subsequent
choice of a, b and % are outlined below.
For the robust prior, it can be seen that an information consistent Bayes Factor between two
models Mj and M0 only occurs if and only if N ≥ lj + l0 + 2a and also that N ≥ lj + l0 + 1
and therefore a ≤ 1/2. a = 1/2 is consistent with the choice of Berger and this also gives the
robust prior (3.15) Cauchy tails, which makes the choices robust and fits with other proposals
of parameters by Jeffrey [52] .
For the choice of b and % one should consider the affect of them on the robust prior with
a = 1/2, by considering the intrinsic prior (when b/n→ c)
pRj (g
∗) =
1
2
[%j(c+ 1)]
1/2(g∗ + c)−3/21{g∗>%j(c+1)−c}. (3.20)
This is flat-tailed distribution and so only the choice of the median 4%j(1+c)−c is important.
For the choice of the median one does not need to consider both % and c as they are confounded
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and so for simplicity c = 0 is chosen. As b/N → c = 0, the choice of b is arbitary. Hence for
computational purposes b = 1 is chosen.
The choice of %j is then the hardest choice to make. Many previous examples have % depend-
ent on N , however this violates the consistency criteria previously stated. Since it also must be
the case that %j ≥ 1/(1 +N) for g > 0 and N ≥ l0 + lj and so it is chosen for % ≥ 1/(l0 + lj) as
this is seen to be the smallest possible value of %j .
For this case the values set by Bayarri et al are used [54] with a = 1/2, b = 1 and %i =
(l0 + l1)
−1.
This prior is seen to be a good fit for model selection and one of the main advantages of
it is that it creates closed form inferences for the Bayes Factor. Thus meaning that the Bayes
Factor can be calculated for each given model Mj and is therefore easier to compare models.
Calculations can be done to show that the Bayes Factor for the model Mj compared to the null
model M0 is
Bj0 =
[
N + 1
lj + l0
] lj
2 Q
−N−l0
2
j0
lj + 1
F1
[
lj + 1
2
;
N − k0
2
;
lj + 3
2
;
(1−Q−1j0 )(lj + l0)
(1 +N)
]
. (3.21)
where F1 is the standard hypergeometric distribution [58] and Qj0 = SSEj/SSE0 is the
ratio of the sum of squared errors of models Mj and M0. To implement the model selection
a prior odds ratio Pj0 is also needed and in this case, it was chosen for all models to have an
equal probability as stated in (3.6).
As the robust prior leads to the conditional for βj to be the maximum likelihood estimate
(3.19) then it is known by standard theory that this can be calculated by
βˆj =
(
XTj Xj
)−1
XTj Y , (3.22)
where Xj is the design model for the model Mj and the vector of parameters βj is the
corresponding parameter estimates. The SSEj for each model can be calculated without having
to explicitly calculate the entire model estimates for not only βj but also for σ. The error of a
linear regression ej is known to be
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ej =Y −Xjβˆj
= Y −Xj
(
XTj Xj
)−1
XTj Y . (3.23)
Then then SSEj is e
T
j ej which can be simplified to be
eTj ej =
(
Y −Xj
(
XTj Xj
)−1
XTj Y
)T(
Y −Xj
(
XTj Xj
)−1
XTj Y
)
= Y TY − Y TXj
(
XTj Xj
)−1
XTj Y
= Y
(
I−Hj
)
Y , (3.24)
where
Hj = Xj
(
XTj Xj
)−1
XTj Y . (3.25)
This then means that the full closed form of the Bayes Factor given in (3.21) can be calculated
with help from (3.24) without any need for the estimation of the parameters for each individual
model to actually be obtained. This helps with both calculations and time constraints making
it easier to deal with computationally.
3.3. Model Selection Through Gibbs Sampling
By using the robust prior explained in the section before, closed form inferences for the Bayes
Factor (3.21) can be found. However, as previously stated there are 2P different models and as
such, too many to calculate probabilities for all of them. Instead a Monte Carlo Markov Chain
Gibbs Sampler was used to sample some of the models, to try to converge to the best model.
This method is a form of a stochastic search variable selection (SSVS) and will be used to give
the “best model” by iterating through models.
Another way in which one could sample some of the models is to use the Metropolis-Hastings
Algorithm. This method uses a proposal distribution and an acceptance distribution. The al-
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gorithm simulates samples from a probability distribution by making use of the full joint density
function and independent proposal distributions for each of the variables of interest. It begins
by initialising a sample value for each of the random variables which is usually sampled from the
prior distribution. The next step is to propose a sample or candidate value xc from the proposal
distribution p(xi|x(i−1)). Then, differently to other methods such as Gibbs sampling, one then
computes an acceptance probability for this sample. The acceptance probability α(xc|x(i−1)),
which is based on the proposal distribtution and the full joint density is computed and the
sample is then accepted with a probability of 1 − α. Then if the candidate is accepted the
sample transitions to the value, if not then nothing is updated. This method has many advant-
ages, however the acceptance rate and therefore overall mixing rate is dependent on σ2 with
small variances meaning a high acceptance rate and thus the mixing to converge will be slow,
yet large variances will mean the acceptance rate is very low.
Both the Gibbs Sampling and the Metropolis-Hastings algorithm could be used, however, in
this scenario and the rest of the thesis it was chosen that the Gibbs sampler would be used.
Once the parameters have been integrated out of the model stated above, the only unknowns
are the actual variables in the model. Set γ = (γ1, . . . , γP ) to be a P-length binary vector, where
each componenet γp is set to be 1 if the corresponding variable xp is in the given model and 0
otherwise.
The method then proceeds as follows. For each iteration r = 1, . . . , R, simulate the value of
each γp to see whether the corresponding variable xp is to be included in the model for the given
iteration r for each parameter p = 1, . . . , P . To do this at each iteration r and each variable xp
and its corresponding γp set up two binary vectors
a = (γ1, . . . , γp−1, 1, γp+1, . . . , γP ), (3.26)
b = (γ1, . . . , γp−1, 0, γp+1, . . . , γP ),
where γ1, . . . , γp−1, γp+1, . . . , γP are given from the model at the previous iteration r − 1.
Once this is done, calculate the Bayes Factor using ( 3.21) for both the model vectors given by
Ba0 for model a and Bb0 for model b and then calculate
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ϕp =
Ba0
Ba0 +Bb0
. (3.27)
This ϕp will be between 0 and 1 and will be closer to 1 if Ba0 is large compared to Bb0 and
vice versa. Then the value of γp for the next iteration (0 or 1 by definition of γp) can be sampled,
given the other variables and the data from
γp|γ1, . . . , γp−1, γp+1, . . . , γP ,Y ∼ Bernoulli(ϕp). (3.28)
This is repeated for all γp at each iteration and is then simulated through R iterations usually
with some burn in period. Using these results variable and model selection can begin for the
standard linear regression model.
3.3.1. Model Selection for the UKPDS Data
From initial results, change from baseline HbA1c was predicted as this has less variability than
predicting the HbA1c after 1 year. This is the difference between the baseline HbA1c and the
value at 1 year,
HbAd1c = HbA
b
1c −HbA1y1c , (3.29)
where HbAd1c is the difference that is being predicted, HbA
b
1c is the baseline value so that at
diagnosis of diabetes and HbA1y1c is the level of HbA1c after 1 year of treatment.
To help provide personalised medicine tools, prediction models for each separate treatment
at baseline (insulin, metformin, chlorpropamide and glibenamide) were created and thus variable
selection for each of the treatmenta was required. For each treatment only patients with initial
monotherapy on that specific treatment for at least 1 year were considered to maintain only that
specific therapies effect on the individuals.
The variable selection algorithm outlined above was run using the robust prior. The al-
gorithm gives many summaries of the posterior distribution which can then be used to help
build the model, which are discussed below.
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3.3.2. Summaries of the Variable selection Gibbs Sampler
The Highest Posterior Probability Model (HPM), is the most probable model given the data, or
the model visited with the highest associated Bayes Factor. That is
HPM = arg max
j∈1,...,2p
p(Mj |Y ). (3.30)
Another important criteria to consider is the inclusion probabilites - the probability each
variable has of being included in the model. Given a variable xp the inclusion probability qp is
calculated as
qp =
∑
Mj γp=1
p(Mj |Y ). (3.31)
These inclusion probabilities have some interesting properties and can especially be useful
when the number of models is large and so the posterior probability of a single model may be
essentially useless and as such the HPM model may not be the best choice for selection. In this
case the Median Probability Model (MPM) may be chosen, which takes includes all variables
where qp ≥ 0.5. Surprisingly Barbieri and Berger showed [59] that often the MPM has better
predictive performance than the HPM, which may be due to the comparitively small number of
possible models the SSVS method reaches in comparison to the actual amount of models. When
the HPM has a substantially higher posterior probability, then this is typically seen to be the
MPM model also. For this reason the MPM model will be carried forward for the analysis and
compared for sensitivity analysis with the HPM model.
3.3.3. Variable Selection Results
Using the robust prior the stochastic search algorithm was run and this gives summaries of the
variables included in form of the highest probability model (HPM) and the median probability
model (MPM). Since the MPM is shown to give best results in terms of predictions it was this
which was carried forward for the analysis. In actual fact it was seen that for insulin, metformin
and glibenclamide that the HPM and MPM were equivalent. Chlorpropamide included one less
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variable (age), however this did have an inclusion probability of 0.589 and age known to have
an effect on diabetes it was included in the model.
To predict which variables should be included in the regression models for estimating change
from baseline for HbA1c after 1 year, for subjects in the UKPDS dataset, there were 18 initial
variables and a further 7 interaction variables for covariates with a high correlation leading to
P = 25 and thus 225 = 33554432 differing models. The variables considered for variable selection
are outlined previously in the baseline Table 2.1.
Correlations over 0.2 between 2 variables was used as an indicator to which interaction terms
should be involved in the model. A list of the interaction terms and their respective correlation
coefficient for the entire dataset is given in Table 3.1.
Interaction Term Correlation Coefficient
HbA1c × FPG 0.77033
HOMA-%B × HOMA-%S -0.3254
LDL Cholesteror × Cholesteror 0.8307
Systolic BP × Diastolic BP 0.6907
BMI × HOMA-%S -0.2305
FPG × HOMA-%B -0.5932
Table 3.1: List of Interaction Terms
As there are too many models to individually compare, the SSVS methodology was used,
with the null model as the initial starting point.
To try and cover as large a sample as possible the SSVS algorithm was run for 30,000
iterations. As this method started with the null model (intercept only), some burn in was
required to allow the algorithm to get closer to the actual ‘best’ model and thus a burn in of
5,000 iterations was discarded from the results. After this the remaining models were summarised
to give the HPM, MPM and inclusion probabilities.
The variable selection procedure was run on all the complete data with no missing values
for each of the treatments and the results are listed in Table 3.2. This gives both n, the number
of subjects with no missing data and the inclusion probabilities to see that these are over 0.5 in
every instance as only those included in the MPM model which have qp ≥ 0.5 are listed in the
Table 3.2.
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Treatment n Variables Included in Inclusion No. of models visited
the MPM model Probability including variable
Insulin 164 HbA1c 1.000 25000
HbA1c× FPG 0.998 24950
Fasting Plasma Glucose (FPG) 0.719 17975
BMI 0.592 14800
Age 0.544 13600
Race 0.539 13475
Metformin 98 HbA1c 1.0000 25000
Fasting Insulin 0.892 22310
HOMA−%B 0.876 21900
HOMA−%S 0.621 15525
HOMA−%B ×HOMA−%S 0.599 14975
Triglycerides 0.518 12950
Chloropropamide 128 HbA1c 1.000 25000
Fasting Plasma glucose (FPG) 0.965 24125
Systolic Blood Pressure 0.929 23235
Race 0.599 14975
Age 0.589 14725
Glibenclamide 143 HOMA−B% 0.994 24850
HbA1c 0.992 24800
BMI 0.839 20975
Gender 0.721 18025
Race 0.702 17550
HDL Cholesterol 0.590 14750
Table 3.2: Variable Selection Results for each Treatment
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To check sensitivity on this variable selection process, the stochastic search algorithm was
run a number of times starting from the null model, the full model (all γp = 1) and also from
random starts. Each run resulted with the same variables being inclueded in the MPM model,
the probabilities of inclusion do differ slightly but the conclusions are the same.
3.3.4. Implications of Variable Selection
It can be seen from Table 3.2 that HbA1c consistently has a high probability of inclusion in all 4
models, which is unsurprising as this is obviously highly correlated with the outcome of interest
which is the predicted HbA1c change after one year and as such the baseline value will be very
important. In all models, this has an inclusion probability of almost 1, meaning that almost
all the models the SSVS algorithm searched through, for all 4 treatments, included HbA1c as a
predictor.
Age which is a well known predictor of risk in diabetes is also present in the MPM models
except for glibenclamide and metformin, which may mean those individuals of an older age may
be better suited to one of these treatments. However, from these results not too much about the
actual association with HbAd1c (the change in HbA1c) can really be fathomed until the regression
model has been run and the coefficients have been determined and more essentially the sign of
the coefficients.
For the variable selection method it was decided that these set variables would be chosen for
the final model and a new model run to determine the estimates, rather than a Bayesian model
averaging approach. The Bayesian Model averaging approach effectively averages predictions
and models over all those found from the posterior distribution, after a burn in and this may
include only every 10th or so iteration to reduce auto-correlation. This allows one to now base
all inferences on one sole model, instead of using more information gathered from the posterior
samples which the Bayesian Model averaging approch does. It can also be seen that using this
method generates better predictive ability then one sole model. Although, this would then
appear to be advantageous, it does lead to some problems with reproducability. By using this
approach with a whole number of variables, it would then require much more information to be
known about an inividual to create a prediction for them. Although, one can determine which
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variables are giving more weight to the estimate it is not as easy to fathom how they are changing
the predictions individually as a variable. Therefore, it means that one cannot determine how
exactly one variable will change the estimate of response. This then means that it cannot be
compared between models such as that, for example, a high cholesterol may lead to a better
response on a certain treatment. By using Bayesian Model selection also, one would need to run
this long iterative method each time a prediction may be required and this cannot be reproduced
to generate an actual set prediction for an individual in an easy manner for clinicians, say, to
generate. Since the motivation behind this thesis was to create predictions for individuals with
diabetes to see which treatment may be best suited to them, a set model is better suited to this
use then a model average and therefore this was used not only for variable selection but also
throughout the rest of the thesis.
3.4. Invertibility
As was shown in the previous section, by having a conditional scale matrix of (V Tj Vj)
−1 the
model output Bayes Factor is unaffected by any changes in the units of measurement. After some
initial results there were some doubts as to whether a linear model was the right fit. This was
therefore explored to see whether any changes to the initial model or parameter measurements
were required.
3.4.1. Generalised Inverse Solution
In the case of a standard linear regression, yi = α + β1x1 + · · · + βP−1xP−1, G is simply the
data matrix X with an additional column at the beginning containing 1’s for the intercept α,
so is an N × P matrix.
G can be factored into a singular value decomposition (SVD)
G = USV T , (3.32)
where
• U is an N by N orthogonal matrix with columns that are unit basis vectors spanning the
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data space RN .
• V is a P × P orthogonal matrix with columns that are basis vectors spanning the model
space Rp.
• S is a N × P diagonal matrix with diagnoal elements called singular values.
Every matrix can be seen to have a singular value decomposition [60]. The singular values
of S can be seen to be zero, if the first p values are non-zero then S can be partitoned as
S =
Sp 0
0 0
 . (3.33)
Then by defining the first p columns of U and V to be Up and Vp respectively, the SVD of
G can be simplified into its compact form
G = UpSpV
T
p . (3.34)
The SVD ofG can be used to find the generalised inverse - the Moore-Penrose psuedo inverse
[61] [62].
G∗ = VpS−1p U
T
p . (3.35)
Then this inverse can be used to find the solution for a model.
m∗ = G∗d
= VpS
−1
p U
T
p d. (3.36)
Using this inverse to find a solution, it can be seen that m∗ is also the least squares solution
[63].
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3.4.2. Resolution Matrix
To characterise the bias of a generalised inverse solution a model resolution matrix can be
assessed. This can be used to see how closely the solution matches a given model. Begin with
a model mtrue, and when this is multiplied by the data model matrix G, it gives dtrue. Thus
meaning that when G∗ is multipled by dtrue this gives the generalised inverse solution.
m∗ = G∗Gmtrue. (3.37)
The best solution would ideally then be when m∗ is equal to mtrue, however in general this
is not the case. So instead the model resolution matrix is assessed, to characterise the effect.
Rm = G
∗G
= VpS
−1
p U
T
p UpSpV
T
p
= VpV
T
p . (3.38)
The resolution matrix is a nonidentity symmetric matrix which characterises how the gen-
eralised solution smears out the original model. If the trace of Rm is close to the number of
parameters, then the resolution matrix is close to identity matrix, as desired.
For the UKPDS full data set, the resolution matrix was found to be very close to the identity
matrix, with the trace being equal to the number of parameters and all other values being very
close to 0 with all being ≤ 1−16. Thus showing that a general linear model can be considered a
good fit and all variables could be included. This was also tested separatly for each treatment
after variable selection had been done and the model resolution matrix was also found to be of
a good fit in this case and thus the model in (3.1) holds.
3.4.3. Condition Number
Since the model resolution matrix was found to be of a good form, the next port of call when
considering the model would be to look at the condition number. The condition number gives
46 3.4. Invertibility
a value of the instability of the model, or how small changes in the data d will affect the model.
Start with the formula for the general solution and this can be written using a linear com-
bination of the columns of Vp.
m∗ = VpS−1p U
T
p d =
p∑
i=1
UT.,id
si
V.,i. (3.39)
The presence of a small si in the denominator in ( 3.39) will give a large coefficient for
the model space basis vector V.,i, which can then dominate the solution. The measure of the
instability can then be found by the condition number. To do this assume that there is a slightly
perturbed data vector d′, with an associated generalised inverse solution also m∗′ . Then
m∗ −m∗′ = G∗(d− d′), (3.40)
||m∗ −m∗′ ||2 ≤ ||G∗||2||d− d′||2. (3.41)
Then using the fact that the largest difference in the inverse model will occur when d − d′
is in the direction of U.,p and that the inverse model is smallest in norm when d points is in the
direction of V.,p it can be shown that
||m∗ −m∗′ ||2
||m∗||2 ≤
s1
sp
||d− d′||2
||d||2 . (3.42)
Using (3.42), it can be seen that this will change dramatically based on the values of the
singular values. The condition number is then defined to be
Cond(G) =
s1
sk
. (3.43)
In the case with the UKPDS data, it is seen that all the singular values are non-zero and
thus here k = P .
Regression models for insulin change from baseline were considered when looking at this
initially. After variable selection had been performed, there were 6 parameters and the intercept
found to be the best for prediction. The model resolution matrix looked fine for this, however,
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the condition number was found to be 2015. This is a high number and shows that a small
deviation in the data, could change the model parameters a lot. This could be thought to be
down to the non-normality of many of the variables. Therefore, transformations of the variables
were performed to make them as close to coming from a normal distribution as possible. Once
this was complete, the condition number dropped to 168, however, this could still be seen to be
too high. Due to the nature of the variables in question, many of these were found to be on very
differing scales, which could be impacting the instability in the model. To counteract this, all
variables were then scaled, so that they had a mean of 0 and a standard deviation of 1. Using
this data, a condition number of 1.6 was seen. From this, it was decided to use the scaled data
to perform the regression.
The same method was applied to the other 3 treatments and these also had a drastically
reduced condition number after scaling had been applied on the input variables. The condition
numbers for metformin, chlorpropamide and glibenclamide were 2.3, 1.1 and 3.5 respectively.
These seem to be sufficient and thus it can be seen scaling the data brings much more stability
to the model.
3.5. Linear Regression Methods
Once the variable selection was completed and the variables for use in the model were found via
the median probability model, the next step was to create a linear regression model to predict
the change in HbA1c - HbA
d
1c after 1 year of treatment for all 4 of the treatments. This next
section outlines the linear regression model, first for Frequentist and then for Bayesian analysis
to create a prediction model for HbA1c after the first year of treatment. The standard frequentist
way of doing this is to use the least squares method.
3.5.1. Least Squares Linear Regression
In classical least squares regression models, the aim is to find the regression coefficient estimates
βˆ of β which minimises SSR(β), where
SSR(β) =
∑
(yi − xiβ)2 = (y −Xβ)T (y −Xβ), (3.44)
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where
y = (y1, y2, . . . , yN ). (3.45)
This is minimised if (y −Xβ) is orthogonal to X
0 = XT (y −Xβ)⇔Xy = XTXβ, (3.46)
βˆols = (X
TX)−1XTy.
This method also gives us the unbiased variance estimate
σˆ2 =
1
N − P
∑
(yi − xiβˆols)2, (3.47)
V (βˆols|σ2) = σ2(XTX)−1 ≈ σˆ2(XTX)−1.
Using maximum likelihood estimation in which the aim is to find βˆ, σ2 to maximise p(y|X,β, σ2),
it comes out as
βˆmle = βˆols, (3.48)
ˆσ2mle =
1
N
∑
(yi − xiβˆmle)2.
When using Bayesian methods to create a regression model, semi-conjugate priors can be
used, which when non-informative priors are used, give similar results to the maximum likelihood
method. Using Bayesian methods, a likelihood is placed on the data, in this case a normal
Guassian distribution and then prior distributions are given for the unknown parameters. From
here the posterior distribution and full conditionals can be found and iterative methods are used
to update the unknown parameter estimates.
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3.5.2. Priors of the Bayesian Gaussian Regression Model
To create a Bayesin linear regression model one needs to calcaulate the posterior which is pro-
portional to the likelihood multiplied by the prior. In this case the likelihood is assumed to come
from a normal Gaussian distribution. Then one needs to define the prior distributions and from
here the conditional distributions for each unknown parameter can be found.
For the unknown parameters of β and σ2, standard semi-conjugate priors are assumed
β ∼MVN(β0,Σ0), (3.49)
σ2 ∼ inverse− gamma(ς0/2, ς0σ20/2). (3.50)
Then given the outcome y = (y1, y2, . . . , yn), the likelihood y|Xβ, σ ∼Multivariate-Normal(Xβ, σ)
and as such full conditionals for β and σ can be found.
To begin, consider p(β|σ,y,X), which is given a multivariate normal prior distribution with
parameters β0 and Σ0, such that
p(β) = |2piΣ0|−1exp{−1
2
(β − β0)TΣ−10 (β − β0)}. (3.51)
It can be shown that the full conditional for β is proportional to the prior of β and the
likelihood of the data p(y|β,X, σ) since
p(β|σ,y,X) ∝ p(β|X, σ,y) = p(β)p(y|β,X, σ). (3.52)
The likelihood of the data y is assumed to be normal also and thus this is of the form
p(y|β,X, σ) = (2piσ2)−N/2exp{−1
2
(y −Xβ)T (y −Xβ)/σ2}. (3.53)
When calculating full conditionals, only proportionality is required and so in the case of
the conditional for β, only parts inside the exponential are required and hence these can be
expanded out
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Prior : (β − β0)TΣ−10 (β − β0) = βTΣ−10 β − 2βTΣ−1β0 + βT0 Σ−1β0, (3.54)
Data : (y −Xβ)T (y −Xβ)/σ2 = yTy/σ2 − 2βTXTy/σ2 + βTXTXβ/σ2. (3.55)
Since the prior and the likelihood need to be multiplied to calculate the full conditional and
( 3.54) and ( 3.55) are looking at the terms inside the exponential, these need to be added
together. Since only proportionality is required, any terms not involving β can be discarded
Prior ×Data : βT (Σ−10 +XTX/σ2)β − 2βT (Σ−10 β0 +XTy/σ2) + . . . (3.56)
It is known that a vector z can be defined as a multivariate normal with mean m and
variance matrix V if and only if p(z|m, V ) ∝ exp{−12(zTV −1z − 2zTV −1m)}. Hence ( 3.56)
fits this form and so β is normal with mean m and variance V where
V −1 = Σ−10 +X
TX/σ2, (3.57)
m = V (Σ−10 β0 +
1
σ2
XTy). (3.58)
To be consistent with the prior, the unknown parameters are labelled as βn and Σn, and
thus
β|y, σ,X ∼MVN(βn,Σn), (3.59)
Σ−1n = Σ
−1
0 +
1
σ2
XTX,
βn = Σn(Σ
−1
0 β0 +
1
σ2
XTy) = (Σ−10 +
1
σ2
XTX)(Σ−10 β0 +
1
σ2
XTy).
Next the full conditional for σ2 can be found in the same way as above. The conditional for
σ is proportional to the prior multiplied by the likelihood, where
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p(σ2|β,y,X) ∝ p(σ2)p(y|σ,β,X), (3.60)
∝ {(σ2) ς02 +1e
ς0
2
σ20
σ2 } × {(σ2)n2 e −12σ2
∑
(yi−xiβ)2},
= (σ2)−
ς0+N
2 exp{−1
2
[ς0σ
2
0 +
∑
(yi − xiβ)2]/σ2}.
The last line of ( 3.60) is seen to be the kernel of an inverse gamma distribution and so it
has been shown
σ2|β,y,X ∼ inverse− gamma[1
2
(ς0 +N),
1
2
(ς0σ
2
0 +
∑
(yi − xiβ)2]. (3.61)
It can then be seen that the priors, which were set for β and σ in ( 3.49), are said to be
semi-conjugate priors. This is since the prior distributions originally stated, are the same as the
full conditionals for these unknown parameters which we get from ( 3.59) and ( 3.61). With the
β being normal and σ being inverse gamma. The distribution of β given σ, does not depend on
σ.
Often when doing regression of this form, a non-informative prior is placed on the variance
β by making Σ0 very “large”, or the precision very “small”, in a sense saying that theres is no
prior information set about these values. When this is done the estimate of β can be seen to be
almost the same as found by the maximum likelihood method in ( 3.46). When Σ0 is large Σ
−1
0
is almost zero, hence
Σn ≈ σ2(XTX)−1, (3.62)
(3.63)
then
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βn = σ
2(XTX)−1
1
σ2
XT y
= (XTX)−1XT y = βˆmle.
Since the full conditionals have been found, a Gibbs sampling method can be used to estimate
values of β and σ for the normal Bayesian regression model. Given starting estimates for
the unknown parameters β0 and σ0, the following routine can be run using the conditional
distributions from ( 3.59) and ( 3.61).
• Sample β(l+1) ∼ p(β|σl,y,X),
• Sample σ(l+1) ∼ p(σ|βl,y,X).
This can be run for a total R iterations and a burn in of M will be discarded. Then inform-
ation for these estimates can be found from taking every, say mth, value (based on correlations)
from M + 1 to R from the iterations.
3.6. Convergence of the Regression Model
Once the Gibbs Sampler has been run this needs to be assessed through plots and diagnostics
to see whether the sampler needs to be run for any longer and also whether any thinning needs
to be done. To do this it was chosen to initially look at the autocorrelation between iterations
to see whether any thinning is required. Then after this the Raftery-Lewis diagnostic can be
calculated which gives a value for the number of iterations required to reach convergence and
how much burn in may be required. Finally, once the model has been run with for the required
number of iterations and burn in with thinning applied the convergence of two separate chains
starting at disperse starting values can be assessed via Gelman-Rubin plots and statistics. Trace
plots can then also be visually inspected to ensure that there is good mixing between the chains
with an equal mean throughout.
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3.6.1. AutoCorrelation
Autocorrelation between iterations for the variables is important to see whether any thinning
needs to be performed on the iterations. This means that, for example, only every 10th value
would be taken for analysis from the resulting posterior. Autocorrelations can be computed for
the lag between iterations (see Appendix A.3.3. for details) and plotted in an autocorrelation
plot.
In general very little autocorrelation was seen for the variables for all treatments, some
variables however, saw little correlation and as such every 10th value was used for this reason.
For illustrative purposes, plots for insulin only will be displayed within the main thesis and
the plots for metformin, chlorpropamide and glibenclamide will be within the Appendix, unless
other wise stated (B.1.1.).
The autocorrelation plot for the insulin model with no lag is shown in figure (3.3).
Figure 3.3 shows that many of the variables have no auto correlation, however α, β1 - HbA1c,
β2 - FPG and β6 - HbA1c× FPG have some correlation until around a lag of about 10 and
therefore only every 10th value was used for analysis.
3.6.2. Raftery-Lewis Diagnostic
Once it was decided on the lag of the iterations, the number of iterations to be run is the next
thing of note. To do this the Raftery-Lewis test can be run as outlined in the Appendix A.3.2.
to see how many iterations should be run to estimate a posterior quantile. For this the 0.025
quantile was to be estimated within±0.005 with probability 0.96 (q = 0.025, r = 0.005, s = 0.95).
It can be noted here that with these requirements an Nmin can be found to determine the
minimum number of iterations which are required. When the lag is taken as stated above and
Zt is defined to be a binary 0− 1 process
Zt = δ
(
Ut ≤ u), (3.64)
where δ is the indicator function and U is a function of our posterior estimate (here the
0.025 quantile) , then using the fact that L: the number of required iterations is minimised
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Figure 3.3: AutoCorrelation Plot for Insulin Model
if the successive values of {Zt} are independent and using the results given in the appendix
(A.3.2.)
Lmin = Φ
−1(1
2
(1 + s)
)2
q
(
1− q)/r2, (3.65)
where Φ(.) is the standard normal cumulative distribution function. When q = 0.025, r =
0.005 and s = 0.95 this makes Lmin = 3, 748. Another way to check the Raftery-Lewis diagnostic
is to consider the Indicator function Irl
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Irl =
(
M + L
)
L
, (3.66)
which calculates the increase in the number of iterations needed to ensure convergence due
to dependence within the samples in the chain. Here values of Irl close to 1 are desired with
high values (Irl > 5) indicating high within chain variation and likely convergence failure and
as such reparameterization may be required.
For insulin the Raftery-Lewis diagnostics are given in Table 3.3.
Statistic No.
M - Burn in 5
L - Total Number of Iterations 4978
Irl - Dependence Factor 1.43
Table 3.3: Raftery-Lewis Statistics for Insulin Model with no burn in
It is seen that very little burn in is required for convergence and then around 5000 iterations
should be used to estimate the posterior distribution. For completeness and to make the burn
in as long as the total number, 10000 iterations were stored, with only every 10th iteration being
stored and the initial 5000 were discarded for burn in. All other models gave similar statistics
with L being around 5000 and M being low and hence Irl being close to one meaning that 10000
stored iterations with 5000 burn in was suitable for the models for all 4 treatments.
3.6.3. Gelman-Rubin Statistic
A final check to test convergence once the number of iterations has been run and the lag has been
decided and discarded, is to calculate a Gelman-Rubin statistic for each variable. This statistic
is outlined in the Appendix A.3.1. The Gelman-Rubin plots for insulin are given in Figure 3.4
and the same is given for metformin, chlorpropamide and glibenclamide in the Appendix B.1.2.
The actual value and 95% credible interval (CI) can also be found and for insulin, both the
value and upper credible interval were given as 1. It was also seen in the other 3 treatments that
both the estimate and the upper interval were given to be 1 and thus there is no concern with
regards to convergence. For this two chains were needed to be run and all subsequent results
were based on both the chains.
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Figure 3.4: Gelman-Rubin Plots for Insulin Model
3.6.4. Trace Plots
The final way to check convergence is to assess the trace density plots. These are plots which
trace every iteration of the parameter estimates and the densities are given for the estimate of
the parameter. Here for good mixing to be seen, the trace plots for the two chains run, should
mix well with a steady mean throughout and the densities should be approximately normally
distributed. The trace and density plots for the insulin mode for α and β1 are given in Figure
3.5. The trace plots for other variables and models all looked similar with good mixing and
steady means.
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Figure 3.5: Trace and Density Plots for Insulin Model - α, β1
3.7. Bayesian Linear Regression Results
Having set up the regression model to assess change in HbA1c after one year of treatment, the
next step was to run this using the data and the next section will outline the results found from
the model. Using the results found in Table 3.2 for the variables to be included in the model,
this was run and root mean square error (rmse), correlation, r2 and adjusted r2 values were
calculated.
All data was transformed if necessary and scaled before creating the models, to account for
the different scales within the variables which are seen. Hence the intercept can be interpreted
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as the outcome value, when all variables are set to be their mean.
To begin with, uninformative priors for β were used with mean β0 being 0 and precision
Σ0 0.001I, which gives a wide distribution. A more informative prior was used for σ
2, with the
mean of the inverse-gamma distribution being equal to the mean of the outcome variable y seen
within the data for that treatment. 2 simultaneous chains were run, the first with starting points
all at zero and the second with starting values as those given from the standard frequentist linear
regression also with large variances.
These prior distributions are different to those used in the Robust Prior for variable selection.
This was chosen so that the priors used for variable selection were the best fit for the conditions
set by Jeffrey’s desiderata, which is why the robust method was chosen. Since this method was
used to give the best median probability model rather than the Bayesian model average method
for reproducability purposes a new model has then been run using these set variables. These
were chosen to be non informative in the hope to give as little information to the posterior
distribution as possible and also to make this as close to the standard Frequentist models.
This again creates the simplest, most reproducable model possible. The priors from the robust
prior could have been used again and for sensitivity purposes the model was run with this
prior distributions and the results were almost identical, therefore for ease and computational
purposes the non-informative priors were carried forward.
The results from this are listed in Table 3.4. Here n is equal to the number of subjects with
no missing values for the used variables.
Treatment n root mse r2 adj r2
Insulin 973 1.289 0.635 0.633
Metformin 366 1.164 0.531 0.521
Chlorpropamide 693 1.432 0.605 0.602
Glibenclamide 614 1.235 0.477 0.471
Table 3.4: Bayesian Regression Results
A plot of actual versus predicted values for insulin is given in Figure 3.6 and for metformin,
chlorpropamide and glibenclamide is given in the Appendix B.1.3.
The results from the standard linear regression are seen to be average, with the r2 values
between 0.5 and 0.63. 6-fold cross validation was completed for all models, where the data
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Figure 3.6: Actual versus Predicted HbA1c Values After 1 Year for Insulin Model
is randomly split into 6 segments and a model created on 5 of them and then tested on the
other split. The results from this are below in table (3.5) with the average values and standard
deviation.
Treatment rmse correlation r2 adj r2
Insulin 1.565 (0.25) 0.739 (0.01) 0.530 (0.03) 0.460 (0.04)
Metformin 1.345 (0.12) 0.755 (0.05) 0.476 (0.07) 0.451 (0.08)
Chlorpropamide 1.985 (0.22) 0.723 (0.05) 0.508 (0.08) 0.480 (0.084)
Glibenclamide 1.883 (0.21) 0.493 (0.14) 0.267 (0.146) 0.211 (0.18)
Table 3.5: Cross Validation Results of Bayesian Regression
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The cross validation results show that predictions on external data do not always give great
results, especially for Glibenclamide with an average r2 of only 0.267 and a larger sd. This could
suggest that there is an issue with the models for prediction purposes.
The estimated β values are given in Table 3.6 with their corresponding 95% highest posterior
density estimates. The Intercept can be seen to be the value if all the input variables are at the
mean.
Treatment Variable β value HPD
Insulin Intercept -0.8296 (-0.9402,-0.7263)
HbA1c -1.405 (-1.553,-1.2630)
FPG 0.1619 (0.0160,0.3017)
Age -0.1327 (-0.2164,-0.0502)
BMI 0.1468 (0.0659,0.2264)
Race 0.2206 (0.0112,0.4333)
HbA1c× FPG -0.2513 (-0.3322,-0.1705)
τ 0.5965 (0.5449,0.6523)
Metformin Intercept -0.9878 (-1.1200,-0.8500)
HbA1c -1.5936 (-1.8180,-1.3890)
Fasting Insulin 1.4155 (0.303,0.2612)
HOMA−%B -0.5866 (-1.3670,0.2125)
HOMA−%S 1.0520 (0.0811,2.0220)
HOMA−%B ×HOMA−%S -0.1335 (-0.7590,0.5228)
Triglycerides 0.07559 (-0.0435,0.1918)
τ 0.6954 (0.5914,0.7956)
Chlorpropamide Intercept -1.2630 (-1.3920,-1.1430)
HbA1c -1.8210 (-1.9790,-1.6650)
Age -0.1787 (-0.2943,-0.0639)
FPG 0.3188 (0.1405,0.5102)
Systolic BP 0.0438 (-0.0626,0.1590)
Race 0.2500 (-0.0148,0.5395)
τ 0.4833 (0.4356,0.5382)
Glibenclamide Intercept -1.1030 (-1.2770,-0.9413)
HbA1c -1.2300 (-1.3690,-1.0840)
HDL Cholesterol 0.0951 (-0.0453,0.2473)
Gender -0.1575 (-0.3693,0.05846)
Race 0.3962 (0.1364,0.6520)
BMI 0.1190 (0.0059,0.2323)
τ 0.6465 (0.5724,0.7161)
Table 3.6: Parameter Estimates from Bayesian Linear Regression
The intercepts are all around the same value, showing that the average drop in HbA1c is
consistent in all 4 therapies. The β values can be seen to be how much influence they have on
the decrease in HbA1c.
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3.8. Bayesian P-Value and Rank Histogram
Having looked at the model results, it appears as though the results are being pulled towards
the mean of the data and therefore values on the edges are not being reached by the model.
One way to check whether the model is a good overall fit of the data is to calcaulate a Bayesian
P-value for a specific discrepancy of the data outlined in the Appendix A.4. Since it was decided
that the model may not work well in the edges of the data, the discrepancy used here was the
maximum and minimum value of change in HbA1c after 1 year of treatment. The Bayesian
P-value effectively gives a proportion of times the simulated data discrepancy is greater than
that seen in the actual data and therefore P-values close to 0.5 are preferred and ones close to
either 0 or 1 may show a lack of fit of the model to the data. The Bayesian P-values for these
two discrepancy measures - minimum change in HbA1c (min) and maximum change in HbA1c
(max) are given in table (3.7)
Treatment P-value for min P-value for max
Insulin 0.027 0.002
Metformin 0.309 0.070
Chlorpropamide 0.008 0.001
Glibenclamide 0.034 0.005
Table 3.7: Bayesian P-Values for the Discrepancies Minimum and Maximum Change in HbA1c
After 1 year of Treatment.
Table (3.7 shows worrying results with the Bayesian P-values being very close to 0 for many
of the treatments. This means that when data is being simulated from the model, only a very
small proportion of the time is it seen to be as extreme as the data actually is. Another way
to look at this graphically is to create a rank histogram. This is where the actual values of
the outcome are systematically split in numerical order, into groups of the same size. Then the
histogram shows how many of the predictions there are in the same period as for the actual
data. A “well fit” model should be almost consistent across all groups and so the histogram to
be as close to uniform as possible.
The rank histogram for insulin is shown in Figure 3.7 and for metformin, chlorpropamide
and glibenclamide in the Appendix (B.1.4.)
The rank histograms shows that the model is not estimating the right spread of the pre-
62 3.8. Bayesian P-Value and Rank Histogram
0
10
20
30
40
50
60
70
Figure 3.7: Rank Histogram for the Insulin Model
dictions to the actual data. There appears to be a number of modes where the predictions are
sitting compared to the spread of the data. One main concern is also at the highest values for y
where there are considerably less predictions in these bins than the actual data is seeing, there
are also less predictions in the lower bins. This means that the model predictions are more
centered to the mean and not variable enough. Increasing the variance within the model was
tried, however, this gave the same results. Due to the shape of the histogram it appears that
another method which can increase the spread of the predictions is required.
Since it appears that there may be some issues with the fit for the standard single linear
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regression models, a number of different models were initially looked at to improve the predic-
tions, including non-linear regression, lasso and different distributions for the outcome such a
t-distribution. However, all of these did not appear to improve the fit of the model. The rank
histogram seems to have two models where the predictions are lying and inspection of the data
seems to imply that, in fact, the data comes from more than 1 distribution. Due to this, mixture
models were then considered for the analysis and the next chapter details this and gives results.
3.9. Regression Model Summary
This chapter began with variable selection for the 4 treatments to determine which variables
to include in the linear regression models. This was done using the robust prior which uses
criteria to establish the best model for robustness as well as computationally. Since there were
too many different models to run all individually and calculate Bayes Factors for them, the
stochastic search algorithm was introduced as way to iterate through variables to create models,
improving at each iteration. Once this was applied to the data and the variables were chosen,
invertibility of the model was considered to see whether any reparamaterization was required
and it was seen that scaling of the variables was needed for stability of the models. After this
a Bayesian linear regression model was set up and run to predict HbA1c after the first year of
treatment. This chapter gives the unknown parameter estimates as well as a look at how well
the predictions fit the actual observed data. From here Bayesian P values and rank histograms
were inspected and it was shown that there is some issue with just one model being fit to all the
data. Due to this being the case Chapter 4 extends on the single regression model to create a
mixture model with clusters of the data having different models applied to them.
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4
Mixture Model for Predicting Subsequent HbA1c Response After
First Year of Treatment
Since the previous chapter showed that it may be more applicable to introduce a mixture model
for the prediction of HbA1c after the first year of treatment, this chapter will create and estimate
this. To do so, the data will be partitioned into ‘batches‘ for which a separate model will be fit
to each of the different groups. Firstly, the Gaussian mixture model will be introduced alongn
with the corresponding Gibbs sampling method to determine which group a data point belongs
to and then how to create the models for each of the groups. The results and estimates of the
unknown paramters are given and analysed. Once this is complete a Naive Bayes method is
outlined to determine which particular batch a new individual will belong to.
Gaussian processes have been used in a number of applications including using Gaussian
process priors for Bayesian regression as seen in the previous chapter for the standard linear
regression. However, in many cases (including the case for the UKPDS data), it can be seen
that the data cannot be fit purely by one single linear regression model and instead the data
comes from different ‘batches’. These ‘batches’ or components act differently to each other and
thus a separate model should be fit to each of them. In some situations it can easily be seen
where the clusters of data lie, such as gender and in that case the data could be easily split
into the two groups and then a separate model fit to each cluster. But this is not always the
case and sometimes it cannot easily been seen where the splits lie and so the estimation of the
component also needs to be calculated for each data point, in this case for each subject.
Gaussian mixture models can be seen to be a flexible approach to the problem of modelling
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a large dataset with heterogeneity and thus a single model may be inadequate, as shown by
Titterington, Smith and Mokov [64] and McLanchan and Peel [65]. Bayesian approaches to a
mixture model have also more recently been shown utilizing Gibbs sampling in Peng, Jacobs
and Tanner [66].
4.1. The Bayesian Mixture Model
Much of the recent attention in mixture models is in mixtures of normal distributions and for
linear regressions the same is done here. Observing the outcome data Y = (y1, . . . , yN ) and
an individuals covarites xi = (xi1, . . . , xip), for i = 1, . . . , N subjects and p = 1, . . . , P different
covariates, the mixture likelihood is of the form
yi|xi1, . . . , xip =
K∑
k=1
pikN(αk + xiβk, σ
2
k), (4.1)
where βk are the regression coefficients,αk is the intercept and σ
2
k is the variance for group
k and (pi1, . . . , pik) are the relative probabilites of belonging to each group for k = 1, . . . ,K
components. The weights of assignment to each component pik sum to one
K∑
k=1
pik = 1. (4.2)
These are all unknown parameters and will be referred to by θk = (αk,βk, σ
2
k) and pi =
(pi1, . . . , pik) for ease, all or which are to be estimated from Gibbs Sampling of the model.
The probabilities of assignment to each component k are unknown and so for analysis, a
latent variable zi will be regarded for each variable such that zi = k if subject i belongs in class
k. The number of subjects belonging to each class k for k = 1, . . . ,K is
nk =
N∑
i=1
I(zi = k), (4.3)
where I(zi = k) is an indicator variable such that it is equal to 1 if zi = k and zero otherwise.
It can also be seen that
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P (zi = k) = pik. (4.4)
Differing to some models here, it is assumed that all the subjects belonging to component k
come from the same linear regression model and the estimated βk coefficients and variance σ
2
k
will be set for each of the k models. This means that there will be K different regression models
which can be found in the same way as for the linear regression model using the full conditionals
found in equations (3.59) and (3.61).
It is assumed that the number of components K is known but that that allocations to each
component pi is not.
4.1.1. Priors
For Bayesian analysis the posterior must be found. This is proportional to the likelihood mul-
tiplied by the prior distributions for the unknown parameters. It is assumed that the likelihood
follows a mixture of Gaussian distributions, then priors are assumed and from here the condi-
tional distributions of the unknown parameters can be calculated for the Gibbs sampler.
Let Y be the outcome data, Y = (y1, . . . , yN ), for the N subjects and all the unknown
regression parameters be θ = (θ1, . . . ,θK). The posterior for all the unknown parameters is
then
p(θ,pi|Y ) ∝ p(θ,pi)p(Y |θ,pi), (4.5)
where
p(Y |θ,pi) =
K∑
k=1
pikp(Y |θk,X, z). (4.6)
The distribution of Y given the unknown parameters and the known covariates is assumed
to be of a Normal Guassian likelihood in the same way as the standard regression (3.53).
The θ and pi are assumed to be independent and the unknown parameters θk are assumed
to be independent, thus it can be seen that
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p(θ,pi) = p(pi)
K∏
k=1
p(θk). (4.7)
The priors for the regression coefficients θ are used as the same as in the single regression
model. In that the βk are assumed to be normal with mean 0 and a large variance. The variance
σk is assumed to be inverse gamma.
βk ∼MVN(βk0,Σ0), (4.8)
σ2k ∼ Inv − gamma(ν0/2, νoσ2k0/2). (4.9)
For the inclusion probabilities of each component, these are assumed to follow a Dirichlet
distribution
p(pi1, . . . , pik) ∼ D(δ1, . . . , δK). (4.10)
The Dirichlet distribution is a family of continuous multivariate probability distributions and
can be seen to be the multivariate generalization of the beta distribution. It is parameterized
by a vector of postive reals δ = (δ1, . . . , δK) for K rival events. For the probabilities of K
events (pi1, . . . , piK), K ≥ 2 with the sum being equal to 1 (4.2) and concentration parameters
δ, δk > 0, k = 1, . . . ,K the pdf is
1
B(δ)
∏K
k=1 pi
δk−1
k
, (4.11)
where
B(δ) =
∏K
k=1 Γ
(
δk
)
Γ
(∑K
k=1(δk)
) , (4.12)
where Γ(.) is the standard gamma function.
In this case a non-informative prior was used so that no knowledge of how many subjects
would fall into each component was assumed, to do this δk,k = 1, . . . ,K = 1 was used and hence
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p(pi1, . . . , piK) ∼ D(δ, . . . , δ)
∼ D(1, . . . , 1). (4.13)
The choice of δ to be 1 was an arbitary choice, since any number could be chosen and this
would be seen to be non informative, since it is giving equal weight to all models. The choice of
1 leads to the case of the uniform distribution which is the standard non-informative Dirichlet
distribtuion. δ=12 could also be chosen leading to Jeffreys prior.
4.1.2. Identifiability
The above model has some identifiability issues in that the likelihood is invariant under the
possible permutations of the indices, which will be inherited in the posterior inference leading
to model unidentifiability. When performing MCMC inference this leads to what is known as
the ‘label switching’ problem which leads to misleading estimators. With K components, the
MCMC will explore the entire parameter space, which will include K! regions by permuting
the mixture component labels. Then when the iterations are averaged over all the visits, the
estimator of a components parameter will converge to a weighted average of that parameter in
all of the components. It is noted by Titterington, Smith and Makov 1985 [64] that in this
multivariate setting there does not exist one set of parameter restrictions which will identify the
model for all possible choices of the parameters.
Following on from similar models such as that by Lenk 2000 [67], to reduce permutations
and stop “label swicthing” the mixture probabilites are ordered
pi1 < pi2 < · · · < piK . (4.14)
This works for all scenarios other then when two or more of the mixture probabilities are
equal and if this is believed then more parameter restrictions will need to be added. However,
in this case it is assumed that no mixture probabilities are equal and thus no added parameter
restrictions will be required.
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This then alters the prior distributions of pi to be an ordered Dirichlet with the restriction
in (4.14)
4.1.3. Mixture Model Gibbs Sampling Routine
The Gibbs Sampling routine outlined in the Appendix (A.2.1.) is used to estimate the unknown
parameters by iterating through the conditional distributions. It has been seen that it is easier
to implement this for the mixture model by simulating the latent variable zi instead of the
probabilities pi for each subject, then from this the inference about pi can be easily found from
z = (z1, . . . , zN ). The algorithm is then done is two steps.
For each iteration l, l = 1, . . . , L
1. for each subject i, update p(zi|θ(l−1),Y ) where θ(l−1) are the current values of the un-
known parameters.
2. Update θ from p(θ|z(l),Y ), where z(l) is a vector of all the z values for each individuals
generated from step 1.
In step 1 there are actually 2 parts, in which the values of zi are updated and in turn these
update the inclusion probabilities pi. At each iteration l, let c
(l−1)
k be the number of subjects
allocated to component k in the previous iteration.
clk =
N∑
i=1
I(z
(l−1)
i = k). (4.15)
Then zli is generated by sampling
p(zli = k|Y ,θ,pi,xi) ∝ pi(l−1)k p(Y |θ(l−1)k ,xi), (4.16)
where p(Y |θ(l−1)k ) is a Gaussian distribution for component k given the parameters values for
this component. To do this zi is simulated from a multinomial distribution. The multinomial
distribution is a generalization of the binomial distribution and with the event probabilities
pi1, . . . , pik (the probabilitiy of belonging to each of the k, k = 1, . . . ,K groups) and ck being the
number allocated to each group the pdf is
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n!
c1! . . . cK !
pic11 . . . pi
cK
K . (4.17)
For simulating the zi, i = 1, . . . , N this is proportional to the probability of belonging to each
group pik multiplied by the probability of the outcome given the current parameters (4.16). To
do this one should sample from
zi ∼ multinomial
(
pi1p(yi|θ(l−1)1 ,xi)∑K
k=1 pikp(yi|θ(l−1)k ,xi)
, . . . ,
piKp(yi|θ(l−1)K ,xi)∑K
k=1 pikp(yi|θ(l−1)k ,xi)
)
. (4.18)
Once zi has been simulated for i = 1, . . . , N , new values for ck can be found using (4.15) to
give c
(l)
k
Then new values of the pi for the next iteration are generated by sampling
p(pi
(l+1)
1 , . . . , pi
(l+1)
k ) ∼ D(δ + c(l)1 , . . . , δ + c(l)k ). (4.19)
Once step 1 has been completed, the regression coefficients are updated in step 2. This is
for each θk by taking all the subjects assigned to group k and using these as a subset of data to
update the coefficients in the same way as for the single component model from a multivaraite
normal for βk and from an inverse-gamma distribution for σ
2
k. The full Gibbs Sampling routine
si then run by the following algorithm:
For each iteration l, l = 1, . . . , L.
1. Draw zli for i = 1, . . . , N from the multinomial distribution:
zli ∼ multinomial
(
pi1p(yi|θ(l−1)1 ,xi)∑K
k=1 pikp(yi|θ(l−1)k ,xi)
, . . . ,
piKp(yi|θ(l−1)K ,xi)∑K
k=1 pikp(yi|θ(l−1)k ,xi)
)
. (4.20)
2. Draw pik, for k = 1, . . . ,K from the Dirichlet distribution.
p(pil1, . . . , pi
l
k) ∼ D(δ + c(l−1)1 , . . . , δ + c(l−1)k ). (4.21)
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3. Draw the parameter values βk, for k = 1, . . . ,K from the multivariate normal distribution.
βlk ∼MVM
(
βn,k,Σn,k
)
, (4.22)
where
Σ−1n,k = Σ
−1
0,k +
1
(σlk)
2
XTkXk, (4.23)
βn,k = Σn,k
(
Σ−10,kβ0,k +
1
(σlk)
2
XTk Yk
)
, (4.24)
where Xk and Yk are the covariate matrix and outcome vector for the subjects sampled
in group k at the current iteration l and β0,k and Σ0,k are the priors.
4. Draw the variance parameter σk for k = 1, . . . ,K from the inverse gamma distribution
σlk ∼ I −Gamma
(
1
2
(
ν0 + c
l
k
)
,
1
2
(
ν0σ
2
0,k +
∑
i:zi=k
(yi − xiβlk)2
))
. (4.25)
where the prior for σk is inverse gamma (ν0/2, ν0σ
2
0/2).
4.1.4. Number of Components
All above calculations have been formulated with a known number of components - K. In the
case for insulin responses for the UKPDS data, the initial guess was that K = 2 or 3 as the
density plot appears to have 2 modes and possibly a third - Figure 4.1.
In order to compare models with differing numbers of components, a Bayes Factor can be
calculated as was done for model selection (3.4). However, for the mixture model, this includes
many covariates and will be complex to calculate. Instead an approximation can be used called
the Bayesian Information Criteria (BIC) [68]. The BIC gives a large-sample estimator of a
transformation of the posterior probability associated with the model.
BIC = −2lnL(θ|Y ) + Pln(N), (4.26)
where lnL(θ|y) is the log likelihood, P is the number of variables in the model, and N is
the number of subjects. The estimates for θ are given by running the full model and taking the
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Figure 4.1: Density Plot of Change from Baseline in HbA1c - Insulin.
median estimate from the posterior distribution for the regression parameters from the sampling
routine. This is similar to the AIC (Akaike information criteria) with the same goodness of fit
term, however, the penalisation term is more stringent for BIC - Pln(N) compared with 2P
which means that it favours simpler models.
AIC = 2P − 2lnL(θY ). (4.27)
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An advantage of the BIC is that it has no need for the prior distribution to be specified and
as such is much simpler to calculate compared with the Bayes Factor.
The log-likelihood for the mixture model is simple to compute, as this can be done using the
mixture of k Guassian distributions.
LogL =
N∑
i=1
log
(
K∑
k=1
pikf(yi|xi,θk)
)
. (4.28)
Models can then be compared using the BIC, by looking at the difference between the 2 BIC
values. A smaller BIC leads to a better model fit and Kass and Raftery [69] provide the Table
4.1 below to compare the BIC or Bayes Factor for two competing models.
BIC1 −BIC2 Evidence agaisnt Model 1
0-2 Not worth a mention
2-6 Positive
6-10 Strong
> 10 Very Strong
Table 4.1: Comparing 2 models using the BIC
The mixture model was then run for K = 1, 2, 3 different components and the results are
outlined below in Table 4.2, with BICk defined to be the BIC (4.26) for the model with K
components.
Treatment Model Comparison Difference
Insulin BIC1 −BIC2 47.046
BIC1 −BIC3 34.963
BIC2 −BIC3 -12.083
Metformin BIC1 −BIC2 73.433
BIC1 −BIC3 43.420
BIC2 −BIC3 -30.013
Glibenclamide BIC1 −BIC2 97.976
BIC1 −BIC3 38.410
BIC2 −BIC3 -59.556
Chlorpropamide BIC1 −BIC2 152.937
BIC1 −BIC3 157.542
BIC2 −BIC3 1.206
Table 4.2: BIC Comparison Results
Table 4.2 shows that models with K = 2, 3 parameters are preferred very strongly compared
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with the standard single regression model for all treatments. However, BIC2 − BIC3 < 0,
meaning that the model with 2 components is preferred to the more complex 3 component model
for insulin, metformin and glibenclamide due to the extra complexity when K = 3. Although
the r2 values are slightly higher when more components are added (r2 = 0.86 for insulin 3
component and r2 = 0.801 for insulin 2 component) the extra complexity doesn’t warrant the
slight increase in r2. It could also be that extra components lead to overfitting of the data and
as such future predictions may not be as accurate. From these results, it seems clear to continue
with K = 2 for all insulin, metformin and glibenclamie. For chlorpropamide BIC2−BIC3 = 1.2
which according to table (4.1) this is “not worth a bare mention”. Therefore there is little to
differentiate between the two models and so for ease and consistency K = 2 will also be used.
4.2. Convergence Diagnostics
After the results of the last model, it was decided that the initial run of iterations would be 5000
runs. Then after this the amount of thinning was determined by autocorrelation plots and the
number of total iterations to run were assessed via the Raftery-Lewis diagnostic. Once these
were found and the model could be run for the full number of iterations with a burn in and then
convergence was tested using Gelman-Rubin plots and statistics as well as visual inspection of
the trace plots.
4.2.1. Auto Correlation
Autocorrelation can be calculated for each of the variables in the models (A.3.3.). In this case
there are two regression models and coefficients as K = 2. The Auto correlation plots for insulin
are shown in Figure 4.2 for the respective 2 regression models.
These plots show that there is some correlation for some of the variables, most noticeably for
α2 and τ1 where there is correlation up to around about a lag of 20. The plots for metformin,
chlorpropamide and glibenclamide can be seen in the Appendix B.2.1. and these show a similar
story and therefore for this model only every 20th iteration was stored and used for the results.
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Figure 4.2: Auto Correlation Plots for the Mixture Model for Insulin
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4.2.2. Raftery-Lewis Diagnostics
After an intial run of 5000 iterations, Raftery-Lewis diagnostics were used to see how long
the chain should be run for (A.3.2.). This was performed with the standard diagnostics of
q = 0.025, r = 0.005 and s = 0.95, which is the requirement that the 0.025 quantile is to be
estimated within ±0.005 with probability 0.95.
In a similar way to the standard linear regression model, convergence was seen to be rather
quick and thus the Raftery-Lewis diagnostic gave a required burn in M to only be 8 for insulin.
The other 3 treatments also saw burn ins of less than 10 required. It also gave a Lmin to be
4062 giving an independence factor Irl = 1.08. Therefore, to be consistent with before it was
decided that the chain would be run for 10000 iterations, discarding the first 5000 as burn in.
4.2.3. Gelman Rubin Statistic
Once 2 chains with differing starting points had been run with every 20th value being stored,
5000 discarded and then the next 5000 used for inference, one chain with starting points at
0 and the other with starting points as the coefficient values given by the linear regression
model, convergence was tested by the Gelman-Rubin Statistic (A.3.1.). Values close to 1 show
convergence and it was seen that all the statistics were 1. Upper intervals were also found
and these were found to be mainly 1, with a few being 1.01, but this was the highest seen for
all estimates of the coefficients for all the models. Gelman Rubin plots of the two regression
models for the different components for insulin are shown in Figure 4.3. These plots show good
convergence for all variables for both the models.
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Figure 4.3: Gelman Rubin Plots Plots for the Mixture Model for Insulin
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4.2.4. Trace Plots
Once convergence has been found a final way to check the model is to visually inspect the trace
plots of the coefficient estimates over the iterations. Here it should show good mixing in that
both the chains should overlap with a steady mean. All trace plots for all the models here looked
fine with regards to convergence and an example is shown in Figure 4.4.
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Figure 4.4: Example of the Trace Plots for the Insulin Model
80 4.3. Model Results
4.3. Model Results
After convergence has been determined, as done above, the final model parameters can be found
from the posteriors found through Gibbs Sampling. The estimates of these are found from the
posterior distributions found through iterating through the conditional distributions and these
can be used for predicting HbA1c after the first year of treatment for each individual.
4.3.1. Prediction using the Mixture Model
For the subjects data used to build the model, predictions for the outcome of interest Y can be
easily found by taking the median value of the posterior predictions for each subject. At each
iteration, every subject is allocated a model (1 or 2) using (4.16) and from here the values of
θk are updated. Then an output prediction yˆi can be calculated for each subject i = 1, . . . , N
using the current regression coefficients θtk given the value of z
t
i and the subject covariate vector
xi as in for a normal regression model.
Once the model had been run and converged, a prediction yˆi can be found for each subject
along with a probability piik, which is the probability of subject i belonging to group k = 1, . . . ,K,
as well as an overall probability of belonging to group k, pik which is the average proportion over
all iterations of subjects belonging to group k.
For each of the models using this prediction a good fit was found with the results presented
in Table 4.3. This shows quite high r2 values all above 0.7 which is an improvement on the
standard regression model of r2 of around 0.5− 0.6. The root mean squared errors are also low
at around 1 or less, which means the errors of the predictions are lower.
Treatment rmse r2 Adjusted r2
Insulin 0.9516 0.801 0.798
Metformin 0.9075 0.703 0.697
Glibenclamide 0.8740 0.738 0.732
Chlorpropamide 1.038 0.792 0.788
Table 4.3: r2 results from the Mixture Model
A plot of the actual versus predicted values for the insulin model is shown in Figure 4.5 and
the same for metformin, chlorpropamide and glibenclamide can be found in Appendix B.3.1.
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Figure 4.5: Plot of Actual Versus Predicted Values for the Insulin Mixture Model
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Figure 4.5 shows that the predictions are a relatively good fit. There appears to be no
obvious outliers with the biggest errors appearing to be when the actual HbA1c increases after
1 year. Intuitively this would always be likely to be harder to predict since it is always expected
that an individual should reduce their HbA1c after taking treatment for a prolonged period of
time such as one year. However, within the given data and the model there is no account for
adherence and therefore, if the treatment is being taken as it should which will have a great
effect on glycemic control.
95% Credible intervals can also be calculated for for individual from their posterior distri-
bution. A credible interval plot of metformin is shown in Figure 4.6.
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Figure 4.6: Plot of Actual Versus Predicted Credible Intervals for the Metformin Mixture Model
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4.3.2. Differences between the Components and Model Results
From Figure 4.5 and the results in Table 4.3 it seems as though the mixture model is a better
overall fit for the data compared with the standard linear regression model. This means that the
data appears to be in two batches and that these have differing models. For the insulin model
p(pi1) = 0.2819 and so approximately 28.19% of the data follow one model and the remaining
78.81% fit into a different one. When the subjects are partitioned into one of the two groups,
by which group their zi visited the most during the iterations, for i = 1, . . . , N , there were some
noticable differences in some of the baseline variables used for construction of the model.
Treatment Variable Group 1 Group 2 P Value
Insulin HbA1c 7.930 8.723 0.000013
Age 52.785 49.602 0.000219
FPG 8.845 8.918 0.0011
BMI 26.440 26.924 0.3028
Race (White) 81.68% 77.57% 0.2643
Metformin HbA1c 8.136 7.151 < 0.00001
Fasting Insulin 17.116 14.327 0.02096
HOMA−%B 44.363 51.071 0.1136
HOMA−%S 36.839 47.699 0.00112
Triglycerides 2.018 1.698 0.01335
Glibenclamide HbA1c 7.749 7.501 0.0989
Age 52.351 54.051 0.01409
HDL Cholesterol 1.049 1.039 0.7348
Gender (Male) 61.069% 58.806% 0.6297
Race (White) 80.150% 83.806% 0.2868
BMI 27.239 27.015 0.5583
Chlorpropamide HbA1c 9.353 7.826 < 0.00001
Age 48.706 52.936 0.0002
FPG 11.717 9.459 < 0.00001
Systolic Blood Pressure 130.279 135.535 0.02782
Race (White) 86.217% 88.120% 0.7962
Table 4.4: Mean values for the Variables in each of the Groups for the Mixture Model
Table 4.4 shows that there are statistically different mean values for HbA1c for all treatments
except glibenclamide where p = 0.0989 which still implies a small numerical difference if not
statistically significant. For the other three treatments higher baseline HbA1c values occur in
the one of the groups: group 2 for insulin and group 1 for metformin and chlorpropamide. By
identifiability it is known that pi1 < pi2 and as such less subjects fall into this category for
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metformin and chlorpropamide, but conversely more subjects are in the higher baseline HbA1c
group for insulin. For insulin there are statistical differences between age and FPG with the
higher HbA1c subjects being younger but with a slightly higher FPG. Subjects treated with
metformin, group 1 are also seen to have a statiscally higher fasting insulin, lower HOMA−%S
and higher Triglyceride levels. Chlorpropamide subjects with a higher baseline HbA1c are also
seen to be younger, with a higher FPG and lower Systolic Blood Pressure. For glibenclamide
where baseline HbA1c is not strictly significant, the patients in the two groups appear to be closer
together in terms of its covariates with only age being significant. This shows that for most of
the models (insulin, metformin and chlorpropamide) there are significant differences between
the two groups in terms of the patient characteristics and these are subsets of the population
where different models better account for the prediction of lowering of HbA1c after 1 year of
treatment. The most obvious and consistent difference is that of HbA1c at baseline to account
for in the model.
The estimates and 95% credible intervals for the unknown parameters for insulin are given
in Table 4.5
Parameter Group 1 Group 2
α 0.012 (-0.379,0.509) -1.207 (-1.348,-1.074)
HbA1c -0.788 (-1.216,-0.311) -1.704 (-1.860,-1.548)
FPG 0.229 (-0.251,0.694) 0.149 (0.003,0.290)
Age -0.198 (-0.405,0.041) -0.029 (-0.123,0.068)
BMI 0.207 (-0.179,0.429) 0.100 (0.0213,0.181)
Race 0.509 (-0.079,1.132) 0.082 (-0.126,0.287)
HbA1c × FPG -0.377 (-0.636,-0.113) -0.158 (-0.237,-0.078)
τ 0.4519 (0.336,0.591) 1.374 (1.071,1.787)
p 0.282 (0.241,0.329)
Table 4.5: Parameter Estimates from the Mixture Model Regression for Insulin
The parameter values in Table 4.5 show some interesting points, especially when compared
with Table 4.4 showing the differences between the groups. It is known from Table 4.4 that
group 2 have a statistically higher baseline HbA1c. The intercept for the second group model is
−1.207 compared with −0.012 in the first group and thus a higher baseline HbA1c will correspond
to a larger decrease after 1 year when all variables are at the mean. Also, the coefficient for
the HbA1c variable has a larger effect for group 2 (−1.704 compared with −0.788) and so this
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larger baseline also relates to a bigger comparative drop. These results are not unexpected since
patients with a lower HbA1c will have less of a need to decrease their values as much and a higher
baseline value allows for more of a drop. Higher HbA1c has also in the past been associated
with a larger drop in HbA1c [32].
Another point of interest when looking at the parameter estimates is that in group 1 (lower
average baseline HbA1c) all coefficients other than the intercept and HbA1c are of a larger effect
(greater negative or positive value) than group 2. This seems to suggest that when baseline
HbA1c is lower and closer to the goal of normoglycaemia, other elements have a greater effect
on what happens after 1 year. However, when a larger baseline HbA1c is observed, most of the
effect seen after 1 year is due to this larger baseline value rather than any other factor or patient
characteristic.
The estimates for metformin are given in Table 4.6. Group 1 with a higher baseline HbA1c
have a small decrease in intercept, however the effect of baselineHbA1c is larger (-2.040 compared
with -1.264). The biggest effect here is that for the second group with a lower baseline HbA1c,
fasting insulin and triglycerides and a higher HOMA−%S, fasting insulin and HOMA−%S:
have very large positive coefficients and therefore will negate some of the decrease from the
intecept when above the mean. The negative effect of HOMA−%B is also larger. Once again,
it can be interpreted that when baseline HbA1c is high, this is the main driver to predict its value
after 1 year of treatment. However, when patients are originally closer to the normoglycaemic
range, other factors come into account more in terms of predictions.
Parameter Group 1 Group 2
α -0.660 (-0.982,-0.147) -1.345 (-1.548,-1.192)
HbA1c -2.040 (-3.006,-1.471) -1.264 (-1.505,-0.939)
Fasting Insulin 0.925 (-1.182,3.927) 5.759 (4.076,7.605)
HOMA−%B -0.527 (-3.576,1.475) -1.378 (-2.331,-0.221)
HOMA−%S 0.519 (-1.098,2.791) 5.214 (3.687,6.813)
HOMA−%B ×HOMA−%S -0.508 (-2.578,1.803) 0.339 (-0.551,1.140)
Triglycerides 0.090 (-0.294,0.496) 0.099 (-0.043,0.227)
τ 0.954 (0.389,0.751) 1.614 (1.063,2.667)
p 0.411 (0.232,0.501)
Table 4.6: Parameter Estimates from the Mixture Model Regression for Metformin
Table 4.7 shows the coefficients for the glibenclamide Mixture Model. Here, there are not
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as many differences seen between the two components or groups. Group 1 do appear to have
a numerically higher baseline HbA1c and are younger. This first group have a more negative
intercept and HbA1c coefficient and therefore this plays a bigger effect in that higher HbA1c will
relate to a bigger decrease after 1 year of treatment. Group 1, who have a statistically lower
age, have a positive coefficient for age and therefore, older subjects will not decrease as much
after 1 year of glibenclamide treatment. However, for group 2 age is a negative coefficient and
it is seen that older subjects in this group will in fact decrease more. Therefore, older subjects
with a high HbA1c may be better suited to a different treatment where age always appears to
have a negative effect (relating to a bigger decrease in HbA1c). BMI also has a larger coefficient
in group 2 and thus this plays a bigger role than for group 1.
Parameter Group 1 Group 2
α -1.727 (-1.913,-1.549) -0.537 (-0.804,-0.272)
HbA1c -1.759 (-1.886,-1.623) -0.705 (-0.909,-0.493)
Age 0.101 (-0.014,0.223) -0.136 (-0.303,0.278)
HDL Cholesterol 0.035 (-0.076,0.146) 0.156 (-0.006,0.309)
Gender -0.089 (-0.319,0.137) -0.168 (-0.505,0.168)
Race 0.382 (0.076,0.696) 0.504 (0.096,0.962)
BMI 0.148 (0.019,0.280) 0.069 (-0.099,0.243)
τ 2.150 (1.572,2.797) 0.655 (0.543,0.782)
p 0.469 (0.401,0.500)
Table 4.7: Parameter Estimates from the Mixture Model Regression for Glibenclamide
Table 4.8 shows the coefficents for the chlorpropamide mixture model. Again, group 1 is
seen to have a statistically higher baseline HbA1c and FPG, but lower age and systolic blood
pressure. This group is seen to only decrease slightly when at mean (α -0.026 compared with -
1.546), however, the HbA1c coefficient is higher in absolute value. This group, do have a stronger
positive effect (relating to less decrease in HbA1c) for FPG and Race, whereas group 2 are hardly
affected at all by these covariates. This is different to the other models in that a higher HbA1c
has stronger coefficents for the other variables.
4.3.3. Bayesian P Value
To test how well the given models fit to the data, Bayesian P Values were calculated using the
method outlined in Appendix A.4. Here, the discrepancy measures were the largest increase,
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Parameter Group 1 Group 2
α -0.026 (-0.686,0.695) -1.546 (-1.668,-1.436)
HbA1c -2.213 (-2.742,-1.663) -1.792 (-1.938,-1,645)
Age -0.103 (-0.569,0.356) -0.101 (-0.201,-0.001)
FPG 1.122 (0.448,1.763) 0.0634 (-0.018,0.141)
Systolic Blood Pressure -0.047 (-0.526,0.445) 0.063 (-0.018,0.141)
Race 1.051 (-0.082,2.380) 0.088 (-0.128,0.316)
τ 0.248 (0.175,0.334) 1.376 (1.084,1.686)
p 0.197 (0.116,0.275)
Table 4.8: Parameter Estimates from the Mixture Model Regression for Chlorpropamide
decrease and average change in HbA1c values after 1 year. The results of this are given in Table
4.9
Treatment P value for Min P Value for Mean P Value for Max
Insulin 0.380 0.421 0.109
Metformin 0.365 0.239 0.099
Glibenclamide 0.599 0.391 0.182
Chlorpropamide 0.321 0.402 0.114
Table 4.9: Bayesian P Values for the Mixture Model
Table 4.9 shows that the models appear to be a good fit for the data with the Bayesian P
Values not being close to either 1 or 0. The only concern is that for the maximum change in
HbA1c after 1 year. These are not too extreme to be of concern for the overall model, however,
they do show that the fit may not be as good around the higher values. This is consistent with
what is seen in the actual versus predicted plots and intuitively would be the case. Subjects
who increase after 1 year of treatment would be harder to predict since adherence to the drug
is not included within the model.
Comparing Table 4.9 with Table 3.7 giving the Bayesian P-values for the standard regression
model, one can see that the mixture model appears to fit the data better and be predicting the
full range of possible values. Other than for metformin minimum value, all the Bayesian P values
for the regression model were ≤ 0.1 meaning that less than 10% of the simulated data sets from
the models were generating the data range as large as the observed data. However, the mixture
model gives almost all (other than metformin maximum) above 0.1 and thus the model is seen
to be predicting the full range of the observed values.
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4.3.4. Sensitivity Analysis
To check that the model has converged and that the prior distributions are not giving too much
information to the final posterior results, a senstivitiy analyis should be run. For the Gelman-
Rubin statistic 2 chains are run at different starting points and the statistic shows convergence.
To ensure that these starting values are not influencing the model results, a further 2 runs with
2 chains each were run with even larger differences between the starting values and these also
showed convergence.
For the majority of the parameters, non-informative priors were used so that they can take
almost any value. Chains were rerun with smaller variances and more informative prior mean
values (given by the standard linear regression models) and the posterior results were all seen
to be less than 0.5% different to those given by the non-informative case.
Finally, the entire analysis was rerun with quadrupled variance priors to see the effect. The
overall conclusions were the same with the median posterior estimates being less than 1.1%
different to the given results.
4.4. Naive Bayes Classification
To estimate which group k, k = 1, 2, each subject belongs to, the Naive Bayes Classifier routine
was implemented. The Naive Bayes approach is a family of algorithms all based on the same
principle: all Naive Bayes Classifiers assume that the value of a particular feature is independent
of the value of any other given feature, given the class variable.
The Naive Bayes approach was chosen due to it fitting with the way the original Bayesian
model works. It is a fully Bayesian approach using the basics of Bayes Theorem. This method
is a fast, fully scalable algorithm which gives nice succient probabilities of allocations which can
be easily put in to the mixture models as the pik probabilites of belonging to each group. It also
requires no other information other than the values of the variables which are already included
within the model. The approach is fast and easy to classify and also to get out probabilities of
classification which can handle a mixture of both real and discrete data. It is seen to be not
too sensitive to irrelevant features which is important in this scenario where it is seen that some
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baseline covariates strongly effect prediction, over some others. All features in this model are
assumed to be independent.
For each class variable k = 1, . . . ,K, this can be estimated as a dependent factor of the input
variables xi = (xi1, . . . , xiP ) where xi is the values of each variable at baseline for an individual
i. Using Bayes Theorem (A.1.1.) the relationship between the class k and the input variables
for each individual i, i = 1, . . . , N is
p(k|xi1, . . . , xiP ) = p(k)p(xi1, . . . , xiP |k)
p(xi1, . . . , xiP )
. (4.29)
Then using the naive independence assumption that the conditional probability of the inde-
pendent variables are statistically independent
p(xip|k, xi1, . . . , xi(p−1), xi(p+1), . . . , xiP ) = p(xip|k), (4.30)
for all p = 1, . . . , P . Therefore, the likelihood can be decomposed into a product of terms.
p(xi|k) ∝
P∏
p=1
p(xip|k). (4.31)
The relationship then simplifies to
p(k|xi1, . . . , xiP ) =
p(k)
∏P
p=1 p(xip|k)
p(xi1, . . . , xiP )
. (4.32)
Since the denominator in (4.32) - p(xi1, . . . , xiP ) is a constant given the input, one only needs
to work in proportionality:
p(k|xi1, . . . , xiP ) ∝ p(k)
P∏
p=1
p(xip|k). (4.33)
This will then give a probability of belonging to each different group k which can then be
the probability of assingment for each of the classes k for use in (4.1) with pii = p(k|xi1, . . . , xiP )
for each subject i, i = 1, . . . , N .
Then, the estimated group for each subject will be
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kˆ = arg max
k
p(k)
P∏
p=1
p(xip|k). (4.34)
To implement this in the scenario for this model, each subject was classified to one of the two
groups from their probability of belonging to each group from the model run. The probability
of belonging to group k is ( p(k) = pik). Then for each group, each covariate was assumed to be
normally distributed, since previously all variables were transformed to be a Gaussian density
and so the Gaussian Naive Bayes form was used. Where the likelihood of the features is assumed
to be Gaussian:
p(xip|k) = 1√
2piσ2pk
exp
(
−(xip − µpk)2
2σ2pk
)
, (4.35)
where µpk is the mean value of the variable p, p = 1, . . . , P in the group k, k = 1, 2 and
σ2pk is the variance of variable p in group k. This then essentially gives the probability of the
variable xip belonging to the density of the variable seen in group k.
4.4.1. Naive Bayes Results
Once the estimated probability of belonging to each group has been found for the individuals
using (4.33) to get
piik = p(k|xi1, . . . , xiP ), (4.36)
where the estimated values of αk and βk (αˆk, βˆk) have been found from the model, the
outcome can be estimated for each individual using
yi|xi1, . . . , xiP =
K∑
k=1
piikN
(
αˆk + xiβˆk, σˆ
2
k
)
. (4.37)
Table (4.10) below shows the r2 results using Naive Bayes and by using the initial model,
with the probability of belonging to each group being the overall estimate from the model pik
and not individual. This is then estimated by
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yi|xi1, . . . , xiP =
K∑
k=1
pikN
(
αˆk + xiβˆk, σˆ
2
k
)
. (4.38)
This shows that in terms of prediction for a new subject, the Naive Bayes will give a better
estimate.
Treatment Naive Bayes r2 Same probability Model
Insulin 0.691 0.618
Metformin 0.491 0.431
Glibenclamide 0.569 0.502
Chlorpropamide 0.608 0.532
Table 4.10: Naive Bayes Prediction Results
We can see that by completing Naive Bayes Prediction, the r2 values are higher and therefore
the predictions are more accurate. Insulin and chlorpropamide appear to have better predictions
and this may be down to the fact that pi1 is lower and the corresponding HbA1c in those groups
are also higher. This means that there are bigger differences between the groups and therefore
it is easier to predict the correct grouping. Although in general the correct group is being
assigned with a high probability (82%, 65%, 61% and 79% for insulin, metformin glibenclamide
and chlorpropamide respectively) there are still some issues with the prediction. Within the
UKPDS data, there are some subjects with a high intial HbA1c of over 10, which means the
Naive Bayes routine is assigning a high probability of being in group 2 for say insulin and are thus
predicted to have a greater fall in HbA1c after 1 year. Although in reality there are a handful of
these subjects who do not have a large fall in values and thus the prediction is widely incorrect.
When running the full model they are assigned to the second group, but a new patient with
these baseline parameters would fit more comfortably into group 1. This means that although
for the majority the predictions are seen to be of a good fit, there is some variability which is
not being picked up as to why certain patients who begin with high HbA1c values are not falling
as greatly as the large majority of others. This could be due to the fact that no adherence of
disease knowledge data is used within the model. In future models should take this into account
which may reduce some of this unknown variability.
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4.5. Mixture Model Summary
The main aim of this chapter was to create a mixture of normals prediction model for HbA1c
after the first year of initial treatment. To do this the model was introduced where the data is
partitioned into separate groups or batches and then each of the batches has a different model
fitted to them. The conditional distributions were found and the two step Gibbs sampling
approach was defined in how to run this and hence find the paramter estimates. Once this was
done the results were analysed they showed a better fit between the predicted and actual HbA1c
results compared with the linear regression results found in chapter 3. It also showed that the
predictions this time spread across all of the data and there was therefore less shrinkage towards
the mean. Finally, the Naive Bayes approach was introduced for estimating which group a new
individual belongs to for their prediction. When this was done for newly diagnosed individuals
it gave an r2 between 0.491 and 0.691 and as such since this gives good results for the prediction
the next thing of interest with regards to personalised medicine is to model an individuals HbA1c
over time. Chapter 5 focuses on creating a degradation model which can predict next marker
values after this initial drop and can also be used to prediction how long one can stay below a
critical boundary for.
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5
Degradation Models for predicting progressive HbA1c Over Time.
Having predicted the initial HbA1c values after 1 year for an individual, the next thing of
importance for personalised medicine is to analyse how the rate of HbA1c deteriorates over
time. This chapter will set up a Wiener process model where each step in HbA1c is modeled via
a normal distribution with a postive drift. This drift comprises two parts - a covariate effect as
well as an individual drift. This full model is then outlined with the conditional distributions
found before the parameter estimates for the drift can be used to estimate next marker values as
well as the first passage time (the time it takes to cross a critical boundary). This model is seen to
work well when both baseline variables and time data for the individual drift is known. However,
for a newly diagnosed individual only the baseline covariates would be known. Therefore, the
model is extended to create a two step process in which an initial estimate can be made and
then as time data is known for an individual this can update the model for predictions.
As seen in the previous chapters an initial drop usually occurs in HbA1c and then this
deteriorates and the values start creeping back up. Most clinical guidelines recommend aiming
for HbA1c values of < 7.0% or as close to the normal range as possible. Then over time depending
on these values, treatments are started, increased, added or replaced as the disease progresses.
Although large studies can show an overall effect on a population of an anti-diabetic drug, there
is little known about the individual effect of any particular agent on how long it can maintain
HbA1c values below the guideline levels.
The next chapter of the thesis extends unpublished work by Young, Onar, Pettit and Hol-
man who created a Bayesian Hierarichal model to understand the rate of HbA1c deterioration
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over time for different therapies. This was extended to look more at individual effects. The
same UKPDS dataset was used as in previous chapters and again this looked at patients on
monotherapy for newly diagnosed type 2 diabetes.
A general model for degradation and the associated inference procedures was suggested by
Lu and Meeker, who developed statistical methods to estimate time to failure models for a
range of distributions [70]. This was extended by Lu et al to suggest likelihood-based estimator
methods, however, these methods are seen to not be suitable for all types of degradation. [71].
In general many of the degradation based models do not have a closed form expression when
non-linear and therefore approximation methods are used, for example Lu and Meeker [70] and
Ramos and Pantula [72].
Bayesian models are shown to have an advantage over maximum likelihood based estimates as
inferences can always be provided without the need for approximation [73] due to Markov-Chain
Monte Carlo methods such as Gibbs Sampling (A.2.1.). Within pharmacokinetics Bayesian
methods have been used before for degradation models such as by Wakefield [74], however,
these methods do not have much exposure in the analysis of the disease pathway. Here, a
Bayesian degradation model with a Wiener process is used, as proposed by Pettit and Young
[75].
5.1. The Bayesian Degradation Model
Throughout the UKPDS dataset HbA1c was collected at least annually. Fasting Plasma Glucose
(FPG) levels were collected at either three or four-monthly patient visits, however it has since
been recognised that HbA1c is better for predicting the long-term risk of diabetic complications
as this is less sensitivee to daily food intake and exercise levels, whereas FPG can be seen to
fluctuate greatly throughout the day, particularly in relation to meals. Hence it was decided that
the model would focus on HbA1c levels over time, for patients with monotherapy, who reduced
to under 7% after 1 year of treatment.
It can be seen that HbA1c levels do increase over time after an initial drop from therapy
being introduced, but how quickly they increase can be quite variable individually. The inherent
upward and downward fluctuations of biomarker levels over time clarify the degradation process.
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For this reason a Wiener process was used to model the degradation. The use of a Wiener
process for a degradation model was used by Pettit and Young [75]. Others have suggested
this is a good process for health as Pennell et al [76] who suggested that “a Wiener process is
a realistic model for health status because although the patient health will tend to decline over
time improvements or depreciation are both possible and are accomodated by the bidirectional
movements of the Wiener process”. For the UKPDS data it seems that a Wiener process is a
reasonable assumption of average deteroration with independent normal increments. However,
it should be noted that for many patients their profile showed successive measurement of HbA1c
levels which were considerably lower or higher.
It is useful to note that this study was performed over a number of years and therefore
there is a high number of subjects who either drop out or are lost to the study. This then
means that after their withdrawal no more information is known about the patient. The model
here deals with this in that it allows for any length of study involvement by focusing on time
increments rather than across the entire study time frame. Also, in this model it is only looking
at monotherapy and as such some subjects then have no more data which can be used in the
model, however they are still involved in the study. Further work could look at treatment effects
after initial monotherapy.
5.1.1. The Wiener Process
The Wiener process is a continuous time stochastic process, often referred to as Brownian motion.
A Wiener process Wt is defined by 3 basic properties
Definition 5.1. Wiener Process
1. W0 = 0.
2. The function t→Wt is almost surely everywhere continuous.
3. Wt has independent increments with Wt −Ws ∼ N(0, t− s) with 0 ≤ s < t.
The process
Xt = νt+ σWt, (5.1)
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is then defined to be a Wiener process with drift ν and votality σ. The drift here is the
degradation amount, with the process increasing more over time with a larger positive drift.
For the data, the incremental changes in the log-transformed response variable HbA1c were
modeled by a Wiener process with a drift composed of linear covariate effects as seen in previous
chapters νi and an individual level fraility parameter θi. The aim is to get an overall picture
of each individuals progression and also to predict at which time the degradation process will
reach a clinically important threshold. In this thesis it was decided to look at predicting when
a patient will cross over 7% for HbA1c as this can be seen as the time when therapies could be
added or changed and this is referred to as the First Passage Time (FPT).
Each patient i has ki HbA1c measurements at predetermined time points ti usually at yearly
intervals and some individuals have measurements quarterly for some years also. Therefore, each
of the N patients has HbA1c measurements, j = 1, . . . , ki measured at times tij . Each patient
also has a vector of P covariates Zi.
Define H(t) to be the HbA1c value at time t, t ≥ t0 to be the degradation process, where
t0 is the time when the degradation is first detected. Without loss of generality this can be set
at t0 = 0 and in this case corresponds to diagnosis and thus H(t0) is independent of treatment.
H(t0) > 0 since all HbA1c values are positive. This value is used as an estimate of the starting
point of the Wiener process and the analysis presented is conditional on H(t0). To begin with
and for stability the first initial HbA1c value was estimated as the geometric mean of the first
two observed HbA1c values - randomization and 6 months after randomization. This was to try
and stabilise the initial drop seen by an individual after treatment is initially given, which can
be seen from the previous chapter is quite variable among patients.
It is assumed that the observation times for each patient ti1, . . . , tiki are uninformative such
that their joint distribution does not depend on the parameter vector of the model. This can
be assumed since these observation times are set by the clinics and are therefore not dependent
on HbA1c.
The log transformed values of HbA1c (H(t)), defined to be X(t), were then modelled via a
Wiener process with drift ν as defined above, with drift νi = vi + θi. This then leads to two
seperate parts of the drift where vi represents the covariate effect and θi is the individual fraility
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parameter. σ2i is used to denote the patient specific diffusion parameter. This form of a drift can
lead to a negative drift, assigning a positive probability that an individuals condition may never
reach a criticial boundary. In reality this may indicate that their diabetes can be effecitively
managed and controlled for the forseeable future.
5.1.2. The Full Model
To model a patient’s degradation over time, it is useful to model their marker increments
Yij = X(tij)−X(ti(j−1)), (5.2)
for j = 1, . . . , ki and i = 1, . . . , N . These marker increments can then be assumed to follow
a Normal distribution
Yij ∼ N
(
(vi + θi)(tij − ti(j−1)), σ2i (tij − ti(j−1))
)
. (5.3)
It is initially assumed that the drift parameter depends linearly on the covariates, which is
taken to be similar to previous chapters. Therefore, define vi = Z
T
i β. Where β is a P ×1 vector
of unknown degradation regression coefficients.
From the definition of a Wiener process two seperate increments are independent random
variables and the same condition holds for both of them. Defining
Y i = (X(ti1)−X(ti0), X(ti2)−X(ti1), . . . , X(tiki)−X(ti(ki−1)))
= (Yi1, Yi2, . . . , Yiki), (5.4)
for the ith patient i = 1, . . . , N , with ki HbA1c measurements then
Y i ∼ Nki
(
Aiβ + θiti, σ
2
i Vi
)
, (5.5)
where Ai is a ki ×P matrix formed by multiplying ti and ZTi with tTi =
(
ti1 − ti0, . . . , tiki −
ti(ki−1)) and Vi is a ki× ki diagonal matrix with the jth diagonal entry tij − ti(j−1). β is a vector
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of P unknown regression coefficients.
The unknown parameters of this model were estimated in a Bayesian approach using MCMC
techniques as before - the Gibbs sampler (A.2.1.). An advantage of using the Bayesian approach
is that priors can be used which incorporate existing knowledge.
5.1.3. Priors for the Bayesian Model
For the model defined in (5.5) conjugate priors were used to create the posteriors. The condi-
tional distributions are found by multiplying the likelihood by the priors for the unknown para-
meters of interest. Similarly to previously, the covariate coefficients were assigned a multivariate-
normal prior and the diffusion parameter was modeled by an inverse gamma distribution.
β ∼MVN(β0,Σ)
= |2piΣ|−1exp(− 1
2
(β − β0)TΣ−1(β − β0)
)
, (5.6)
σ2i ∼ Inv −G(ω,Λ)
=
Λω
Γ(ω)
(σ2i )
−(ω+1)exp
(− Λ
σ2i
)
. (5.7)
As before the inverse gamma distribution parameters were fixed and the prior values were
estimated using an independent subset of the original data and maximum likelihood methods
and the same inverse gamma prior was used for all patients. The parameters for the covariate
coefficients were deemed to be hierarchical and therefore given hyperpriors.
f(β, σ2i ) ∼ NP (β0,Σ)IG(ω,Λ). (5.8)
The hyper prior for β0, a P × 1 vector, for the mean of β was also assumed to be a multi-
variate normal
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β0 ∼ NP (µ, C). (5.9)
The variance-covraice matrix of β - Σ, was given a conjugate inverse-Wishart prior
Σ−1 ∼W (ρ, (ρU)−1), (5.10)
where U was chosen to be equal to C and ρ is taken to be equal to the most vague choice of the
number of covariates.
For the individual level fraility parameter θi a multivariate-normal distribution was also
used with prior values found from individual level maximum likelihood estimation which was
performed previously to any analysis. This involved fitting the maximum likelihood estimate
for an individual. This was then specified as
θi ∼ N
(
θ0i, σθ0i
)
. (5.11)
5.1.4. Maximum Likelihood Estimates for the Initial Prior Values
As mentioned previously, maximum likelihood methods were used for the priors of the values
of µ and C for the hyper-prior parameters of β0, assuming that only a covariate effect is seen
and no individual θi effect. This was chosen over a non informative case primarily due to the
model taken a long time to converge when no prior information was included in the model and
converging to one with almost no baseline covariate effect. Since the model encorporates both
an individual effect as well as a baseline covariate effect it was seen that when the model was run
using non informative priors that all of the predictive information came from the individual effect
θi, rather than from the baseline variables β. Although after some amount of time, this would
be seen to be the parameter which is most likely to give good predictive results, earlier in an
individuals treatment this individual parameter would be very hard to estimate well. Therefore,
by using empirical priors which include the estimate of the baseline covariates without this
individual effect, then the model will more quickly converge to one which encompasses both of
the effects, which is better in terms of overall prediction.
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When this is the case the log-likelihood - L can be estimated and this is proportional to
L ∝ N log σ2 +
N∑
i=1
(
Yi −Aiβ
)T
V −1i
(
Yi −Aiβ
) 1
σ2
. (5.12)
To get the maximum likelihood estimate for β only proportionality in β is required:
L ∝
β
N∑
i=1
(
Yi −Aiβ
)T
V −1i
(
Yi −Aiβ
)
=
N∑
i=1
(
Y Ti V
−1
i Yi − 2Y Ti V −1i Aiβ + βTATi V −1i Aiβ
)
. (5.13)
Result 5.2. if Q is a symmetric matrix and α = xTQx then
dα
dx
= 2xTQ. (5.14)
Then by differentiating using Result 5.2, setting the result equal to 0 and then rearranging
in terms of β the maximum likelihood can be found.
dL
dβ
= −2
N∑
i=1
Y Ti V
−1
i Ai + 2β
T
N∑
i=1
ATi V
−1
i Ai. (5.15)
Rearranging this in terms of β:
βT =
( N∑
i=1
Y Ti V
−1
i Ai
)( N∑
i=1
ATi V
−1
i Ai
)−1
. (5.16)
Then setting βˆ to be the estimated maximum likelihood estimate
βˆ =
( N∑
i=1
ATi V
−1
i Ai
)−1( N∑
i=1
ATi V
−1
i Yi
)
. (5.17)
This will then be the vector of prior intial estimates given by µ.
The variance covariance matrix estimate of β - C can also be calculated for the prior by
maximum likelihood methods. To do this set V −1i = W and note that W
T = W .
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var(βˆ) = var
(( N∑
i=1
ATi WAi
)−1 N∑
i=1
ATi WYi
)
= var
(( N∑
i=1
ATi WAi
)−1 N∑
i=1
ATi W (Aiβ + )
)
= var
(( N∑
i=1
ATi WAi
)−1 N∑
i=1
ATi W
)
. (5.18)
Result 5.3.
var(a) = avar()aT .
Then using result (5.3), (5.18) becomes
var(βˆ) =
( N∑
i=1
ATi WAi
)−1 N∑
i=1
ATi W
(
var()
)
WAi
( N∑
i=1
ATi WAi
)−1
. (5.19)
Note that var() = σ2Vi = σ
2W−1. Then
var(βˆ) =
( N∑
i=1
ATi WAi
)−1 N∑
i=1
ATi W (σ
2W−1)WAi
( N∑
i=1
ATi WAi
)−1
= σ2
( N∑
i=1
ATi WAi
)−1 N∑
i=1
ATi WAi
( N∑
i=1
ATi WAi
)−1
= σ2
( N∑
i=1
ATi WAi
)−1
, (5.20)
Cˆ = σˆ2
( N∑
i=1
ATi V
−1
i Ai
)−1
. (5.21)
Where the estimate of the variance σˆ2 can be found also using maximum likelihood methods
as above by differentiating (5.12) with respect to σ2:
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dL
dσ2
=
N
σ2
−
∑N
i=1(Yi −Aiβˆ)TV −1i (Yi −Aiβˆ)
(σ2)2
α = N −
∑N
i=1(Yi −Aiβˆ)TV −1i (Yi −Aiβˆ)
σ2
. (5.22)
Then rearraginging in terms of σ2 the maximum likelihood estimate can be found
σˆ2 =
1
N
N∑
i=1
(
Yi −Aiβˆ
)T
V −1i
(
Yi −Aiβˆ
)
, (5.23)
where βˆ is the estimate given by eq (5.17). The estimate found in eq (5.23) will not be
purely used for a prior here as an inverse gamma distribution is assumed, therefore the estimate
will be used as the mean for the prior distribution with ω = 2 and Λ = σˆ2 for which the mean
is Λ/(ω − 1) which is therefore equal to σˆ2. Also in the full model, the σ2 is assumed to be
individual and therefore σ2i .
In the same way the maximum likelihood estimator can be found for the individual drift
effects for θi assuming that only an individual effect is used. In this case the maximum likelihood
can be found for each individual and so no summation is necessary and thus the likelihood is
proportional in θi to
L ∝
θi
(
Yi − θiti
)T
V −1i
(
Yi − θiti
)
,
∝
θi
tTi θ
T
i V
−1
i θiti − 2tTi θTi V −1i Yi. (5.24)
Then using the same formulation as above the maximum likelihood estimator θˆi can be found
by differentiating with respect to θi and rearranging in terms of θi.
dL
dθi
= −2tTi V −1i Yi + 2θTi tTi V −1i ti, (5.25)
θˆi =
(
tTi V
−1
i ti
)−1(
tTi V
−1
i Yi
)
. (5.26)
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This can then be used for the prior of θi
θˆi = θ0i. (5.27)
In the same way the variance for the individual drift effects can also be found using maximum
likelihood estimates for σ2θ0i where
σ2θ0i =
(
Yi − θˆiti
)T
V −1i
(
Yi − θˆiti
)
. (5.28)
The likelihoods were estimated seperately so that the priors were set as if that was the only
effect, this also meant that there would not be dependencies in the estimators on other unknown
coefficients. The mixing of the unknown parameters for β and θi would still be achieved in the
Gibbs Sampling routine for the conditional distributions are dependent on each other as shown
in the next section.
5.1.5. Conditional Distributions for Degradation Model
Once the priors have all been set up, the resulting conditional distributions for each parameter,
given all the other parameters can be found by multiplying the prior and the likelihood distri-
butions. This then means that the Gibbs Sampling routine (A.2.1.) can run for a total of L
iterations, each time updating the conditional distribution for each parameter, given the current
estimates, until convergence is found.
The full degradation model in (5.5) is a multivariate normal distribution for Y i including ki
points for each subject i, i = 1, . . . , N . The density of this is
f(Y i) = (2pi)
ki
2 (σ2i Vi)
− 1
2 exp
(
− 1
2σ2i
(
Y i − (Aiβ + θiti)
)T
V −1i
(
Y i − (Aiβ + θiti)
))
. (5.29)
The prior distribution of β is assumed to be multivariate normal with mean vector β0 and
covariance matrix Σ. This has the density
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f(β) = (2pi)
P
2 |Σ|− 12 exp
(
− 1
2
(β − β0)TΣ−1(β − β0)
)
. (5.30)
Then the full conditional for the unknown coefficient parameters β can be found by p(β)p(Y |β,σ,θ).
With Y being defined as the matrix with the outcomes for all i = 1, . . . , N subjects, each with
with ki data points. To find the conditional distribution for β only proportionality in β is needed
and thus only inside the exponential is required for the analysis -
p(β) ∝
β
exp
(
− 1
2
(βTΣ−1β − 2βTΣ−1β0)
)
. (5.31)
To find the conditional distribution for β by multiplying the prior and the likelihood only
proportionality in β from the likelihood (5.29) is required. The likelihood needs to then be the
sum of all Yi and this can be found by multiplying out and doing some arranging to give
p(Y |β,σ,θ) ∝
β
exp
(
− 1
2
N∑
i=1
1
σ2i
(
Yi −Aiβ − θiti
)T
V −1i
(
Yi −Aiβ − θiti
))
,
∝
β
exp
(
− 1
2
N∑
i=1
1
σ2i
(− 2βTATi V −1i Yi + βTATi V −1i Aiβ + 2βTATi V −1i θiti)),
= exp
(
− 1
2
N∑
i=1
1
σ2i
(
βT (ATi V
−1
i Ai)β − 2βT (ATi V −1i
(
Yi − θiti)
)))
. (5.32)
Therefore the full conditional of β can be found by multiplying the prior and likelihood
proportional in β by each other which gives it proportional to
exp
(
− 1
2
(
βT ((
N∑
i=1
1
σ2i
ATi V
−1
i Ai) + Σ
−1)β− 2βT (( N∑
i=1
1
σ2i
ATi V
−1
i Y i− θiti) + Σ−1β0)
))
. (5.33)
Result 5.4. A vector z is defined to be a multivariate normal with mean m and covariance
matrix V if and only if
p(z|m,V ) ∝ exp
(
− 1
2
(zTV −1z − 2zTV −1m)
)
. (5.34)
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Then using result (5.4) it can be seen that β fits this form and is thus a multivariate normal,
which is to be expected since conjugate priors were applied. The resulting full conditional is
such
β ∼ NP (β∗,Σ∗), (5.35)
where
β∗ = Σ∗
( N∑
i=1
1
σ2i
(
ATi V
−1
i (Y i − θiti)
)
+ Σ−1β0
)
, (5.36)
Σ∗ =
( N∑
i=1
1
σ2i
(
ATi V
−1
i Ai
)
+ Σ−1
)−1
. (5.37)
The hyper prior for the mean of β, β0 was also chosen to be a multivariate normal distribution
with mean µ and covariance matrix C found via least squares estimation.
p(β0) = (2pi)
P
2 |C|− 12 exp
(
− 1
2
(β0 − µ)TC−1(β0 − µ)
)
. (5.38)
To find the conditional distribution of β0 this is p(β0)p(β|β0,Σ). Again, this only needs to
deal with proportionality and so is proportional to
p(β0)p(β|β0,Σ) ∝
β0
exp
(
− 1
2
(β − β0)TΣ−1(β − β0)
)
× exp
(
− 1
2
(β0 − µ)TC−1(β0 − µ)
)
,
= exp
(
− 1
2
(
βTΣ−1β − 2βTΣ−1β0 + βT0 Σ−1β0 + β0C−1β0 − 2βT0 C−1µ+ µTC−1µ
))
,
∝
β0
exp
(
− 1
2
(
βT0 (Σ
−1 + C−1)β0
)− 2βT0 (Σ−1β + C−1µ)). (5.39)
Then using Result 5.4 again it is shown that β0 is also a multivariate normal distribution
the full conditional of which is
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β0 ∼ NP (β∗0,Σ0), (5.40)
where
β∗0 = Σ0
(
C−1µ+ Σ−1β
)
,
Σ0 =
(
Σ−1 + C−1
)−1
. (5.41)
The next conditional considered is that for θi, similar to before this can be seen to be
proportional to p(θi)p(Y i|θi,β, σi). The prior distribution for the θi is normal and for Y i one
only needs to use the individual multivariate normal distributions as noted in (5.29).
p(θi) =
1
σθ01
√
2pi
exp
(
− 1
2σ2θ0i
(θi − θ0i)T (θi − θ0i)
)
. (5.42)
Then the full conditional for θi is
p(θi)p(Y i|θi,β, σi) ∝
θi
exp
(
− 1
2σ2θ0i
(θi − θ0i)T (θi − θ0i)
)
× (5.43)
exp
(
− 1
2σ2i
(
Y i − (Aiβ + θiti)
)T
V −1i
(
Y i − (Aiβ + θiti)
))
. (5.44)
Only proportionality in θi is needed and this is
∝
θi
exp
(
− 1
2σ2θ0i
(
θTi θi − 2θTi θ0i
)− 1
2σ2i
(− 2Y Ti V −1i θiti + 2βTATi V −1i θiti + tTi θTi V −1i θiti)),
= exp
(
− 1
2
(
θTi
( 1
σ2θ0i
+
tiV
−1
i ti
σ2i
)
θi
)
− 2θTi
(
θ0i
σ2θ01
+
(Y i −Aiβ)TV −1i tTi
σ2i
))
. (5.45)
Then again using Result 5.4, eq 5.45 is seen to be a multivariate normal density. Thus the
conditional for θi is
θi ∼ N(θ∗i , σ2θi), (5.46)
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where
θ∗i =σ
2
θi
(
θ0i
σ2θ01
+
(Y i −Aiβ)TV −1i tTi
σ2i
)
, (5.47)
σ2θi =
(
1
σ2θ0i
+
tiV
−1
i ti
σ2i
)−1
. (5.48)
Next to consider is the conditional for σ2i which is an inverse gamma with fixed paramters
ω and Λ. The density of σ2i is
p(σ2i ) =
Λω
Γ(ω)
σ
2(−ω−1)
i exp
(
− Λ
σ2i
)
. (5.49)
It can be seen that
p(σ2i |Y i,β, θi) ∝ p(σ2i )p(Y i|σi, θiβ), (5.50)
where
p(σ2i ) ∝
σ2i
(σ2i )
−(ω+1)exp
(
Λ
σ2i
)
, (5.51)
p(Y i|σ2i , θi,β) ∝
σ2i
(σ2i )
− ki
2 exp
(
− 1
2σ2i
(
Y i − (Aiβ + θiti)
)T
V −1i
(
Y i − (Aiβ + θiti)
)
. (5.52)
Therefore
p(σ2i |Y i,β, θi) ∝
σ2i
(σ2i )
−(ω+ ki
2
+1)exp
(
− 1
2σ2i
(
2Λ+(Y i−Aiβ−θiti)TV −1i Y i−Aiβ−θiti)
))
. (5.53)
Which is the kernel of an inverse gamma distribution, which is to be expected since a
conjugate prior was used. So the conditional distribution for σ2i is an inverse gamma with
parameters
σ2i ∼ IG
(
λ+
ki
2
,
1
2
(
2Λ + (Y i −Aiβ − θiti)TV −1i Y i −Aiβ − θiti)
))
. (5.54)
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Finally the last hyper-prior conditional for Σ, the covariance matrix of β needs to be derived.
This is defined to come from an inverse Wishart distribution. Since Σ arises from a Wishart
distribution then the precision matrix Σ−1 comes from a Wishart distribution
Σ−1 ∼Wishart(ρ, (ρU)−1)). (5.55)
The Wishart distribution is seen to be the conjugate prior for the P × P positive definite
matrix for the precision matrix of β. The Wishart distribution arises from the distribution of
the covariance matrix from a multivariate normal distribution. It is defined by 2 parameters, a
- the degrees of freedom with a > P − 1, in this case a = ρ to hold the denisty and B a fixed
positive definite matrix of size P × P , in this case B = (ρU)−1. The density of Σ−1 is then
1
2
ρP
2 |(ρU)−1| ρ2 ΓP
(ρ
2
) |Σ−1| ρ−P−12 exp(− 12 tr(Σ−1(ρU))
)
. (5.56)
Similarly to before the conditional can be found using p(Σ−1) using proportionality and
multiplying by p(β|β0,Σ).
p(Σ−1) ∝
Σ−1
|Σ−1| ρ−P−12 exp
(
− 1
2
tr
(
Σ−1(ρU)
))
, (5.57)
p(β|β0,Σ) ∝
Σ−1
|Σ|−P2 exp
(
− 1
2
(
β − β0
)T
Σ−1
(
β − β0
))
. (5.58)
Then multiplying together gives
p(Σ−1)p(β|β0,Σ−1) ∝
Σ−1
|Σ|− 12 (ρ−1)exp
(
− 1
2
tr
(
ρU + (β − β0)T (β − β0)
)
Σ−1
)
, (5.59)
since
(β − β0)T (β − β0) = tr(β − β0)T (β − β0), (5.60)
is singular. Also tr(aB) = a ∗ tr(B). So rearranging gives the form (5.59) which can be seen
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to be the Kernel of a Wishart distribution, to be expected as conjugate priors were used.
Thus then it can be seen that the conditional for Σ−1 the precision matrix for the prior of
β is
Σ−1 ∼W
(
ρ+ P,
(
(β − β0)T (β − β0) + ρU
)−1)
. (5.61)
It is no surprise that all the above posterior distributions for each of the unknown parameters
are consistent with their corresponding priors, since the latter were conjugate.
5.1.6. Gibbs Sampler
Since all the conditional distributions for the unknown parameters have been calculated, a Gibbs
sampling routine can run for a total of L iterations. Using the prior conditions stated previously
and with sensible starting values, the iterations will run through each of the conditional distri-
butions updating each parameter based on the current iteration values for all the other unknown
parameters. This is the Gibbs Sampling technique as described in the Appendix (A.2.1.). The
routine here goes as follows
For each iteration l = 1, . . . , L.
1. Draw the β estimates for the P × 1 vector for p = 1, . . . , P from
β ∼ Nd(β∗,Σ∗), (5.62)
where
β∗ = Σ∗
( n∑
i=1
1
σ2i
(
ATi V
−1
i (Y i − θiti)
)
+ Σ−1β0
)
, (5.63)
Σ∗ =
( n∑
i=1
1
σ2i
(
ATi V
−1
i Ai
)
+ Σ−1
)−1
. (5.64)
2. Draw the hyer-prior for the mean of β - β0 for the P × 1 vector p = 1, . . . , P from
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β0 ∼ NP (β∗0,Σ0), (5.65)
where
β∗0 = Σ0
(
C−1µ+ Σ−1β
)
,
Σ0 =
(
Σ−1 + C−1
)−1
. (5.66)
3. Draw the hyper-prior for the variance covariance matrix of β - Σ−1
Σ−1 ∼W
(
ρ+ P,
(
(β − β0)T (β − β0) + ρU
)−1)
. (5.67)
4. Draw the individual drift parameter estimates θi for i = 1, . . . , N from
θi ∼ N(θ∗i , σ2θi), (5.68)
where
θ∗i =σ
2
θi
(
θ0i
σ2θ01
+
(Y i −Aiβ)TV −1i tTi
σ2i
)
, (5.69)
σ2θi =
(
1
σ2θ0i
+
tiV
−1
i ti
σ2i
)−1
. (5.70)
5. Draw the patient specific diffusion parameter σ2i for i = 1, . . . , N from
σ2i ∼ Inverse−Gamma
(
λ+
ki
2
,
1
2
(
2Λ + (Y i−Aiβ− θiti)TV Ti Y i−Aiβ− θiti)
))
. (5.71)
5.2. Predicting First Passage Time and Future Marker Values
Modelling a patients degradation over time is indeed very helpful for monitoring diabetes pro-
gression, but it is of clinicial interest to predict the time from diagnosis to a pre-defined boundary
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for a patient on a certain treatment. Being able to accurately predict the first passage time for
a patient would help to manage patient care and help with treatment strategy. The way to do
this is outlined in this next section.
As most clinical guidelines suggest lowering a patients HbA1c to as close to the normal range
as possible an arbitary cut off of < 7% is considered here. This then means that once a patients
HbA1c level rises above 7% that treatments should be added or changed completely. Due to this
the degradation model will be used to find the estimated first passage time to 7% for HbA1c.
Then by predicting this it could help clinicans to see how long a patient could be well maintained
on a specific treatment for.
The increments of the log-transformed HbA1c levels were modeled using a Wiener process and
it is known that the distribution of the first passage time to reach a pre-determined threshold
is inverse Gaussian [77]. Using the results from Gibbs Sampling for the estimates from the
parameters of the degradation model, the parameters of the Inverse Gaussian Distribution can
be estimated also.
Let cr denote the critical boundary of the biomarker process, in this particular case cr = 7
referring to aHbA1c level of 7%. Provided that the drift ν = Ziβ+θi is positive then for a subject
with covariate vector Zi and initial marker value X0i(0) = xi0, the conditional distribution of
the residual time Ti until the biomarker crosses cr is Inverse Gaussian - IG(ti|ϑi, ζi), where
ϑi =(
ci
νi
),
νi =Z
T
i β + θi,
ζi =
c2i
σ2i
,
ci =ln
(
cr
x01
)
. (5.72)
Which means that the density of the first passage times ti is
f(ti|xi0) =
[
ζi
2pit2
]1/2
exp
(
− ζi
2ϑ2i
(t− ϑi)2
t
)
. (5.73)
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These inverse Gaussian densities can then be found to make predictions for the first passage
time for each patient. A problem with such a density distribution is that unless ζi is much larger
than ϑi then the distribution of the first passage time will be highly skewed. This is since it is
a skewed distribution and as ζi tends to infinity the distribution tends to the Normal Gaussian
distribution.
In some cases individuals will have a negative drift, meaning that the first passage time has
a defective distribution. This means that it is infinite with positive probability and thus one
cannot predict the first passage time for an individual. When this is the case a probability of
the individual crossing the critical boundary can be calculated instead. The probability that
the process will cross this boundary for a patient with negative drift νi and diffusion parameter
σ2i is
(
H(0)
cr
) 2|νi|
σ2
i , (5.74)
where in this case cr = 7.
5.2.1. Predicting Future Markers
Another thing of interest for the concept of personalised medicine is to be able to predict the
next marker point once degradation has occured for an individual. Using the Wiener process
degradation model, estimates of the HbA1c values at future time points can be calculated and
the process of doing so is outlined in the next section.
The HbA1c levels for any given time can be predicted as the log-HbA1c levels are modelled
for each patient i, i = 1 . . . , N via a Wiener process with drift νi = Z
T
i β + θi and a diffusion
constant parameter σ2i .
The log-HbA1c value for any given time t can be written as
H(t) =H(0)eX(t), (5.75)
X(t) =
(
ZTβ + θ − σ2)t+ σWt,
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where Hi(0) is the initial baseline value for individual i and Wt the standard Wiener process.
This means that Hi(t) is a standard geometric Wiener process. Here it is important to note that
a given future state Hi(t + h) depends only on the future increment of the Brownian Motion,
which is independent.
H(t+ h) = H(0)exp
(
X(t+ h)
)
,
= H(0)exp
(
X(t) +X(t+ h)−X(t)),
= H(0)exp
(
X(t)
)
exp
(
X(t+ h)−X(t)),
= H(t)exp
(
X(t+ h)−X(t)), (5.76)
by using eq. (5.75).
This then means that our process has the Markov Property.
The expectation and variance of the process can then be found and thus an estimate of the
log-HbA1c for a given time point t. To do this first of all create the moment generating function.
MX(t)(s) =E
(
exp
(
sX(t)
))
=exp
(
t
(
(ZTβ + θ)s+
σ2
2
s2
))
. (5.77)
Then the expectation and variance can be found
E
(
H(t)
∣∣H(0) = H0) =E(H(0)eX(t)),
=H(0)MX(t)(1),
=H(0)exp
(
t
(
ZTβ + θ +
1
2
σ2
))
, (5.78)
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V ar(H(t)|H(0) = H0) =E
(
H2(t)
)− E(H(t))2,
=H(0)2exp
(
2t
(
ZTβ +
1
2
θ
)
t+ σ2t
)(
exp(σ2 − 1)). (5.79)
Then predictions for t a residual time can be found given the initial baseline log-HbA1c value,
the indivdiaul fraility and diffusion parameters θi and σ
2
i and the given covariates and β values.
5.3. Convergence and Assessment of the Model
To assess convergence 2 chains were run for each model with different starting values. Those
found by the maximum likelihood methods and another chain with 0 for all starting values. To
do this autocorrelation plots were first of all inspected to gather what thinning should be used.
Then Raftery-Lewis statistics for the number of iterations and burn in can be found and the
final chain can then be run. Once this has been complete, final convergance was assessed using
Gelman-Rubin plots and statistics and by visual inspection of trace plots.
5.3.1. Auto Correlation
The chains were initially run for 5000 iterations keeping each value. Then Autocorrelation can be
calculated using the methods in Appendix (A.3.3.). In this model there are a number of different
variables to assess. The β values but also each individual has their own drift θi and variability
σ2i . For illustrative purposes the β iterations are shown, but the individual parameters were also
assessed and gave similar results. The Auto-Correlation plots for insulin are given in Figure 5.1.
The Auto Correlation plots for metformin, chlorpropamide and glibenclamide and given in the
Appendix C.1.1.
Figure 5.1 shows that there is some auto correlation and therefore every 20th value was stored
for the model. The θi and σi had some individuals with an autocorrelation and so every 20
th
value would also be appropriate here. However, in general most of the individual parameters
had almost no auto-correlation.
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Figure 5.1: Autocorrelation Plots for the Insulin Degradation Model
5.3.2. Raftery-Lewis Diagnostic
The Raftery-Lewis Diagnostic was calculated for all models, again focusing primarily on the β
values using the method in Appendix A.3.2.. Here, M for all models was seen to be larger then
in the previous chapters of around 500, but again with every 20th value the chain was required
to be run for around 4000-5000. Therefore, for consistency with other chapters the chain was
run initially for a burn in of 5000 iterations and then the remaining 5000 iterations are used for
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the posterior distributions for the analysis.
5.3.3. Gelman-Rubin Statistic
The Gelman-Rubin statistic analyses the convergence once the full chains have been run. The
plots for the insulin Model are shown in Figure 5.2. These show that convergence has been
achieved and all the estimates are below 1.1. For all treatment models the Gelman-Rubin
Statistics were between 1 and 1.1, these are low enough to be considered converged. The Gelman
Rubin plots for metformin, chlorpropamide and glibenclamide are given in the Appendix C.1.2.
5.3.4. Bayesian P Value and Sensitivity Analysis.
To assess how good of a fit the model is, a Bayesian P-value can be calculated as outlined in
Appendix A.4.. In this case discrepancies were chosen to be set values, namely the within-
subjects standard deviations and the values of the steps for individuals Yij , i = 1, . . . , N , j =
1, . . . , ki. These were chosen as a good overall view of the data to ensure that the model is
sensible and predicts steps that are consistent with the data. To look at a full view of the data
P-values were found for the minumum and the maximum of these two discrepancies. Therefore
the P-value needs to be as close to 0.5 as possible and not lying in the extremes so either
close to 0 or 1. This then would correspond to a good “fit”. A histogram plot of the sampled
discrepancies can also see whether these give a good model. 1000 posterior draws were sampled
for the posterior predictive check.
For the model for insulin the Bayesian P-Values were found to be of a good fit and closer to 0.5
then to the extremes. A plot of the minimum and maximum discrepancies are shown in Figure 5.3
for the Yi values - increment values and in Figure 5.4 for the within-subject standard deviations.
Figures 5.4 and 5.3 give histograms for the simulated values for the discrepancy measures and
the solid line is the actual value from the data. The legend then gives the corresponding Bayesian
P-value.
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Figure 5.2: Gelman Rubin Plots for the Insulin Degradation Model
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Figure 5.3: Histogram of simulated Yi values and corresponding Bayesian P-Values
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Once these were found and the model was found to be appropriate, the sensitivity of the
prior to these results were all examined. Following the example of previous chapters the entire
analysis was repeated with quadrupled variance for the priors for all parameters. This was found
to have the same results with similar predictions and estimates for all values and thus the model
appears to be of a good fit. The models were also run originally with different starting values
and these shows convergence and thus it is assumed that the model is insensitive to priors or
starting values. A table of all the Bayesian P Values is given in Table 5.1.
Treatment Min P Value Max P Value Min P Value Max P Value
Marker Increments Marker Increments Patient sd Patient sd
Insulin 0.77 0.48 0.71 0.15
Metformin 0.11 0.89 0.81 0.50
Chlorpropamide 0.370 0.521 0.553 0.773
Glibenclamide 0.652 0.455 0.541 0.489
Table 5.1: Bayesian P Values for the Degradation Model
5.4. Model Validation through Prediction of Markers
The model appears to be of a good fit through convergence, sensitivity analysis and Bayesian
P-Values. However, the main aim of the model is to predict an individuals HbA1c value at
certain time points. First of all, it was decided to look at how well the model could predict the
next time point. Any time point here could be chosen, however the last time point was picked
to fit with the use of the model. The clinical interest of this model would be to be able to
predict the next marker value at a time point for an individual given already observed values.
To do this the model was rerun excluding the final time point for each individual. This also
showed similar estimates for all the parameters. Then the final time point for each individual
was estimated using (5.78). A plot of the actual versus the predicted final time points for each
individual is shown in Figure 5.5 for the insulin model.
The plots for metformin, chlorpropamide and glibenclamide are given in the Appendix C.2.1.
These are seen to be of a good fit with r2 values of 0.601, 0.511, 0.521 and 0.359 for insulin,
metformin, chlorpropamide and glibenclamide respectively.
The main idea as stated around the model is to predict the next value of HbA1c given values
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Figure 5.5: Actual versus Predicted values for the Final Time point.
over time. Since the model assumes that the marker increments are normally distributed with
a positive drift at each point in time, the next value of HbA1c will always be estimated to be
a higher value than currently seen. This is since the mean value of the distribution is positive
Aiβ + θiti. However, in reality the marker increments can increase or decrease, but with this
positive drift. The model takes this into account and the estimated value increase averages out
both the increases and decreases of the markers over time with the positive drift. A random
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example was chosen to show how the estimates work over time. Using the estimated β and
individual fraility parameter θi the estimated HbA1c was estimated for an individual at every
year and plotted agaisnt the actual values in Figure 5.6.
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Figure 5.6: Actual HbA1c and estimates HbA1c values for an example individual over time
This plot shows that on average the estimated HbA1c values are close to the actual levels
excluding noise seen over time.
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5.5. First Passage Time Results
As found earlier a prediction of the First Passage Time (FPG) until a patient reaches a certain
level can be estimated as an Inverse Gaussian Distribution with the parameters in (5.72). Since
the ADA recommend reducing HbA1c levels to as close to the normal range as possible, in this
case the critical boundary was set to be cr = 7. Then the estimated parameter values for β and
the individual frailty parameters θi for i = 1, . . . , N are found from the model. A plot of the
actual versus predicted FPG times for insulin is given in figure 5.7
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Figure 5.7: Actual versus Predicted values for FPT for Insulin
Figure 5.7 shows a good fit with the actual and predicted values being close. These results
gave an r2 = 0.652 and rmse=2.058 for insulin. The r2 for metformin was 0.703 and rsme 1.03,
for chlorpropamide r2 = 0.580 and rmse was 2.24. Finally, glibenclamide gave an r2 of 0.676
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and rsme of 1.799.
However, there is more which should be looked at here. The idea of the model is to estimate
how long an individual can stay below a given critical boundary (7%) here and so the actual
estimation should be looked at. One thing then to consider is how far off the estimate is, as it
would be crucial that the estimates are within some kind of time frame. To look at this Table
5.2 gives the number of estimates within a given time frame from the actual FPT. Here one
should note that predictions were found for 351 patients for insulin, 143 for metformin, 185 for
chlorpropamide and 198 for glibenclamide.
Treatment Number of years from actual FPT Number of patients (%)
Insulin 1 123 (35.04%)
2 232 (66.10%)
3 302 (86.04 %)
4 329 (93.73%)
5 350 (99.72%)
Metformin 1 57 (39.86%)
2 98 (68.52%)
3 126 (88.11%)
4 137 (95.80%)
5 143 (100%)
Chlorpropamide 1 73 (39.46%)
2 122 (65.95%)
3 149 (80.54%)
4 175 (94.59%)
5 179 (96.76%)
Glibenclamide 1 82 (41.41%)
2 142 (71.71%)
3 180 (90.91%)
4 194 (97.98%)
5 198 (100%)
Table 5.2: Number and Percentage of Patients within a certain time frame for Insulin Model
Table 5.2 shows that all bar one of the patients for insulin were predicted within 5 years of
their actual FPT. Although this may not sound too close, with FPT between 1 and 15 years it
at least can give an idea of whether a patient can remain for a long or short time on a certain
drug. Over 66% are also within 2 years of the actual FPT value and over 86% within 3 years
for insulin. This means that for over 4 in every 5 patients the model can predict within 3 years
how long they will remain on insulin for and then therapy can be adjusted appropriately.
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The estimated parameters of β and their associated 95% credible intervals are in table (5.3)
Treatment Parameter βˆ
Insulin Intercept 0.000043 (-0.005966,0.006222)
HbA1c 0.001259 (-0.014576,0.017359)
FPG 0.001816 (-0.020426,0.021406)
Age -0.000203 (-0.006554,0.005850)
BMI 0.000023 (-0.007231,0.006353)
Race -0.000905 (-0.015463,0.015331)
HbA1c×FPG -0.002748 (-0.030768,0.027860)
Metformin Intercept -0.000329 (-0.005772,0.005108)
HbA1c -0.000718 (-0.006931,0.005371)
HOMA−%B -0.005615 (-0.055990,0.044367)
HOMA−%S -0.004953 (-0.051997,0.039345)
HOMA 0.007961 (-0.065105,0.082644)
Insulin -0.000931 (-0.007379,0.005510)
Triglycerides 0.000204 (-0.004688,0.005405)
Chlorpropamide Intercept -0.000364 (-0.005128,0.004193)
HbA1c -0.000031 (-0.004606,0.004585)
Age -0.000014 (-0.003679,0.004569)
FPG 0.000165 (-0.005408,0.006286)
Systolic Blood Pressure 0.000039 (-0.003928,0.003885)
Race 0.000392 (-0.011122,0.011999)
Glibenclamide Intercept -0.000217 (-0.006308,0.007157)
HbA1c 0.000421 (-0.004407,0.004972)
HOMA−%B 0.000076 (-0.004490,0.004424)
HDL Cholesterol -0.000114 (-0.004699,0.004477)
Gender -0.000152 (-0.009869,0.009150)
Race 0.000487 (-0.011379,0.014424)
BMI -0.000125 (-0.005107,0.004830)
Table 5.3: Estimated Paramter Values for the Insulin Model
These appear to be very small values for β and therefore most of the information for the
model appears to be taken from the individual paramters θi, the summaries of this are given in
Table 5.4
It can be seen from Figure 5.7 that there is a large amount of variability in a patient FPT.
There are some first passage times which can be up to 5 years out from the actual FPT. This
leads to looking at some of the residuals for the first passsage times.
Since the estimates come from an Inverse Gaussian distribution, it is known that the mean
value and thus the estimate yˆi is ϑi and the variance is
ϑ3i
ζ . A density plot of the residuals in
Figure 5.8 shows that the residuals are approximately normally distributed as would be expected,
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Treatment Minimum 1st Qu. Median Mean 3rd Qu. Max
Insulin -1.1491 0.0179 0.0304 0.0385 0.0489 0.5877
Metformin -0.0234 0.0183 0.0284 0.0354 0.0421 0.3026
Chlorpropamide -0.1665 0.0125 0.0309 0.0415 0.0524 0.5390
Glibenclamide -0.0763 0.0170 0.0348 0.0536 0.0639 0.6661
Table 5.4: Summary Statistics for θi
but with a large tails on either side.
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Figure 5.8: Density Plot of Residuals
Credible Intervals for an individual can be found for the FPT. Figure 5.9 shows the 80%
credible intervals for the insulin model.
However, as Figure 5.9 shows there is a big difference in the size of the credible intervals.
The FPT times follow an Inverse Gaussian distribution. For an Inverse Gaussian distribution
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Figure 5.9: Credible Interval Plot for the First Passage Time Predictions from the Insulin Model.
for x with parameters (µ, λ) then it is known that the variance is
var(x) =
µ3
λ
(5.80)
Therefore, when the mean which is equal to µ is large, then the variance will also be large. In
the same way, a small mean will lead to a small variance. 80% credible intervals were looked at
here as the 95% credible intervals had all the larger FPT predictions having intervals of around
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40 plus years. The 80% credible intervals are instead more realistic for most of the predictions.
However, the smaller estimates are very close with many having an interval of less than 1 year.
62.99% of the intervals contain the actual value, with almost all of the intervals which do not
contain the actual value being for predictions of less than 4 years for insulin.
The credible interval plots for metformin, chlorpropamide and glibenclamide are given in the
Appendix C.2.2.
5.6. Prediction for a new individual with no time data
The model above incorporates both an overall baseline covariate effect as well as an individual
fraility parameter. This individual fraility parameter is found through the patients HbA1c
increments over time and therefore to predict the next time point yik|yik where yik is all the
increments not including the time point k is easy with this method. However, for a newly
diagnosed individual with no increment data the model would not run so well. Therefore, it
may be useful to be able to give some kind of estimation with no increment HbA1c data. Using
the β values in Table 5.3 it may be useful to be able to estimate the θi values. However, when
the full model is run, it is seen that the β values are very small and give little information to
the actual result, with the majority coming from the individiaul drift parameters θi. Therefore,
instead it was decided to try a multi-level model, where the β values are approximated first and
then the individual drift parameters θi can be calculated afterwards when more time information
about each individual is known.
The reason for creating this multi level model is so that predictions can be found for an
individual at baseline and at early times in their treatment. The overall model using the data
for individuals at all known time points. However, in reality a newly diagnosed individual would
have almost no information about their HbA1c levels previous to diagnosis. The original mixture
model in the previous chapter would first be used to predict theirHbA1c after 1 year of treatment,
however, predictions past this would be almost impossible. Also, even after this first year any
further predictions would also not have a great amount of time data to predict the individual
fraility parameter. It is known that an individual drops at first when treatment is initiated too.
Therefore, by creating a multi-level model one can start predictions on an individuals course
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over time and this can regularly be updated when more time has passed and as such more data
can be used to predict the individual parameter θi. In terms of reproducability in creating these
predictions in real life scenarios having this flexibility would be a great advantage to a clinician.
Assuming now that the model is comprised purely of the covariate effects νi = Ziβ. Then
Yik ∼ N
(
Ziβ(tij − ti(j−1)), σ2i (tij − ti(j−1)
)
. (5.81)
Then definig
Y i = (X(ti1)−X(ti0), X(ti2)−X(ti1), . . . , X(tiki)−X(ti(ki−1)))
= (Yi1, Yi2, . . . , Yiki), (5.82)
for the ith patient i = 1, . . . , N , with ki HbA1c measurements then
Y i ∼ Nki
(
Aiβti, σ
2
i Vi
)
, (5.83)
where Ai is a ki ×P matrix formed by multiplying ti and ZTi with tTi =
(
ti1 − ti0, . . . , tiki −
ti(ki−1)) and Vi is a ki×ki diagonal matrix with the jth diagonal entry tij − ti(j−1). β is a vector
of P unknown regression coefficients.
The same prior distributions are used here as previously for the unknown parameters. To
find the conditional distribution for β one needs to deal with proportionality and calcuate
p(β)p(Y |β, σ2i )
p(Y |β, σ2i ) ∝
β
exp
(
− 1
2
N∑
i=1
1
σ2i
(Yi −Aiβ)TV −1i (Yi −Aiβ
)
,
∝
β
exp
(
− 1
2
N∑
i=1
(βTATi V
−1
i Aiβ − 2βTATi V −1i Yi
)
. (5.84)
Then
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p(β) ∝
β
exp
(
− 1
2
(βTΣ−1β − 2βTΣ−1β0)
)
. (5.85)
So the full conditional can be found
p(β)p(Y |β, σ2i ) ∝
β
exp
(
− 1
2
(
βT (
N∑
i=1
1
σ2i
ATi V
−1
i Ai + Σ
−1)β − 2βT (
N∑
i=1
1
σ2i
ATi V
−1
i Yi + Σ
−1β0
))
.
(5.86)
Then using Result 5.4 it can be seen that the β follow a multivariate normal distribution.
β ∼MVN(β∗,Σ∗), (5.87)
where
β∗ = Σ∗
( N∑
i=1
1
σ2i
ATi V
−1
i Yi + Σ
−1β0
)
,
Σ∗ =
( N∑
i=1
ATi V
−1
i Ai + Σ
−1)−1. (5.88)
Here it can be seen that if non-informative priors are given for β and so Σ−1 ≈ 0 and as such
Σ−1β0 ≈ 0 then the mean of the multivariate distribution is close to the maximum likelihood
estimate of β in eq. 5.17 but with the individual variances σ2i included and as such the results
show that the β values are in fact very close to that of the maximum likelihood estimates.
The conditionals for β0 and Σ are the same as before since they are not dependent on the
individual drift θi and so the only other conditional distribution which needs to be calculated is
that for σ2i . This can be done in a similar way to before such that the conditional is
p(σ2i |Y i,β) ∝
σ2i
(σ2i )
−(ω+ ki
2
+1)exp
(
− 1
2σ2i
(
2Λ + (Y i −Aiβ
)T
V Ti Y i −Aiβ
))
. (5.89)
Which is the kernel of an inverse gamma distribution, which is to be expected since a
5.6. Prediction for a new individual with no time data 133
conjugate prior was used. So the conditional distribution for σ2i is an inverse gamma with
parameters.
σ2i ∼ Inverse− gamma
(
λ+
ki
2
,
1
2
(
2Λ + (Y i −Aiβ)TV Ti Y i −Aiβ)
)
. (5.90)
5.6.1. Gibbs Sampling Routine for Model with no Time Data
Once the conditionals have been found then the Gibbs Sampling routine can be run to find the
estimates of β primarily.
For each iteration l = 1, . . . , L.
1. Draw the β estiamtes for p = 1, . . . , P from
β ∼MVN(β∗,Σ∗), (5.91)
where
β∗ = Σ∗
( N∑
i=1
1
σ2i
ATi V
−1
i Yi + Σ
−1β0
)
,
Σ∗ =
( N∑
i=1
ATi V
−1
i Ai + Σ
−1)−1. (5.92)
2. Draw the hyer-prior for the mean of β - β0 for p = 1, . . . , P from
β0 ∼ Nd(β∗0,Σ0), (5.93)
where
β∗0 = Σ0
(
C−1µ+ Σ−1β
)
,
Σ0 =
(
Σ−1 + C−1
)−1
. (5.94)
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3. Draw the hyper-prior for the variance covariance matrix of β - Σ−1
Σ−1 ∼W
(
ρ+ P,
(
(β − β0)T (β − β0) + ρU
)−1)
. (5.95)
4. Draw the patient specific diffusion parameter σ2i for i = 1, . . . , N from
σ2i ∼ IG
(
λ+
ki
2
,
1
2
(
2Λ + (Y i −Aiβ)TV Ti Y i −Aiβ)
)
. (5.96)
The Gibbs Sampler can then be run for a total of r iterations with a burn-in and the
convergence of the chain can be assessed.
5.6.2. Results of the Model with no Time Data
This model is a more simplified version of the full model. Therefore, it is seen that the chains
converge quicker then for the full model. As such the Gelman-Rubin Statistic for all treatments
and variables were seen to be 1. For consistency the chain was run for 10000 iterations storing
every 20th value and discarding the first 5000 as a burn in.
The estimates of the β variables are given in Table 5.5, these estimates are almost identical to
the maximum likelihood estimates and thus in future models it may be that only the maximum
likelihood estimator needs to be calculated.
Comparing this to Table 5.3 it can be seen that the β coefficents are much larger in absolute
value than those for the full model, which is to be expected since there is no individual drift.
However, since no time data is included for the model then the results are not seen or expected
to be as consistent, using the FPT as a validation for the model. Here the r2 = 0.151 for insulin
and only 51.81% of patients were estimated within 2 years of their actual FPT. This is just over
50% which is still a significant prediction and the rmse = 2.73.
The model here still has some interesting properties and can still give some good initial
estimates for patients when there is absolutely no time data known. 80.22% of patients were
predicted within 4 years of their actual first passage time (FPT) which is promising but still
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Treatment Variable Estimate
Insulin Intercept 0.030218
HbA1c -0.011470
FPG -0.003612
Age -0.000640
BMI 0.003276
Race 0.005403
HbA1c× FPG 0.007255
Metformin Intercept 0.030257
HbA1c -0.003653
HOMA−%B -0.011253
HOMA−%S -0.008058
HOMA 0.014412
Insulin 0.002438
Triglycerides -0.001537
Chlorproamide Intercept 0.030667
HbA1c -0.008805
Age -0.003862
FPG 0.002817
Systolic Blood Pressure 0.000714
Race 0.007002
Glibenclamide Intercept 0.034411
HbA1c -0.006076
HOMA−%B 0.000078
HDL Cholesterol 0.002082
Gender 0.002245
Race 0.006014
BMI -0.002495
Table 5.5: β Coefficients for the No Time Data Model
means that almost 20% of individuals had predictions which were more than 4 years wrong at
baseline.
This model, however, does give a good starting point in that an individuals time data can
be included once it is known to give predictions.
5.6.3. Model incorporating Time Data
Once the β estimates have been found for the population, an individuals own pathway can be
estimated and updated over time. One of the main advantages of Bayesian analysis is that the
models can be updated with more knowledge and as such predictions for FPT and the next
marker values can continually be updated as more information is known about an individual.
136 5.6. Prediction for a new individual with no time data
To do this the model can be run in almost the exact same way, however, fixing the estimates
of β to be those in Table 5.5 -βˆ. Therefore, the Gibbs Sampler need only iterate through the
individual drift θi and the individual dispersion parameter σ
2
i .
For each iteration l = 1, . . . , L.
1. Draw the individual drift parameter estimates θi for i = 1, . . . , N from
θi ∼ N(θ∗i , σ2θi), (5.97)
where
θ∗i =σ
2
θi
(
θ0i
σ2θ01
+
(Y i −Aiβˆ)TV −1i tTi
σ2i
)
, (5.98)
σ2θi =
(
1
σ2θ0i
+
tiV
−1
i ti
σ2i
)−1
. (5.99)
2. Draw the patient specific diffusion parameter σ2i for i = 1, . . . , N from
σ2i ∼ IG
(
λ+
ki
2
,
1
2
(
2Λ + (Y i −Aiβˆ − θiti)TV Ti Y i −Aiβˆ − θiti)
))
. (5.100)
where βˆ is the estimates from the model with no time data information.
5.6.4. Results of Incorporating Time Data
Once the model has been run to calculate an individuals drift parameter θi the FPT can be
calculated using the Inverse-Guassian distribution (5.72) as before. This was done for all the
known time data for the individuals and therefore all the same data as for the origianl full model.
The results are seen to very similar to the full model for insulin with r2 = 0.64698 compared
with 0.6518 for the full model. r2= 0.671 compared with 0.703 for metformin, 0.542 compared
with 0.580 for glibenclamide and 0.649 compared with 0.676 for chlorpropamide.
Once again the thing of most importance is how close a prediction is to an individuals actual
FPT as this could determine when treatment may need to be added or changed and thus could
dictate how much attention to levels should be given to an individual throughout the course of
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their disease. In this case similar number were predicted for each and in fact the correlation
between the 2 predictions was seen to be 0.945 for insulin and they gave very similar predictions.
The number of subjects with predictions and actual FPT are 351 for insulin, 143 for metformin,
185 for chlorpropamide and 198 for glibenclamide and the results are given in Table 5.6.
Treatment Number of Years from Actual FPT Number of Patients (%)
Insulin 1 121 (34.47%)
2 223 (63.53%)
3 304 (86.61%)
4 329 (93.73%)
5 350 (99.71%)
Metformin 1 58 (40.56%)
2 95 (66.43%)
3 120 (83.92%)
4 131 (91.61%)
5 142 (99.30%)
Chlorpropamide 1 73 (39.46%)
2 120 (64.86%)
3 145 (78.38%)
4 170 (91.89%)
5 178 (96.21%)
Glibenclamide 1 84 (42.42%)
2 137 (69.20%)
3 176 (88.89%)
4 191 (96.46%)
5 197 (99.49%)
Table 5.6: Number of Patients Predictions within a certain time frame for the Multi-level Model.
This second multi-level model was provided more as a way of prediction throughout an
individuals course of their disease as it can be updated easily for an individual to give predictions
of next data points and FPT without the need to re-run the entire model. The model with only
the β values also does give some idea of an estimate when their is no time data known and
although this is not as good as when time points are known, this is to be expected and still
generally places individuals in the right frame of whether they can safely stay on a treatment
for a long or short amount of time.
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5.7. Summary of Degradation Model
This chapter has outlined the Wiener process degradation model for modelling an individuals
HbA1c degradataion over time after the initial drop in values. This model uses a Wiener process
to model each step in time as coming from an normal distribution with a positive drift. The
positive drift is made up of two effects, firstly, the baseline covariate effect and also an individual
drift. This model can be used to monitor their degradation over time as well as to predict next
marker increaments with credible intervals to take into account that although the path will
tend to depreciate over time, both improvements and depreciations can occur. The estimated
paramaters can also be used to predict how long it will be until an individual crosses a ciritical
boundary. In this case HbA1c of above 7% was considered to be this boundary as for clinical
interest this may be when treatments are either changed or added as one is then going above
the normo-glycaemic range. This critical boundary can easily be changed though to whatever
value is of interest. The next part of this chapter extended this full model to introduce a two
step model for which a newly diagnosed individual with no time data could create predictions
also. This model also has a positive drift with the same two components, however, the covariate
effects are modeled first and kept stationary and then the model can be updated whenever new
time information about the patient is known. This may not always give as good predictions as
the full model, however, is of more clinical interest as it is easy to update for an individual and
can also create predictions from diagnosis. The models give good estimates for FPT with r2 of
above 0.6 and over 60% of patients being predicted within 2 years of their actual FPT.
6
Conclusion and Discussion
6.1. Conclusions
The main aim of this thesis was to create prediction models for individuals with type 2 diabetes
to help guide a move towards more personalised medicine. Chapters 3 and 4 focus on predicting
a patients HbA1c 1 year after initial treatment and then Chapter 5 looks at creating a model to
predict an individuals HbA1c degradation over time with an aim to predict next values as well
as how long one can stay safely on a certain treatment. All models were created using Bayesian
methods which have the advantage that they can be updated with new data and be rerun to
give estimates.
6.1.1. Conclusions of Predicting HbA1c After 1 year of Initial Treatment
To predict an individuals HbA1c after 1 year of treatment for insulin, metformin, chlorprop-
amide and glibenclamide it can be seen that a mixture model gives the best results in terms
of prediction. This then seems to suggest that not all subjects follow a single standard model
as to how they will react on a treatment and instead two differing models are best to achieve
accurate predictions. The main difference seen between the two sub groups of the population
for the models was the baseline HbA1c which was statistically significant in insulin, metformin
and chlorpropamide and numerically different for glibenclamide. The model coefficients also
showed some interesting differences between the groups. Although the baseline HbA1c coeffi-
cient is always negative relating to a larger drop in HbA1c, which is to be expected since the
higher baseline one has the more decrease is needed to reach normoglycaemic levels, it was al-
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ways seen to be more negative for the group with higher baseline values. Insulin, metformin
and glibenclamide also showed that for the group with a higher baseline HbA1c all the other
coefficents had smaller absolute values. This could then suggest that when a larger HbA1c is
seen at baseline that this is the main primary effect to predict what will happen after 1 year of
treatment. On the other hand, a HbA1c value at baseline closer to the normal range, still has
a large influence on the prediction, but other variables come into effect here to a much larger
extent. Interestingly, chlorpropamide showed larger absolute value coefficents for the group with
a higher baseline HbA1c. However, this group only encorporated 19.7% of the total population
on chlorpropamide, the smallest percentage seen. The other group also had a large intercept of
-1.546, so a large decrease was seen when all variables were at their mean. Group 1 on the other
hand had an intercept of just -0.026.
This chapter also looked at variable selection for the 4 treatments, to decide which variables
to include in all further analysis. Unsurprisingly baseline HbA1c was included in all models and
had the largest effect on the decrease after 1 year. Many of the variables were seen in only
one of the treatment models and the corresponding coefficient can then help make decisions
based on a high or low value of that variable seen. For example, a large positive coefficient
may suggest that an individual with a large value may not be best suited for that treatment.
Such as fasting insulin for those in the lower HbA1c group for the metformin model. This is
a very large coefficient in comparison to others and as such it could be suggested that large
baseline fasting insulin values with a close to normoglycaemic HbA1c may not be best suited to
metformin treatment. A number of the variables were also seen the be included in more than
1 model, such as age in insulin, glibenclamide and chlorpropamide. The majority of these gave
negative coefficients so that older individuals will have a larger decrease after 1 year. However,
the glibenclamide model has a negative coefficient for those with a smaller HbA1c and a positive
coefficient for the group with a larger average baseline HbA1c. Therefore, an individual with a
higher HbA1c who is older may be better suited to insulin or metformin. Another thing of note
is BMI which is included in the insulin and glibenclamide models. Both of these gave coefficient
estimates of positive value and as such a larger baseline BMI may correspond with less overall
decrease in HbA1c. As BMI is not included in the metformin or chlorpropamide model, a subject
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with a high baseline BMI may be better suited to one of these treatments.
6.1.2. Conclusions of Degradation Models for Progressive HbA1c over time.
Once an initial drop in HbA1c levels has been seen by an individual, their values slowly deteri-
orate over time and increase non-monotonically. To model this progression is difficult due to
both improvements and depreciations occuring, whilst having an overall upward trend. For this
reason a Wiener process was chosen and in general this was seen to be a good fit. In terms of
predicting an individuals first passage time (FPT) or time until they reach a criticial boundary,
the models gave predictions which were close to the actual values. In all treamts around 60−70%
of individuals had predictions within 2 years of their actual FPT. In terms of predicting the next
marker value for HbA1c the model generally does this well. An average postivie drift can predict
what the deterioration would be, but the individual variances allows the prediction to take into
account that an improvement may be seen or that the depreciation could be larger than origin-
ally thought. Since the models were all run using Bayesian techniques, they can continually be
rerun when more information about the individual is known and thus there is more data. The
FPT predictions can also be found for a number of different critical boundaries of interest.
In terms of the baseline covariates, these are seen to have not quite as big an effect on the
predictions as in previous chapters, as most of the information is taken up by the individual
drift parameter θi. Again, the baseline HbA1c plays a large role in the predictions since they
are found using
ci = ln
(
cr
x01
)
(6.1)
where x01 is the intial baseline HbA1c value. Therefore, the closer this is the boundary the
smaller the prediction for the FPT will be. The rest of the variables show nothing surprising
and are relatively small in terms of their coefficients. It can be seen that they on average make
around 1 to 3 years of difference in the prediction of FPT between the largest and smallest values
observed for the individuals. When the model was estimated using purely these varaibles, the
predictions were not as close as when the individual drift was included. However, over 50%
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of predictions were within 2 years and thus this can still give a good starting point for the
prediction when no further time data is known. Then over time the model can be rerun for an
individual and can constantly be updated when new time points are seen to give more acurate
predictions for both next time points and for the time to cross a critical boundary (FPT).
6.2. Issues with Adherence
Although the models provided in this thesis give some estimates for prediction, they are missing
one vital piece of information - adherence to the drug. The models created assumed that all
individuals were taking their medication as provided, however, it is known that this would
not always be the case. For example a study of insulin treated patients in Scotland showed
adherence to be around 71% and that the level of adherence was a significant predictor of
HbA1c indicating that improved adherence results in better glycaemic control [78]. A similar
study which also looked at disease knowledge found a significant correlation between HbA1c,
knowledge and adherence [79]. Qazaz et al also showed a significantly higher score for knowledge
and adherence found in patients with a lower HbA1c.Therefore, adherence and knowledge data
could help improve the models as those with good adherence and education of the disease may
be more likely to have a larger decrease in HbA1c after 1 year as well as be able to stay on a
treatment for a longer period of time. Without having this knowledge in creating the models,
it also means that some of the estimates may be skewed by a sub group of the population with
low adherence. For example, there are a number of patients who being with large baseline
values of HbA1c but who still increase after 1 year of treatment. These cannot be excluded from
the analysis since adherence was not known and one cannot assume non-adherence, however,
it would appear likely they these individuals may not have been taking their medication as
prescribed.
6.3. Future Work
The first thing of interest for any future work with these models would be to look at validating
the model results. All the models here were creating using the UKPDS dataset and it would be
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useful to check the predictions on any external data which may become available to see how well
the predictions work. It could also be of note to rerun the models on new data to see whether
the results found were similar.
The results in this thesis are indeed interesting and are good tools for providing personalised
medicine. As stated information on adherence and disease knowledge would be crucical to
provide a prediction tool as this could be seen to be very influential. Although this data would
be required, all one would need to do would be to replicate the models as the methods work
independent of the data provided.
Of interest may also be to run these models for a range of individuals to see how much their
predictions differ between the treatments as well as for other treatments not focused on in this
thesis.
This research also only focused on monotherapy and newly diagnosed diabetes. Over a
course of an individuals disease they will be treated with a number of different medications and
it would be interesting to look at these interactions to see whether previous therapies may make
a difference to the course of diabetes.
The main delieverables of this thesis focus mainly on the mixture and degradation models.
These give some formulae and ways of predicting an individuals first response to treatment as
well as their degradation over time on initial monotherapy. These models can easily be used and
updated as more information is known which makes them useful in the clinical setting. By being
able to run the models for an individual for all of the known drugs, one can observe the results
and predict which treatment is likely to be most beneficial to that patient. These therefore, can
be used as personalised medicine tools as a way of prescribing an individual the most suitable
treatment for them. In the future the aim is to use these results and formulae to create an app
with which one can input baseline characteristics for an individual and the predictions can be
given. This could then be used as a tool to help guide the decision towards a medication for
patients.
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A
Bayesian Inference
A.1. Background Information
Bayesian inference is the process of fitting a probability model to a set of data and summarising
the result by a probability distribution on the parameters of the model and on unobserved
quantities [80]. To do this 3 steps are generally undertaken:
1. Setting up a full probability model. Specifying the unknown parameters of interest and
relevant probability models.
2. Calculating the posterior distribution - the conditional probability distribution of the
known parameters given the observed data.
3. Evaluating the model, such as the fit, the inferences of the posterior and how sensitive the
model is to prior distributions.
Bayesian methods begin with some prior beliefs about the unknown parameters. Then the
prior beliefs are updated on the basis of the data collected to give a posterior distribution.
This is all done using Bayes theorem and gives answers in direct probability distributions about
the unknown parameters of interest, giving probabilities of a hypothesis given the observed
data. The main difference between conventional (Frequentist) and Bayesian statistical methods
is the way they deal with the data and the hypothesis being tested. Bayesians deal with the
distribution of the quantities of interest, whereas Frequentists deal with the probabilities of data
sets, given a hypothesis and sampling distribution.
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The above means that when performing statistical analysis using Bayesian methods, know-
ledge indicates in general terms what the estimated effect will be. So that actual probabilities are
gained for the hypothesis tested. On the other hand when performing traditional/Frequentist
methods the hypothesis is not directly tested. Instead the null hypothesis is assumed: the hy-
pothesis of no effect and the test produces a measure of evidence in favour of the assumption
in terms of a P-value. When there is weak evidence (low P-value) of the null hypothesis, the
alternative hypothesis of an effect is then concluded indirectly. Hypotheses in traditional tests
also always assume no previous knowledge, even if there have been numerous studies before
which may show an effect. When analysis is done it always begins with the same null hypothesis
of no effect, no matter how much previous evidence there may be. Bayesian methods on the
other hand can incorporate any previous knowledge in terms of a prior probability distribution.
These can be hard to find in some cases and therefore may be replaced by a non-informative
prior, which assumes no previous knowledge and then the inference is made on the data only.
A.1.1. Bayes Rule
Bayesian methods started with Bayes theorem, first published in 1763 posthumously by Rev.
Thomas Bayes and modern Bayesian methods are still based on this theory.
Starting with a joint probability distribution for θ and y, we see that this can be defined
using a prior distribution p(θ) and the data distribution p(y|θ):
p(θ, y) = p(θ)p(y|θ)
Therefore, when conditioning on the known value y, we can evaluate a posterior density for
the distribution, based on our prior distribution and likelihood distribution we get from the
data.
p(θ|y) = p(θ, y)
p(y)
=
p(θ)p(y|θ)
p(y)
(A.1)
We can also see that with fixed y, p(y) can be considered a constant as it does not depend
on θ and so this can be omitted from (A.1) to get the unnormalised posterior density below:
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p(θ|y) ∝ p(θ)p(y|θ) (A.2)
A.1.2. Predictive Distributions
If we wish to make inferences about unknown obervables then we can use predictive inferences,
so that we wish to predict yp - another independent observation from the same distribution of
our data y. This is called the predictive distribution of yp and written as p(yp|y):
p(yp|y) =
∫
p(yp,θ|y)dθ =
∫
p(yp|θ,y)p(θ|y)dθ (A.3)
Since y and yp are conditionally independent given θ in the model, and so yp is independent
of y given θ we can then write equation (A.3) as:
p(yp|y) =
∫
p(yp|θ)p(θ|y)dθ (A.4)
A.2. Bayesian Computation through simulation
When computing Bayesian inferences, the process is sometimes mathematically tractable, for
example if well known distributions and conjugate priors are used, so samples can be generated
from the known posterior distribution. However, in many real life situations this can not be
done and often you get to a posterior (A.2), which can only be calculated up to a constant of
proportionality, and thus numerical techniques need to be used. Simulation techniques means
that complex hierarchical models, made to be as realistic as possible can be evaluated and
inferences can be made on these. This is because they do not have to be mathematical tractabile
as Markoc Chain Monte Carlo Methods (MCMC) can be used to generate large samples from
the unconditional posterior distributions.
Markov Chain Monte Carlo (MCMC) is a general method for simulation of Bayesian inference
and is based on drawing values of θ from an approximate distribution. Then in the limit these
give samples from the unconditional posterior p(θ|y). In other words, simulations are drawn
sequentially with the distribution of the sampled draws based on the most recently drawn values
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- hence we are drawing from a Markov Chain.
Definition A.1. A Markov Chain is a sequence of random variables θ1, θ2, ... for which, for any
t, the distribution of θt, given all the previous θ′s depends only on the most recent value θt−1.
Markov Chains work for Bayesian inference as they are improved at each step in the sim-
ulation, so that as the iteration increases, they converge to the target distribution. When it
is not possile to sample θ directly from p(θ|y), instead we sample iteratively from conditional
distributions, so in each step we are gaining samples from the distribution p(θ|y). One technique
of MCMC simulation which is often used is the Gibbs sampler method and is outlined below.
A.2.1. Gibbs Sampler
The Gibbs sampler method of MCMC simulation for Bayesian inference was first proposed by
Geman and Geman in 1984 in a discussion of applications to image processing [81]. This is a
widely used form of simulating draws from a posterior distribution and will be used for this
research.
Suppose the model has k parameters, θ = (θ1, θ2, ..., θk)
′
. Assume that the samples can be
generated from each of the full conditional distributions p(θi|θj 6=i, y), i = 1, ..., k in the model.
Under mild conditions the collection of full conditional distributions uniquely determines the
joint posterior distribution p(θ|y), and hence all marginal posterior distributions p(θi|y), i =
1, ..., k. Then choose initial estimates θ01, θ
0
2, ..., θ
0
k and follow the steps below for t ∈ 1 : T :
Step 1 Draw θt1 from p(θ1|θt−12 , θt−13 , ..., θt−1k , y)
Step 2 Draw θt2 from p(θ2|θt1, θt−13 , ..., θt−1k , y)
.
.
.
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Step k Draw θtk from p(θk|θt1, θt2, ..., θtk−1, y)
After running this for sufficently large t, we get a sample of θi from p(θi|y) under certain
limiting conditions.
Often the chain is run in for a burn-in period of length t0, say, so that the initial values
before t0 are ”forgotton”. The convergence of the k− tuple at iteration t to draw from the true
posterior distribution occurs under mild regulatory conditions, which most statistical models
generally follow [81]. So that for large enough t (say bigger than t0, θ
t is a correlated sample from
the true posterior and we can find quantities of interest from these. To avoid serial correlation,
often only every 10th or so iteration is taken. Gibbs sampling specifies the univariate conditional
distributions, even if they are only specified up to a constant, we can then use techniques such
as the ratio of uniforms [82].
For example, from ergodic theory we can see that the posterior mean of θ can be estimated
by averaging over all values or for example every 10th value, from t0 to T of the mean.
In order for a Markov chain to converge to a stationary distribution, it needs to satisfy 3
important properties.
1. irreducible - the chain must be able to reach all interesting parts of the state space;
2. aperiodic - the chain should not oscillate between different states;
3. recurrance - all interesting parts can be reached infinetely often, as least from almost
all starting points.
A.3. Convergence Diagnostics
A.3.1. Gelman-Rubin Statistic
One way to test the convergence of a Gibbs Sampler is to calculate the Gelman-Rubin Statistic
first proposed in 1992 [83]. This method involves running a number of Gibbs Sampling routines
from over-dispersed starting points and using these to calculate a statistic for convergence. The
method is outlined below.
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Step 1 Run m ≥ 2 chains of length 2r from over dispersed starting points
Step 2 Discard the first r draws in each chain
Step 3 Calculate the within-chain (W) and between-chain (B) variance.
W =
1
m
m∑
j=1
s2j (A.5)
where
s2j =
1
r − 1
r∑
i=1
(
θij − θˆj
)2
(A.6)
W is the mean of the variance of each chain.
B =
r
m− 1
m∑
j=1
(
θˆj − ˆˆθ
)2
(A.7)
ˆˆ
θ =
1
m
m∑
j=1
θˆj (A.8)
B is the variance of the chain means multiplied by r since each chain is based on r draws.
Step 4 Calculate the estimated variance of the parameter as a weighted sum of the within-chain
and between-chain variance.
ˆV ar(θ) =
(
1− 1
r
)
W +
1
r
B (A.9)
The ˆV ar(θ) will overestimate the variance due to the overdispersion of the starting values
in Step 1.
Step 5 Calculate the potentioal scale reduction factor.
Rˆ =
√
ˆV ar(θ)
W
(A.10)
Rˆ can then be used as a statistic to judge convergence. When Rˆ is high (say above 1.1 or 1.2)
then the chains should be run for longer to improve convergence to the stationary distribution.
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Once this has been calculated all the mr draws can be combined to produce one chain from the
stationary distribution.
A.3.2. Raftery-Lewis Diagnostic
The Raftery-Lewis Diagnostic comes from the paper by Raftery and Lewis [84] and the main
results are given below.
Here set values for q, r and s such that one requires the cumulative distribution function of q
quantile to be estimated within ±r with probability s. Standard values for these are q = 0.025,
r = 0.005 and s=0.95.
For a given posterior function Ut calculate this for each iteration of the Gibbs Sampler r.
Then define
Zt = δ
(
Ut ≤ u
)
(A.11)
where δ()˙ is the indicator function so that Zt is a binary 0-1 process derived from a Markov
Chain. Then introducing a lag k one can define
Z
(k)
t = Z1+(t−1)k (A.12)
which is then a Markov-Chain for sufficently large k.
Then let P be the transition matrix for (Z
(k)
t ) which is
P =
1− α α
β 1− β
 (A.13)
Then with the requirement for P [Zkm = i|Zk0 = j] to be within  of pii where pi is the
equilibrium pi = (pi0, pii) = (α+ β)
−1(β, α), it leads to M the minimum burn in being
M =
log
(
(α+β)
max(α,β)
)
logλ
(A.14)
where λ = (1− α− β).
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Next up one needs to calculate the number of iterations which should be run n. The require-
ment for this is that
P (q − r ≤ Zˆn(k) ≤ q + r) = s (A.15)
where
Zˆn
(k)
=
1
n
n∑
t=1
Z
(k)
t (A.16)
This can be shown to be satsfied for
n =
αβ(2−α−β)
(α+β)3(
r
Φ
(
1
2
(1+s)
))2 (A.17)
A.3.3. AutoCorrelation
If Xt is a wide-sense stationary process with the mean µ and variance σ
2 time independent then
the autocorrelation depends on the lag between times t and s. The auto correlation can be
calculated for the time lag τ = s− t by
E[(Xt − µ)(Xt+τ − µ)]
σ2
(A.18)
A.4. Bayesian P Value
To determine whether the found model is a good fit to the given data, the Bayesian P - Value
approach proposed by Gelman, Meng and Stern (1996) [85] can be used. A test should always
been done to test if the found model should be excluded because it fails to provide a reasonably
summary of the data given. More classical methods use a goodness of fit test. Instead here a
more Bayesian approach to look at the poisted model and how well discrepancies fit with the
data. This posterior predictive assessment of model fitness works on the idea of simulations from
the model and in complex models can be easily accomplished via Monte Carlow simulation, from
draws of the unknown estimated parameters Ω from the posterior distribtuion P (Ω|M,Y ) where
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M is the model found using the Bayesian inference.
The idea is to draw simulated data sets with sampled values of Ω from the posterior distri-
bution then from here calculate some certain discrepancies and the corresponding P-value is the
proportion of the such discrepanices larger than the actual data discrepancy. This is then done
in a number of steps.
1. From the posterior distributions of Ω randomly draw samples Ωj for j = 1, . . . , J .
2. Given Ωj , draw a simulated replicated data set yrepji from the sampling distribtion P (y
rep
i |M,Ωj).
3. Calculate the given discrepancy for the actual data y = (y1, . . . , yN ) - D(y; Ω
j) and the
simulated data yrepj = (yrepj1 , . . . , y
repj
N - D(y
repj ; Ωj).
4. The P-value is the proportion where D(yrepj ; Ωj) ≥ D(y; Ωj)
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B.1. Linear Regression Convergence
B.1.1. Auto-Correlation Plots
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Figure B.1: Auto-Correlation Plot for Metformin Model
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Figure B.2: Auto-Correlation Plot for Chlorpropamide Model
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Figure B.3: Auto-Correlation Plot for Glibenclamide Model
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B.1.2. Gelman-Rubin Plots
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Figure B.4: Gelman-Rubin Plots for Metformin Model
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Figure B.5: Gelman-Rubin Plots for Chlorpropamide Model
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Figure B.6: Gelman-Rubin Plots for Glibenclaide Model
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B.1.3. Actual Versus Predicted Plots
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Figure B.7: Actual versus Predicted HbA1c values after 1 year for Metformin Model
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Figure B.8: Actual versus Predicted HbA1c values after 1 year for Chlorpropamide Model
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Figure B.9: Actual versus Predicted HbA1c values after 1 year for Glibenclamide Model
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B.1.4. Rank Histogram Plots
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Figure B.11: Rank Histogram for the Chlorpropamide Model
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Figure B.12: Rank Histogram for the Glibenclamide Model
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B.2. Mixture Model Convergence
B.2.1. Auto-Correlation Plots
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Figure B.13: Auto Correlation Plots for the Mixture Model for Metformin
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Figure B.14: Auto Correlation Plots for the Mixture Model for Chlorpropamide
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Figure B.15: Auto Correlation Plots for the Mixture Model for Glibenclamide
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B.3.1. Actual Versus Predicted Plots
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Figure B.16: Plot of Actual Versus Predicted Values for the Metformin Mixture Model
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Figure B.17: Plot of Actual Versus Predicted Values for the Glibenclamide Mixture Model
B.3. Mixture Model Results 173
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
−15 −10 −5 0 5 10
−
10
−
5
0
5
Actual
Pr
ed
ict
ed
Figure B.18: Plot of Actual Versus Predicted Values for the Chlorpropamide Mixture Model
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Degradation Results
C.1. Convergence
C.1.1. Auto Correlation Plots
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Figure C.1: Auto-Correlation Plot for Metformin Degradation Model
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Figure C.2: Auto-Correlation Plot for Chlorpropamide Degradation Model
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Figure C.3: Auto-Correlation Plot for Glibenclamide Degradation Model
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C.1.2. Gelman Rubin Plots
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Figure C.4: Gelman Rubin Plots for the Metformin Degradation Model
C.1. Convergence 179
0 1000 2000 3000 4000 5000
1
2
3
4
5
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 1000 2000 3000 4000 5000
1.
0
1.
2
1.
4
1.
6
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 1000 2000 3000 4000 5000
1
2
3
4
5
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 1000 2000 3000 4000 5000
1.
0
2.
0
3.
0
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 1000 2000 3000 4000 5000
1.
00
1.
10
1.
20
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
0 1000 2000 3000 4000 5000
5
10
15
last iteration in chain
sh
rin
k 
fa
ct
or
median
97.5%
Figure C.5: Gelman Rubin Plots for the Chlorpropamide Degradation Model
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Figure C.6: Gelman Rubin Plots for the Glibenclamide Degradation Model
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C.2. Prediction Results
C.2.1. Next Marker Value Predictions
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Figure C.7: Actual versus Predicted values for the Final Time point for Metformin Model.
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Figure C.8: Actual versus Predicted values for the Final Time point for Chlorpropamide Model.
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Figure C.9: Actual versus Predicted values for the Final Time point for Glibenclamide Model.
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C.2.2. Credible Interval Plots for the First Passage Time Predictions
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Figure C.10: Credible Interval Plot for the First Passage Time Predictions from the Metformin
Model.
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Figure C.11: Credible Interval Plot for the First Passage Time Predictions from the Chlorpro-
amide Model.
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Figure C.12: Credible Interval Plot for the First Passage Time Predictions from the Glibencl-
amide Model.
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